AZABICYLES SUBSTITUES ET LEUR UTILISATION

SUBSTITUTED AZABICYCLES AND USE THEREOF

Abrégé français

La présente invention concerne de nouveaux azabicycles substitués, un procédé pour leur fabrication, leur utilisation seuls ou en combinaisons pour le traitement et/ou la prophylaxie de maladies ainsi que leur utilisation pour la fabrication de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier pour le traitement et/ou la prophylaxie de maladies cardiovasculaires.

Abrégé anglais

The present application relates to novel substituted azabicycles, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Revendications

- 145 -
Claims
1. Compound of the formula (I)
<IMG>
in which
the ring Q represents 8- or 9-membered heteroaryl,
R1 represents fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, (C1-C4)-
alkyl, (C3-C7)-cycloalkyl or (C1-C4)-alkoxy,
n represents a number 0, 1 or 2,
R2 represents trifluoromethyl, (C1-C6)-alkyl, (C3-C8)-cycloalkyl,
phenyl or 5- or 6-
membered heteroaryl,
where (C1-C6)-alkyl is substituted by a substituent selected from the group
consisting of difluoromethyl and trifluoromethyl,
where (C1-C6)-alkyl may be substituted by 1 to 3 fluorine substituents,
where (C3-C8)-cycloalkyl may be substituted by 1 or 2 substituents selected
independently of one another from the group consisting of fluorine, methyl and
methoxy,
where phenyl is substituted by 1 to 3 fluorine substituents,
where phenyl may be substituted by 1 or 2 substituents selected independently
of
one another from the group consisting of methyl and methoxy,
and
where 5- and 6-membered heteroaryl may be substituted by 1 or 2 substituents
selected independently of one another from the group consisting of fluorine,
trifluoromethyl and methyl,

- 146 -
R3 represents a group of the formula
<IMG>
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,
in which
R4 represents -R5, ¨OR6 or ¨NR7R8,
in which
R5 represents hydrogen, halogen, cyano, (C1-C6)-alkyl, (C2-
C4)-alkynyl, (C1-C4)-alkylcarbonyl or (C1-C4)-
alkoxycarbonyl,
in which (C1-C6)-alkyl and (C2-C4)-alkynyl for their part
may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, (C1-C6)-alkyl, (C3-C6)-
cycloalkyl, difluoromethoxy, trifluoromethoxy, oxo -
(C=O)p-OR9, -C(=O)p-NR9R10, -NR9-(C=O)-R10, -NR9-
(C=O)-OR10,-NR9-(C=O)-NR10R11, NR9-SO2-R10, -S(O)q-
R12 and -SO2-NR9R10,
R6 represents hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl, 4-
to 7-membered heterocyclyl, phenyl or 5- or 6-membered
heteroaryl,

- 147 -
in which (C1-C6)-alkyl, (C3-C7)-cycloalkyl, 4- to 7-
membered heterocyclyl, phenyl or 5- or 6-membered
heteroaryl may be substituted by 1 to 3 substituents
independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl,
(C1-C6)-alkyl, (C3-C6)-cycloalkyl, difluoromethoxy,
trifluoromethoxy, oxo -(C=O)p-OR9, -C(=O)p-NR9R10, -
NR9-(C=O)-R10, -NR9-(C=O)-OR10, -NR9-(C=O)-NR10R11,
-NR9-SO2-R10, -S(O)q-R12 and -SO2-NR9R10,
R7 represents hydrogen or (C1-C4-alkyl,
R8 represents hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl, 4-
to 7-membered heterocyclyl, phenyl or 5- or 6-membered
heteroaryl,
in which (C1-C6)-alkyl, (C3-C7)-cycloalkyl, 4- to 7-
membered heterocyclyl, phenyl or 5- or 6-membered
heteroaryl may be substituted by 1 to 3 substituents
independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl,
(C1-C6)-alkyl, (C3-C7)-cycloalkyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9, -(C=O)p-NR9R10, -
NR9-(C=O)-R10, -NR9-(C=O)-OR10, -NR9-(C=O)-NR10R11,
-NR9-SO2-R10, -S(O)q-R12, -SO2-NR9R10, phenyl, 4- to 7-
membered heterocyclyl and 5- or 6-membered heteroaryl,
in which in each case
p represents the number 0 or 1,
q represents the number 0, 1 or 2,
R9, R10 and R11 independently of one another
each represent hydrogen, (C1-
C6)-alkyl or (C3-C8)-cycloalkyl,
in which (C1-C6)-alkyl for its part
may be substituted by 1 or 2

- 148 -
substituents independently of one
another selected from the group
consisting of fluorine,
difluoromethyl, trifluoromethyl,
hydroxy, (C1 -C6)-alkoxy,
difluoromethoxy,
trifluoromethoxy, (C1-C6)-
alkoxycarbonyl, amino, mono-
(C1-C6)-alkylamino, di-(C1 -C6)-
alkylamino and 4- to 7-
membered heterocyclyl,
or
R9 and R10 together with the atom(s) to which
they are respectively attached form
a 4- to 7-membered heterocycle,
in which the 4- to 7-membered
heterocycle for its part may be
substituted by 1 or 2 substituents
independently of one another
selected from the group consisting
of fluorine, cyano, trifluoromethyl,
(C1-C6)-alkyl, hydroxy, oxo, (C1-
C6)-alkoxy, trifluoromethoxy, (C1-
C6)-alkoxycarbonyl, amino, mono-
(C1-C6)-alkylamino and di-(C1-C6)-
alkylamino,
or
R10 and R11 together with the atom(s) to which
they are respectively attached form
a 4- to 7-membered heterocycle,
in which the 4- to 7-membered
heterocycle for its part may be

- 149 -
substituted by 1 or 2 substituents
independently of one another
selected from the group consisting
of fluorine, cyano, trifluoromethyl,
(C1-C6)-alkyl, hydroxy, oxo, (C1-
C6)-alkoxy, trifluoromethoxy, (C1-
C6)-alkoxycarbonyl, amino, mono-
(C1-C6)-alkylamino and di-(C1-C6)-
alkylamino,
and in which
R12 represents (C1-C6)-alkyl or (C3-C7)-
cycloalkyl,
or in which
R7 and R8 together with the nitrogen atom to which they are
attached form a 4- to 7-membered heterocycle or
5- or 6-membered heteroaryl,
in which the 4- to 7-membered heterocycle and the
5- or 6-membered heteroaryl may be substituted by
1 to 3 substituents independently of one another
selected from the group consisting of fluorine,
cyano, difluoromethyl, trifluoromethyl, (C1-C6)-
alkyl, (C3-C7)-cycloalkyl, hydroxy, oxo, (C1-C6)-
alkoxy, difluoromethoxy, trifluoromethoxy, (C1-
C6)-alkoxycarbonyl, amino, mono-(C1-C6)-
alkylamino and di-(C1-C6)-alkylamino,
and
in which all (C1-C4)-alkyl, (C1-C6)-alkyl, (C3-C8)-
cycloalkyl and 4- to 7-membered heterocyclyl groups
mentioned above, unless stated otherwise, may each
independently of one another additionally be substituted
by 1 to 3 substituents independently of one another

- 150 -
selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, (C3-C7)-cycloalkyl,
hydroxy, difluoromethoxy, trifluoromethoxy, (C1-C4)-
alkoxy, hydroxycarbonyl, (C1-C4)-alkoxycarbonyl, amino,
phenyl, 4- to 7-membered heterocyclyl and 5- or 6-
membered heteroaryl,
the ring P1 represents 5- to 7-membered heterocyclyl, phenyl or 5- or 6-
membered heteroaryl,
in which 5- to 7-membered heterocyclyl, phenyl and 5- or 6-
membered heteroaryl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
halogen, cyano, difluoromethyl, trifluoromethyl, trideuteromethyl,
(C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C7)-cycloalkyl,
oxo,
difluoromethoxy, trifluoromethoxy, thiooxo and a group of the
formula -M-R13,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents selected independently from the group
consisting of fluorine, cyano, trifluoromethyl, (C3-C7)-
cycloalkyl, difluoromethoxy and trifluoromethoxy,
the ring P2 represents 5-membered heteroaryl,
in which 5-membered heteroaryl may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of halogen, cyano, difluoromethyl, trifluoromethyl,
trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-alkenyl,
(C3-C7)-
cycloalkyl, oxo, difluoromethoxy, trifluoromethoxy, thiooxo and a
group of the formula -M-R13,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents selected independently from the group
consisting of fluorine, cyano, trifluoromethyl, (C3-C7)-
cycloalkyl, difluoromethoxy and trifluoromethoxy,

- 151 -
and in which in each case
M represents a bond or (C1-C4)-alkanediyl,
R13 represents -(C=O)t-OR14, -(C=O)r-NR14R15, -
C(=S)-NR14R15, -NR14-(C=O)-R15,-NR14-(C=O)-
OR17, -N-R14-(C=O)-NR15R16, -NR14-SO2-N15R16, -
NR14-SO2-R17, -S(O)s-R17,-SO2-NR14R15, 4- to 7-
membered heterocyclyl, phenyl, benzyl or 5- or 6-
membered heteroaryl,
in which
r represents the number 0 or 1,
s represents the number 0, 1 or 2,
R14,R15 and R16 independently of one
another each represent
hydrogen, (C1-C6)-alkyl,
(C3-C8)-cycloalkyl, 4- to 7-
membered heterocyclyl,
phenyl, benzyl or 5- or 6-
membered heteroaryl,
or
R14 and R15 together with the atom(s) to which
they are respectively attached form
a 4- to 7-membered heterocycle,
in which the 4- to 7-membered
heterocycle for its part may be
substituted by 1 or 2 substituents
independently of one another
selected from the group consisting
of cyano, trifluoromethyl, (C1-C6)-
alkyl, hydroxy, oxo, (C1-C6)-
alkoxy, trifluoromethoxy, (C1-C6)-

- 152 -
alkoxycarbonyl, amino, mono-(C1-
C6)-alkylamino and di-(C1-C6)-
alkylamino,
or
R14 and R15 together with the atom(s) to which
they are respectively attached form
a 4- to 7-membered heterocycle,
in which the 4- to 7-membered
heterocycle for its part may be
substituted by 1 or 2 substituents
independently of one another
selected from the group consisting
of cyano, trifluoromethyl,
alkyl, hydroxy, oxo,
alkoxy, trifluoromethoxy, (C1-C6)-
alkoxycarbonyl, amino, mono-(C1-
C6)-alkylamino and di-(C1-C6)-
alkylamino,
R17 represents (C1-C6)-alkyl or (C3-C7)-
cycloalkyl,
or
R14 and R17 together with the atom(s) to which
they are respectively attached form
a 4- to 7-membered heterocycle,
in which the 4- to 7-membered heterocycle
for its part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
cyano, trifluoromethyl, (C1-C6)-alkyl,
hydroxy, oxo, (C1-C6)-alkoxy,
trifluoromethoxy, (C1-C6)-alkoxycarbonyl,

- 153 -
amino, mono-(C1-C6)-alkylamino and di-
(C1-C6)-alkylamino,
and
in which 4- to 7-membered heterocyclyl, phenyl,
benzyl and 5- or 6-membered heteroaryl for their
part may be substituted by 1 to 3 substituents
independently of one another selected from the
group consisting of halogen, cyano,
difluoromethyl, trifluoromethyl, (C1-C6)-alkyl, (C3-
C7)-cycloalkyl, hydroxy, oxo, thioxo and (C1-C4)-
alkoxy,
and
in which the (C1-
C4)-alkyl, (C1-C6)-alkyl, (C3-C8)-
cycloalkyl and 4- to 7-membered heterocyclyl groups
mentioned above, unless stated otherwise, may each
independently of one another additionally be substituted
by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, (C1-C6)-alkyl, (C3-C7)-
cycloalkyl, hydroxy, difluoromethoxy, trifluoromethoxy,
(C1-C4)-alkoxy, hydroxycarbonyl, (C1-C4)-alkoxycarbonyl,
amino, phenyl, 4- to 7-membered heterocyclyl and 5- or 6-
membered heteroaryl,
and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-
oxides or salts
thereof,
except for the compounds:
2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b)]pyridin-3-yl]-8-methyl-9H-purine,
2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-8-methyl-9H-purine-6-
amine,
N-butyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-8-methyl-9H-
purine-6-
amine.

- 154 -
2. Compound of the formula (I) according to Claim 1 in which
the ring Q represents a group of the formula
<IMG>

- 155 -
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
the ring Q1 together with the atoms to which it is attached forms a 5- to 7-
membered
saturated or partially unsaturated carbocycle or a 5- to 7-membered
saturated or partially unsaturated heterocycle,
R1 represents fluorine, chlorine, methyl, hydroxy or oxo,
R1A represents hydrogen or methyl,
n represents a number 0, 1 or 2,
A1, A2, A3 and A4 independently of one another each represent N, CH or CR1,
with the proviso that not more than two of the A1, A2, A3 and A4 groups
represent N,
R2 represents trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoroprop-1-
yl, 2,2,3,3-
tetrafluorprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl or
pyridazinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl and pyridazinyl may be substituted by 1 or 2 fluorine substituents,
R3 represents a group of the formula

- 156 -
<IMG>
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,

- 157 -
in which
R4 represents -R5, ¨OR6 or ¨NR7R8,
in which
R5 represents hydrogen, chlorine, cyano, (C1-C4)-alkyl or (C2-
C4)-alkynyl,
in which (C1-C4)-alkyl and (C2-C4)-alkynyl for their part
may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-
OR9 and -C(=O)p-N-R9R10,
in which
P represents the number 0,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,

- 158 -
methylamino, ethylamino, dimethylamino
and diethylamino,
R6 represents (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R10 and NR9-(C=O)-R10,
and
in which cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl,
phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl may be
substituted by 1 to 3 substituents independently of one
another selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, isopropyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9 and ¨(C=O)p-NR9R10,
in which in each case
p represents the number 0 or 1,
R9 and R10 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-

- 159 -
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
R7 represents hydrogen, methyl or ethyl,
R8 represents hydrogen, (C1-C6)-alkyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl, cyclopropyl, cyclobutyl and
cyclopentyl are substituted by 1 to 3 substituents
independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl
methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R10, -NR9-(C=O)-R10, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, furanyl,

- 160 -
pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl,
in which
P represents the number 0 or 1,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which
they are respectively attached form
an azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring
for its part may be substituted by 1
or 2 substituents independently of
one another selected from the
group consisting of fluorine,
trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy,
amino, methylamino, ethylamino,
dimethylamino and diethylamino
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, furanyl,

- 161 -
pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl
for their part may be substituted by 1 or 2
substituents independently of one another selected
from the group consisting of fluorine, chlorine,
cyano, difluoromethyl, trifluoromethyl, methyl,
ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, oxo, difluoromethoxy, trifluoromethoxy,
methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=O)p-NR9R10
,
in which
P represents the number 0 or 1,
R9 and R10 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1 , 1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,

- 162 -
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
or
R7 and R8 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl,
pyrazolyl, imidazolyl or triazolyl ring,
in which the azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl,
pyrazolyl, imidazolyl or triazolyl ring may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, cyano,
difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, 1-hydroxyethyl,
cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
methoxy, ethoxy, difluoromethoxy and trifluoromethoxy,
E1 represents O, S or NR18,
in which
R18 represents hydrogen, trifluoromethyl or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, hydroxy, methoxy and
ethoxy,
E2 represents N,

- 163 -
E3 represents N or CR19,
in which
R19 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group of fluorine,
cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond,
methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=O)r-NR14R15, -C(=S)-
-NR14R15, -NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one
another each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of

- 164 -
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl,
ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
E4 and E6 independently of one another each represent N or CR20
in which
R20 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently from the group of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy and trifluoromethoxy,
and in which

- 165 -
M represents a bond, methylene,
ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -C(=O)r-NR14R15, -C(=S)-
NR14R15, -NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1 ,
R14 and R15 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl,
isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,

- 166 -
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
E5 represents NR21,
in which
R21 represents hydrogen or (C1-C4)-alkyl,
in which (C1-C4)-alkyl may itself be substituted by 1 or 2
substituents each independently selected from the group of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
G1, G2, G3 and G4 independently of one another each represent N or CR22,
in which
R22 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond,
methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)t-OR14, -(C=O)r-NR14R15, -C(=S)-
NR14R15, -NR14(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,

- 167 -
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
represents the number 0 or 1,
R14 and R15 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl,
cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-

- 168 -
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
with the proviso that not more than two of the G1, G2, G3 and G4 groups
represent
nitrogen,
and
with the proviso that at least one of the G1, G2, G3 and G4 groups represents
CH,
U represents C=O, C=S or SO2,
V represents O or NR24,
in which
R24 represents hydrogen, trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-
alkenyl, (C3-C7)-cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or
benzyl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, methoxy, ethoxy, methylsulphonyl, ethylsulphonyl,
azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and morpholinyl,
in which azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and
morpholinyl for their part may be substituted by 1 or 2
substituents independently of one another selected from
the group consisting of fluorine, trifluoromethyl, 2,2-
difluoroethyl, 2,2,2-trifluoroethyl, methyl and ethyl,
in which azetidinyl, pyrrolidinyl and piperidinyl for their part may
be substituted by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, trifluoromethyl,
methyl, ethyl, cyclopropyl and cyclobutyl,
in which methyl and ethyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the

- 169 -
group consisting of fluorine, trifluoromethyl, cyclopropyl,
cyclobutyl, hydroxy, methoxy and ethoxy,
and
in which benzyl may itself be substituted by 1 or 2 fluorine,
chlorine, trifluoromethyl, methyl, ethyl, methylsulphonyl and
ethylsulphonyl substituents,
W represents N or CR25,
in which
R25 represents hydrogen or oxo,
R23 represents hydrogen, trideuteromethyl, (C1-C6)-alkyl or (C2-C6)-
alkenyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
R25 represents hydrogen or oxo,
R27 represents hydrogen, (C1-C3)-alkoxycarbonyl or aminosulphonyl,
in which (C1-C3)-alkoxycarbonyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
R28 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, (C3-C6)-cycloalkyl
and
phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine, chlorine,
trifluoromethyl, (C1-C4)-alkyl, methoxy and ethoxy,
R29 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, cyclopropyl,
cyclobutyl and phenyl,

- 170 -
in which phenyl may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine, chlorine,
trifluoromethyl, methyl, ethyl, methoxy and ethoxy,
R30 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
R31 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
and their salts, solvates and solvates of the salts.
3. Compound of the formula (I) according to Claim 1 or 2 in which
the ring Q represents a group of the formula
<IMG>
where

- 171 -
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
R1A represents hydrogen or methyl,
R1B
represents hydrogen or fluorine,
R1C represents hydrogen or chlorine,
A1 represents N or CH,
R2 represents 3,3,3-trifluoroprop-1-yl, 2,2,3,3-tetrafluoroprop-1-yl,
2,2,3,3,3-
pentafluoroprop-1 -yl, phenyl or pyridyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where pyridyl may be substituted by 1 fluorine substituent,
R3 represents a group of the formula
<IMG>
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4 represents -R5, -OR6 or -NR7R8,
in which

- 172 -
R5 represents hydrogen or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, -(C=O)p-OR9 and
-C(=O)p-NR9R10,
in which
P represents the number 0,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, trifluoromethyl, -(C=O)p-
OR9 and -C(=O)p-N-R9R10,
in which
p represents the number 0 or 1,
R9 and R10 independently of one another each
represent hydrogen or methyl,
or
R9 and R10 together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,

- 173 -
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
and
in which pyrazolyl may be substituted by 1 or 2
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,
R8 represents hydrogen, (C1-C6)-alkyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
trifluoromethoxy, -(C=O)p-OR9, -(C=O)p-NR9R10,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl,
furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which
p represents the number 0 or 1,

- 174 -
R9 and R10 independently of one
another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl or
cyclobutyl,
and
in which tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl,
imidazolyl, triazolyl and pyridyl for their part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and
ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl and
trifluoromethoxy,
E1 represents NR18,
in which
R18 represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which

-175-
R19 represents hydrogen, fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl or a group of the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond,
methylene, ethane-1 ,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O),-OR14, -(C=O)r -NR14R15, phenyl,
thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl or
pyrimidinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one
another each
represent hydrogen, methyl, ethyl,
cyclopropyl, cyclobutyl or phenyl,
in which methyl and ethyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy,
trifluoromethoxy and methoxy,
and
in which phenyl, thiazolyl, triazolyl, oxadiazolyl,
thiadiazolyl and pyrimidinyl may each in turn be
substituted 1 or 2 substituents selected independently from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-

- 176 -
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl and cyclobutylmethyl,
U represents C(=0),
V represents NR24,
in which
R24 represents trideuteromethyl, (C1-C6)-alkyl, cyclopropyl,
cyclobutyl, azetidin-3-yl, pyrrolidin-3-yl or piperidin-4-yl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, oxetanyl and morpholin-4-yl,
and
in which azetidin-3-yl, pyrrolidin-3-yl and piperidin-4-yl for their
part may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine,
trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl
and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
4. Compound of the formula (I) according to Claim 1 in which
the ring Q represents a group of the formula
<IMG>

- 177 -
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
R1c represents hydrogen or fluorine,
A2 represents N or CH,
R2 represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl,
pyrimidinyl,
pyrazinyl or pyridazinyl,
where cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl and pyridazinyl may be substituted by 1 or 2 fluorine substituents,
R3 represents a group of the formula
<IMG>

- 178 -
<IMG>
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,
in which
R4 represents -R5, -OR6 or -NR7R8,
in which
R5 represents hydrogen, chlorine, cyano, (C1-C4)-alkyl or (C2-
C4)-alkynyl,
in which (C1-C4)-alkyl and (C2-C4)-alkynyl for their part
may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-
OR9 and -C(=O)p-NR9R10,
in which
p represents the number 0,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-

- 179 -
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
R6 represents (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R10 and -NR9-(C=O)-R10,
and
in which cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl,

- 180 -
phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl may be
substituted by 1 to 3 substituents independently of one
another selected from the group consisting of fluorine,
di fluoromethyl, trifluoromethyl, 2,2,2 -trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, isopropyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=O)p-NR9R10,
in which
represents the number 0 or 1,
R9 and R10 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
R7 represents hydrogen, methyl or ethyl,

- 181 -
R8 represents hydrogen, (C1-C6)-alkyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl, cyclopropyl, cyclobutyl and
cyclopentyl are substituted by 1 to 3 substituents
independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl
methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R10, -NR9-(C=O)-R10, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, furanyl,
pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl,
in which
p represents the number 0 or 1,
R9 and R10 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to
which
they are respectively attached form
an azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl or
morpholinyl ring,

- 182 -
in which the azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring
for its part may be substituted by 1
or 2 substituents independently of
one another selected from the
group consisting of fluorine,
trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy,
amino, methylamino, ethylamino,
dimethylamino and diethylamino
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, furanyl,
pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl
for their part may be substituted by 1 or 2
substituents independently of one another selected
from the group consisting of fluorine, chlorine,
cyano, difluoromethyl, trifluoromethyl, methyl,
ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, oxo, difluoromethoxy, trifluoromethoxy,
methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=O)p-NR9R10,

- 183 -
in which
P represents the number 0 or 1,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and di ethylamino,
or
R7 and R8 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl,
pyrazolyl, imidazolyl or triazolyl ring,
in which the azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl,
pyrazolyl, imidazolyl or triazolyl ring may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, cyano,

- 184 -
difluoromethyl, trifluoromethyl, 2,2 ,2-trifluoroethyl,
1, 1,2,2,2-pentafluoroethyl, methyl, ethyl, 1 -hydroxyethyl,
cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
methoxy, ethoxy, difluoromethoxy and trifluoromethoxy,
E1 represents O, S or NR18,
in which
R18 represents hydrogen, trifluoromethyl or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, hydroxy, methoxy and
ethoxy,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C i-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently from the group consisting of fluorine,
cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond,
methylene, ethane-1 ,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=0)r-NR14R15, -C(=S)-
NR14R15, -NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,

- 185 -
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl,
cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-

- 186 -
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
E4 and E6 independently of one another each represent N or CR20,
in which
R20 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond,
methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=O)r-NR14R15, -C(=S)-
NR14R15,-NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one
another each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,

- 187 -
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl,
ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
E5 represents NR21,
in which
R21 represents hydrogen or (C1-C4-alkyl,
in which (C1-C4)-alkyl may itself be substituted by 1 or 2
substituents each independently selected from the group consisting
of fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
G1, G2, G3 and G4 independently of one another each represent N or CR22,

- 188 -
in which
R22 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently from the group consisting of fluorine,
cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond,
methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=O)r-NR14R15, -C(=S)-
NR14R15, -NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1 ,
R14 and R15 independently of one
another each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,

- 189 -
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl,
ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
with the proviso that not more than two of the G1, G2, G3 and G4 groups
represent
nitrogen,
and
with the proviso that at least one of the G1, G2, G3 and G4 groups represents
CH,
U represents C=O, C=S or SO2,
V represents O or NR24,
in which
R24 represents hydrogen,
trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-
alkenyl, (C3-C7)-cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or
benzyl,

- 190 -
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, methoxy, ethoxy, methylsulphonyl, ethylsulphonyl,
azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and morpholinyl,
in which azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and
morpholinyl for their part may be substituted by 1 or 2
substituents independently of one another selected from
the group consisting of fluorine, trifluoromethyl, 2,2-
difluoroethyl, 2,2,2-trifluoroethyl, methyl and ethyl,
in which azetidinyl, pyrrolidinyl and piperidinyl for their part may
be substituted by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, trifluoromethyl,
methyl, ethyl, cyclopropyl and cyclobutyl,
in which methyl and ethyl for their part may be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, methoxy and ethoxy,
and
in which benzyl may itself be substituted by 1 or 2 fluorine,
chlorine, trifluoromethyl, methyl, ethyl, methylsulphonyl and
ethylsulphonyl substituents,
W represents N or CR25,
in which
R25 represents hydrogen or oxo,
R23 represents hydrogen, trideuteromethyl, (C1-C6)-alkyl or (C2-C6)-
alkenyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of

- 191 -
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
R25 represents hydrogen or oxo,
R27 represents hydrogen, (C1-C3)-alkoxycarbonyl or aminosulphonyl,
in which (C1-C3)-alkoxycarbonyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
R28 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, (C3-C6)-cycloalkyl
and
phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine, chlorine,
trifluoromethyl, (C1-C4)-alkyl, methoxy and ethoxy,
R29 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, cyclopropyl,
cyclobutyl and phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine, chlorine,
trifluoromethyl, methyl, ethyl, methoxy and ethoxy,
R30 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
R31 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
and their salts, solvates and solvates of the salts.

- 192 -
5. Compound of the formula (I) according to Claim 1 or 4 in which
the ring Q represents a group of the formula
<IMG>
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
R1C represents hydrogen, fluorine or methyl,
A2 represents CH,
R2 represents pyridyl or pyrimidinyl,
where pyridyl and pyrimidinyl may be substituted by 1 fluorine substituent,
R3 represents a group of the formula
<IMG>
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,

- 193 -
in which
R4 represents -R5, ¨OR6 or ¨NR7R8,
in which
R5 represents hydrogen, trifluoromethyl or (C1-C1-alkyl,
in which (C1-C4-alkyl for its part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, -(C=O)p-OR9 and
-C(=O)p-NR9R10,
in which
P represents the number 0,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, trifluoromethyl, -(C=O)p-
OR9 and -C(=O)p-NR9R10,
in which
p represents the number 0 or 1,
R9 and R10 independently of one another each
represent hydrogen or methyl,
or

- 194 -
R9 and R10 together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
and
in which pyrazolyl may be substituted by 1 or 2
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,
R8 represents hydrogen, (C1-C6)-alkyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
trifluoromethoxy, -(C=O)p-OR9, -(C=O)p-NR9R10,

- 195 -
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl,
furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which
P represents the number 0 or 1,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl or
cyclobutyl,
and
in which tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl,
imidazolyl, triazolyl and pyridyl for their part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and
ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl and
trifluoromethoxy,
E1 represents NR18,
in which

- 196 -
R18 represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl or a group of the formula -M-R13,
in which (C1-C4-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond,
methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)t-OR14, (C=O)t-NR14R15,
phenyl,
thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl or
pyrimidinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one
another each
represent hydrogen, methyl, ethyl,
cyclopropyl, cyclobutyl or phenyl,
in which methyl and ethyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy,
trifluoromethoxy and methoxy,
and

- 197 -
in which phenyl, thiazolyl, triazolyl, oxadiazolyl,
thiadiazolyl and pyrimidinyl may each in turn be
substituted by 1 or 2 substituents selected independently of
one another from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl,
2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl,
cyclopropyl, cyclobutyl, cyclopropylmethyl and
cyclobutylmethyl,
U represents C(=O),
V represents NR24,
in which
R24 represents trideuteromethyl, (C1-C6)-
alkyl, cyclopropyl,
cyclobutyl, azetidin-3-yl, pyrrolidin-3-yl or piperidin-4-yl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, oxetanyl and morpholin-4-yl,
and
in which azetidin-3-yl, pyrrolidin-3-yl and piperidin-4-yl for their
part may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine,
trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl
and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
6. Compound of the formula (I) according to Claim 1, 4 or 5 in which
the ring Q represents a group of the formula

- 198 -
<IMG>
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
R1C represents hydrogen or fluorine,
A2 represents CH,
R2 represents 3-fluoropyrid-2-yl,
R3 represents a group of the formula
<IMG>
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4 represents -R5 or ¨NR7R8,
in which

- 199 -
R5 represents hydrogen,
R7 represents hydrogen,
R8 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl is substituted by 1 to 3 substituents
independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl,
cyclobutyl, -(C=O)p-OR9 and -C(=O)p-NR9R10,
in which
P represents the number 0,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl or
cyclobutyl,
E1 represents NR18,
in which
R18 represents hydrogen,
E2 represents N,
E3 represents CR19
in which
R19 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which

- 200 -
M represents a bond,
R13 represents -(C=O)r-OR14 or -(C=O)r-NR14R15,
in which
r represents the number 0,
R14 and R15 independently of one another each
represent hydrogen, methyl, ethyl,
cyclopropyl or cyclobutyl,
U represents C(=O),
V represents NR24,
in which
R24
represents (C1-C6)-alkyl,
in which (C1-C6)-alkyl may itself be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl and
hydroxy,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
7. Compound of the formula (I) according to Claim 1 in which
the ring Q represents a group of the formula
<IMG>
where

- 201 -
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
R1C represents hydrogen or fluorine,
A2 represents N or CH,
R2 represents trifluoromethyl, 2,2,2-trifluoroethyl, 3 ,3 ,3-trifluoroprop-
1-yl, 2,2,3,3-
tetrafluorprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyI,
cyclopentyl, cyclohexyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl or
pyridazinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl and pyridazinyl may be substituted by 1 or 2 fluorine substituents,
R3 represents a group of the formula
<IMG>

- 202 -
<IMG>
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,
in which
R4 represents -R5, ¨OR6 or ¨NR7R8,
in which
R5 represents trifluoromethyl or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9 and -
C(=O)p-NR9R10,
in which

- 203 -
p represents the number 0,
R9 and R10 independently of one another each
represent methyl, ethyl, isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
R6 represents (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, (C1-C4)-alkoxy, -(C=O)-OR9, -(C=O)-
NR9R10 and -NR9-(C=O)-R10,

- 204 -
in which
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which
they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
and
in which cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl,
phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl may be
substituted by 1 to 3 substituents independently of one
another selected from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, isopropyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9 and ¨(C=O)p-NR9R10,

- 205 -
in which in each case
P represents the number 0 or 1,
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
R7 represents hydrogen, methyl or ethyl,
R8 represents (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl, cyclopropyl, cyclobutyl and
cyclopentyl are substituted by 1 to 3 substituents
independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl

- 206 -
methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, -
(C=O)-OR9, -(C=O)-NR9R10, NR9-(C=O)-R10, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl,
phenyl, furanyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl and
pyrimidinyl,
in which
R9 and R10 independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl or cyclopentyl,
or
R9 and R10 together with the atom(s) to which
they are respectively attached form
an azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring
for its part may be substituted by 1
or 2 substituents independently of
one another selected from the
group consisting of fluorine,
trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy,
amino, methylamino, ethylamino,
dimethylamino and diethylamino

- 207 -
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, furanyl,
pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl
for their part may be substituted by 1 or 2
substituents independently of one another selected
from the group consisting of fluorine, chlorine,
cyano, difluoromethyl, trifluoromethyl, methyl,
ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, oxo, difluoromethoxy, trifluoromethoxy,
methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl,
cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=O)p-NR9R10,
in which
represents the number 0 or 1,
R9 and R10 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or

- 208 -
R9 and R10 together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,
or
R7 and R8 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl,
pyrazolyl, imidazolyl or triazolyl ring,
in which the azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl,
pyrazolyl, imidazolyl or triazolyl ring may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, cyano,
di fluoromethyl , trifluoromethyl, 2,2,2-
trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, 1-hydroxyethyl,
cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
methoxy, ethoxy, difluoromethoxy and trifluoromethoxy,
E1 represents O, S or NR18,
in which
R18 represents hydrogen, trifluoromethyl or (C1-C4)-alkyl,

- 209 -
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, hydroxy, methoxy and
ethoxy,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond,
methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O),-OR14, -(C=O),-NR14R15, -C(=S)-
NR14R15, (C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one
another each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,

- 210 -
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl,
ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
E4 and E6 independently of one another each represent N or CR20,
in which
R20 represents hydrogen,
fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,

- 211 -
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy and trifluoromethoxy,
and in which
M represents a bond, methylene,
ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=O)r-NR14R15, -C(=S)-
NR14R15, -NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15 independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,

- 212 -
R17 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
E5 represents NR21,
in which
R21 represents hydrogen or (C1-C4)-alkyl,
in which (C1-C4)-alkyl may itself be substituted by 1 or 2
substituents each independently selected from the group of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
G1, G2, G3 and G4 independently of one another each represent N or CR22,
in which
R22 represents hydrogen, fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of
the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy and trifluoromethoxy,
and in which

- 213 -
M represents a bond, methylene,
ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=O)r-NR14R15, -C(=S)-
NR14R15, -NR14-(C=O)-OR17, oxadiazolonyl,
oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or
pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15' independently of one another
each
represent hydrogen, methyl, ethyl,
isopropyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl,
hydroxy, difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl,
isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl,

- 214 -
thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their
part may be substituted by 1 or 2 substituents
independently of one another selected from the group
consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy,
methoxy and ethoxy,
with the proviso that not more than two of the G1, G2, G3 and G4 groups
represent
nitrogen,
and
with the proviso that at least one of the G1, G2, G3 and G4 groups represents
CH,
U represents C=O, C=S or SO2,
V represents O or NR24,
in which
R24 represents hydrogen, trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-
alkenyl, (C3-C7)-cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or
benzyl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, methoxy, ethoxy, methylsulphonyl, ethylsulphonyl,
azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and morpholinyl,
in which azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and
morpholinyl for their part may be substituted by 1 or 2
substituents independently of one another selected from
the group consisting of fluorine, trifluoromethyl, 2,2-
difluoroethyl, 2,2,2-trifluoroethyl, methyl and ethyl,
in which azetidinyl, pyrrolidinyl and piperidinyl for their part may
be substituted by 1 or 2 substituents independently of one another

- 215 -
selected from the group consisting of fluorine, trifluoromethyl,
methyl, ethyl, cyclopropyl and cyclobutyl,
in which methyl and ethyl for their part may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine,
trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy,
methoxy and ethoxy,
and
in which benzyl may itself be substituted by 1 or 2 fluorine,
chlorine, trifluoromethyl, methyl, ethyl, methylsulphonyl and
ethylsulphonyl substituents,
W represents N or CR25,
in which
R25 represents hydrogen or oxo,
R23 represents hydrogen, trideuteromethyl, (C1-C6)-alkyl or (C2-C6)-
alkenyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
R25 represents hydrogen or oxo,
R22 represents hydrogen, (C1-C3)-alkoxycarbonyl or aminosulphonyl,
in which (C1-C3)-alkoxycarbonyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
R28 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, (C3-C6)-cycloalkyl
and
phenyl,

- 216 -
in which phenyl may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine, chlorine,
trifluoromethyl, (C1-C4)-alkyl, methoxy and ethoxy,
R29 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, cyclopropyl,
cyclobutyl and phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of
one another selected from the group consisting of fluorine, chlorine,
trifluoromethyl, methyl, ethyl, methoxy and ethoxy,
R30 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
R31 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy and
ethoxy,
and their salts, solvates and solvates of the salts,
except for the compounds:
2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-8-methyl-9H-purine,
2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-8-methyl-9H-purine-6-
amine,
N-butyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-8-methyl-9H-
purine-6-
amine.
3. Compound of the formula (I) according to Claim 1 or 7 in which
the ring Q represents a group of the formula

- 217 -
<IMG>
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
R1C represents hydrogen or fluorine,
A2 represents CH,
R2 represents 3,3,3-trifluoroprop-1-yl, 2,2,3,3-tetrafluoroprop-1-yl,
2,2,3,3,3-
pentafluoroprop-1-yl, phenyl, pyridyl or pyrimidinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where pyridyl and pyrimidinyl may be substituted by 1 fluorine substituent,
R3 represents a group of the formula
<IMG>
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,

- 218 -
in which
R4 represents -R5, ¨OR6 or ¨NR7R8,
in which
R5 represents trifluoromethyl or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of trifluoromethyl, cyclopropyl,
cyclobutyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-
OR9 and -C(=O)p-NR9R10,
in which
represents the number 0,
R9 and R10 independently of one another each
represent methyl, ethyl, trifluoromethyl,
2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl or
cyclobutyl,
or
R9 and R10 together with the atom(s) to which they are
respectively attached form a pyrrolidinyl,
piperidinyl, piperazinyl or morpholinyl
ring,
in which the pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its
part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino,

- 219 -
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of trifluoromethyl, cyclopropyl,
cyclobutyl, cyclopentyl, difluoromethoxy,
trifluoromethoxy, (C1-C4)-alkoxy, -(C=O)-OR9 and -
(C=O)-NR9R10,
in which
R9 and R10 independently of one another
each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,
and
in which pyrazolyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, difluoromethyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,
R8 represents (C1-C6)-alkyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of trifluoromethyl, cyclopropyl,
cyclobutyl, trifluoromethoxy, (C1-C4)-alkoxy,

- 220 -
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl,
furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl,
imidazolyl, triazolyl and pyridyl for their part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and
ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl,
trifluoromethoxy and oxo,
E1 represents NR18,
in which
R18 represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen, fluorine, difluoromethyl, trifluoromethyl,
(C1-C4)-alkyl or a group of the formula -M-R13,

- 221 -
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond, methylene, ethane-1,2-diyl or propane-
1,3-diyl,
R13 represents -(C=O)r-OR14, -(C=O)r-NR14R15, phenyl,
thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl or
pyrimidinyl,
in which
r represents the number 0 or 1,
R14 and R15
independently of one another each
represent hydrogen, methyl, ethyl,
cyclopropyl, cyclobutyl or phenyl,
in which methyl and ethyl may
additionally be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy,
trifluoromethoxy and methoxy,
and
in which phenyl, thiazolyl, triazolyl, oxadiazolyl,
thiadiazolyl and pyrimidinyl may each in turn be
substituted by 1 or 2 substituents selected independently
from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl and cyclobutylmethyl,
U represents C(=O),

- 222 -
V represents NR24,
in which
R24 represents trideuteromethyl, (C1-C6)-alkyl, cyclopropyl,
cyclobutyl, azetidin-3-yl, pyrrolidin-3-yl or piperidin-4-yl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3
substituents independently of one another selected from the group
consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl,
hydroxy, oxetanyl and morpholin-4-yl,
and
in which azetidin-3-yl, pyrrolidin-3-yl and piperidin-4-yl for their
part may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine,
trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl
and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
9. Process for preparing compounds of the formula (I) as defined in Claims
1 to 8,
characterized in that
[A] a compound of the formula (II)
<IMG>
in which R2 has the meaning given in Claims 1 to 8 and
the ring Q A represents a group of the formula

- 223 -
<IMG>
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
the ring Q1 together with the
atoms to which it is attached forms a 5- to 7-
membered saturated or partially unsaturated carbocycle or a 5- to
7-membered saturated or partially unsaturated heterocycle,
R1 represents fluorine, chlorine, methyl, hydroxy or oxo,
n represents a number 0, 1 or 2,
A1, A2, A3 and A4 independently of one
another each represent N, CH or
CR1,

- 224 -
with the proviso that not more than two of the A1, A2, A3 and A4 groups
represent
N,
is reacted in an inert solvent in the presence of a suitable base with a
compound of
the formula (III-1) or (III-2)
<IMG>
in which G1, G2, G3, G4, E1, E2 and E3 each have the meanings given in Claims
1 to
8,
to give a compound of the formula (I-A-1) or (I-A-2)
<IMG>
in which n, R1, R2, G1, G2, G3, G4, E1, E2, E3 and Q A each have the meanings
given
above,
or
[B] a compound of the formula (I-B-1) or (I-B-2)

- 225 -
<IMG>
in which n, P1, P2, R1, R2 and Q each have the meanings given in Claims 1 to
8,
is reacted in an inert solvent with a suitable nitrite to give a compound of
the
formula (I-I-3) or (I-I-4)
<IMG>
in which n, P1, P2, R1, R2 and Q each have the meanings given in Claims 1 to
8,
or
[C] a compound of the formula (I-B-1) or (I-B-2) is converted in an inert
solvent into a
compound of the formula (IV-1) or (IV-2)

- 226 -
<IMG>
in which n, P1, P2, R1, R2 and Q each have the meanings given in Claims 1 to 8
and
X2 represents bromine, iodine or chlorine,
and this is then reacted in an inert solvent, optionally in the presence of a
suitable
base, with a compound of the formula (V)
<IMG>
in which
R4 represents ¨OR6 or ¨NR7R8,
where R6, R7 and R8 each have the meanings given above,
to give a compound of the formula (I-C-1) or (I-C-2)
<IMG>
in which n, P1, P2, R1, R2, R4A and Q each have the meanings given above,

- 227 -
or
[D] a compound of the formula (VI)
<IMG>
in which n, Q, R1 and R2 each have the meanings given in Claims 1 to 8 and
T1 represents (C1-C4)-alkyl
is reacted in an inert solvent in the presence of a suitable base with a
compound of
the formula (VII)
R24A-X1 (VII)
in which
R24A represents trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C7)-
cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or benzyl,
in which (C1-C6)-alkyl, azetidinyl, pyrrolidinyl, piperidinyl and benzyl may
be substituted within the scope of the meaning given above,
and
X1 represents a suitable leaving group, for example halogen, especially
chlorine or bromine, mesylate or tosylate,
to give a compound of the formula (VIII)

- 228 -
<IMG>
in which n, Q, R1, R2 and R24A each have the meanings given above,
and this is then cyclized in an inert solvent in the presence of a suitable
base to
give a compound of the formula (I-D)
<IMG>
in which n, Q, R1, R2 and R24A each have the meanings given above,
and the resulting compounds of the formula (I) are optionally, optionally with
the
appropriate (i) solvents and/or (ii) acids or bases, converted into their
solvates, salts and/or
solvates of the salts.
10. Compound of the formula (I) as defined in any of Claims 1 to 8 for the
treatment and/or
prophylaxis of diseases.
11. Compound of the formula (I) as defined in any of Claims 1 to 8 for use
in a method for the
treatment and/or prophylaxis of heart failure, angina pectoris, hypertension,
pulmonary
hypertension, ischaemias, vascular disorders, renal insufficiency,
thromboembolic
disorders, fibrotic disorders and arteriosclerosis.

- 229 -
12. Medicament comprising a compound of the formula (I) as defined in any
of Claims 1 to 8
in combination with an inert, non-toxic, pharmaceutically suitable excipient.
13. Medicament comprising a compound of the formula (I) as defined in any
of Claims 1 to 8
in combination with a further active compound selected from the group
consisting of
organic nitrates, NO donors, cGMP-PDE inhibitors, antithrombotic agents,
hypotensive
agents and lipid metabolism modifiers.
14. Medicament according to Claim 12 or 13 for the treatment and/or
prophylaxis of heart
failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias,
vascular
disorders, renal insufficiency, thromboembolic disorders, fibrotic disorders
and
arteriosclerosis.

Description

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
A
- 1
Substituted azabicycles and use thereof
The present application relates to novel substituted azabicycles, to processes
for their preparation,
to their use alone or in combinations for the treatment and/or prophylaxis of
diseases, and to their
use for producing medicaments for the treatment and/or prophylaxis of
diseases, in particular for
the treatment and/or prophylaxis of cardiovascular disorders.
One of the most important cellular transmission systems in mammalian cells is
cyclic guanosine
monophosphate (cGMP). Together with nitrogen monoxide (NO), which is released
from the
endothelium and transmits hormonal and mechanical signals, it forms the
NO/cGMP system.
Guanylate cyclases catalyse the biosynthesis of cGMP from guanosine
triphosphate (GTP). The
representatives of this family known to date can be divided into two groups
either according to
structural features or according to the type of ligands: the particulate
guanylate cyclases which can
be stimulated by natriuretic peptides, and the soluble guanylate cyclases
which can be stimulated
by NO. The soluble guanylate cyclases consist of two subunits and very
probably contain one
haem per heterodimer, which is part of the regulatory centre. This is of
central importance for the
activation mechanism. NO can bind to the iron atom of haem and thus markedly
increase the
activity of the enzyme. Haem-free preparations cannot, by contrast, be
stimulated by NO. Carbon
monoxide (CO) is also able to bind to the central iron atom of haem, but the
stimulation by CO is
much less than that by NO.
By forming cGMP, and owing to the resulting regulation of phosphodiesterases,
ion channels and
protein kinases, guanylate cyclase plays an important role in various
physiological processes, in
particular in the relaxation and proliferation of smooth muscle cells, in
platelet aggregation and
platelet adhesion and in neuronal signal transmission, and also in disorders
which are based on a
disruption of the aforementioned processes. Under pathophysiological
conditions, the NO/cGMP
system can be suppressed, which can lead, for example, to hypertension,
platelet activation,
increased cell proliferation, endothelial dysfunction, arteriosclerosis,
angina pectoris, heart failure,
myocardial infarction, thromboses, stroke and sexual dysfunction.
Owing to the expected high efficiency and low level of side effects, a
possible NO-independent
treatment for such disorders by targeting the influence of the cGMP signal
pathway in organisms is
a promising approach.
Hitherto, for the therapeutic stimulation of the soluble guanylate cyclase,
use has exclusively been
made of compounds such as organic nitrates whose effect is based on NO. The
latter is formed by
bioconversion and activates soluble guanylate cyclase by attack at the central
iron atom of haem.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
4
- 2 -
In addition to the side effects, the development of tolerance is one of the
crucial disadvantages of
this mode of treatment.
In recent years, some substances have been described which stimulate soluble
guanylate cyclase
directly, i.e. without prior release of NO, such as, for example, 3-(5'-
hydroxymethy1-2'-fury1)-1-
benzylindazole [YC-1; Wu et al., Blood 84 (1994), 4226; Miilsch et al., Brit.
J PharmacoL 120
(1997), 681], fatty acids [Goldberg et al., J. Biol. Chem. 252 (1977), 1279],
diphenyliodonium
hexafluorophosphate [Pettibone et al., Eur. I PharmacoL 116 (1985), 307],
isoliquiritigenin [Yu
et al., Brit. J. Pharmacol 114 (1995), 1587] and various substituted pyrazole
derivatives (WO
98/16223).
As stimulators of soluble guanylate cyclase, WO 00/06569 discloses fused
pyrazole derivatives,
and WO 01/083490 a fused aminopyridine derivative. WO 2010/065275 discloses
pyrrolopyrimidones as activators of soluble guanylate cyclase.
It was an object of the present invention to provide novel substances which
act as stimulators of
soluble guanylate cyclase and which have an identical or improved therapeutic
profile compared to
the compounds known from the prior art, for example with respect to their in
vivo properties such
as their pharmacokinetic and pharmacodynamic behaviour and/or their metabolic
profile and/or
their dose-effect relationship.
The present invention provides compounds of the general formula (I)
R2
(R1),,
R3
(I)
in which
the ring Q represents 8- or 9-membered heteroaryl,
R1 represents fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, (C1-C4)-alkyl, (C3-
C7)-cycloalkyl or (C1-C4)-alkoxy,
represents a number 0, 1 or 2,
R2 represents trifluoromethyl, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, phenyl or
5- or 6-membered
heteroaryl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
4
=
- 3 -
where (C1-C6)-alkyl is substituted by a substituent selected from the group
consisting of
difluoromethyl and trifluoromethyl,
where (Ci-C6)-alkyl may be substituted by 1 to 3 fluorine substituents,
where (C3-C8)-cycloalkyl may be substituted by 1 or 2 substituents
independently of one
another selected from the group consisting of fluorine, methyl and methoxy,
where phenyl is substituted by 1 to 3 fluorine substituents,
where phenyl may be substituted by 1 or 2 substituents independently of one
another
selected from the group consisting of methyl and methoxy,
and
where 5- and 6-membered heteroaryl may be substituted by 1 or 2 substituents
selected
independently of one another from the group consisting of fluorine,
trifluoromethyl and
methyl,
R3 represents a group of the formula
## ##
----1-- '...-1-
µµ N \\
or
,
pi P2
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,
in which
R4 represents -R5, ¨0R6 or ¨NR7R8,
in which

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 4 -
R5 represents hydrogen, halogen, cyano, (CI-CO-alkyl,
(C2-C4)-
alkynyl, (C1-C4)-alkylcarbonyl or (Ci-C4)-alkoxycarbonyl,
in which (C1-C6)-alkyl and (C2-C4)-alkynyl for their part may be
substituted by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, (C1-C6)-alkyl, (C3-
C6)-cycloallcyl,
difluoromethoxy, trifluoromethoxy, oxo -(CO)p-OR9, -C(-0)p-
NR9R1o, _
NR9 -(C=0)-11.10, -NR9-(C=0)-0R10, -NR9-(C=0)-
NR10- _
NR9-S02-Rio, _s(o)q_Ri2 and -S02-NR9Rio,
R6 represents hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl, 4- to 7-
membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl,
in which (C1-C6)-alkyl, (C3-C7)-cycloalkyl, 4- to 7-membered
heterocyclyl, phenyl or 5- or 6-membered heteroaryl may be
substituted by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, (C1-C6)-alkyl, (C3-
C6)-cycloalkyl,
difluoromethoxy, trifluoromethoxy, oxo -C(---
0)p-
NR9R1 , -NR9-(C=0)-R3 , -NR9-(C=0)-0R10, -NR9-(C=0)-
NRio- _
NR9-S02-R10, -S(0)q-R12 and -S02-
NR9Rio,
R7 represents hydrogen or (C1-C4)-alkyl,
R8 represents hydrogen, (C1-C6)-alkyl, (C3-C7)-
cycloalkyl, 4- to 7-
membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl,
in which (Ci-C6)-alkyl, (C3-C7)-cycloalkyl, 4- to 7-membered
heterocyclyl, phenyl or 5- or 6-membered heteroaryl may be
substituted by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, (C1-C6)-alkyl, (C3-
C7)-cycloalkyl,
difluoromethoxy, trifluoromethoxy, oxo, -(CO)p-OR9, -(C=0)p-
NR9R1 , -NR9-(C=0)-R1 , -NR9-(C=0)-01e, -NR9-(C=0)-
_
NR9 -S02-R1 , -S(0)q-R12, -S02-
NR9R1 , phenyl, 4- to 7-
membered heterocyclyl and 5- or 6-membered heteroaryl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
a
a
- 5 -
in which in each case
P represents the number 0
or 1,
q represents the number
0, 1 or 2,
R9, le and Rll independently of one another each
represent hydrogen, (C1-C6)-alkyl or (C3-
C8)-cycloalkyl,
in which (C1-C6)-alkyl for its part may be
substituted by 1 or 2 substituents
independently of one another selected
from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, hydroxy,
(C1-C6)-alkoxy,
difluoromethoxy,
trifluoromethoxy,
(C1-C6)-
alkoxycarbonyl, amino, mono-(C1-C6)-
allcylamino, di-(C1-C6)-alkylamino and 4-
to 7-membered heterocyclyl,
or
R9 and RI
together with the atom(s) to which they are
respectively attached form a 4- to 7-
membered heterocycle,
in which the 4- to 7-membered heterocycle
for its part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, cyano, trifluoromethyl, (C1-C6)-
alkyl, hydroxy, oxo, (C1-C6)-alkoxy,
trifluoromethoxy, (C1-C6)-alkoxycarbonyl,
amino, mono-(C1-C6)-alkylamino and di-
(C1-C6)-allcylamino,
or

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
- 6 -
RI and R"
together with the atom(s) to which they are
respectively attached form a 4- to 7-
membered heterocycle,
in which the 4- to 7-membered heterocycle
for its part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
fluorine, cyano, trifluoromethyl, (C1-C6)-
alkyl, hydroxy, oxo, (C1-C6)-alkoxY,
trifluoromethoxy, (Ci-C6)-alkoxycarbonyl,
amino, mono-(C1-C6)-allcylamino and di-
(C1-C6)-alkylamino,
and in which
R12 represents (C1-C6)-alkyl or (C3-
C7)-cycloallcyl,
or in which
R7 and R8
together with the nitrogen atom to which they are attached
form a 4- to 7-membered heterocycle or 5- or 6-membered
heteroaryl,
in which the 4- to 7-membered heterocycle and the 5- or 6-
membered heteroaryl may be substituted by 1 to 3
substituents independently of one another selected from
the group consisting of fluorine, cyano, difluoromethyl,
trifluoromethyl, (Ci-C6)-alkyl,
(C3-C7)-cycloalkyl,
hydroxy, oxo, (C1-C6)-alkoxy, difluoromethoxY,
trifluoromethoxy, (C/-C6)-alkoxycarbonyl, amino, mono-
(C1-C6)-allcylamino and di-(C1-C6)-alkylamino,
and
in which all (C1-C4)-alkyl, (C1-C6)-alkyl, (C3-C8)-cycloallcyl and 4-
to 7-membered heterocyclyl groups mentioned above, unless stated
otherwise, may each independently of one another additionally be
substituted by 1 to 3 substituents independently of one another

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
µ
- 7 -
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, (C3-C7)-cycloallcyl, hydroxy, difluoromethoxy,
trifluoromethoxy, (C1-C4)-alkoxy, hydroxycarbonyl, (C1-C4)-
alkoxycarbonyl, amino, phenyl, 4- to 7-membered heterocyclyl and
5- or 6-membered heteroaryl,
the ring P1
represents 5- to 7-membered heterocyclyl, phenyl or 5- or 6-membered
heteroaryl,
in which 5- to 7-membered heterocyclyl, phenyl and 5- or 6-membered
heteroaryl may be substituted by 1 to 3 substituents independently of one
another selected from the group consisting of halogen, cyano,
difluoromethyl, trifluoromethyl, trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-
alkenyl, (C3-C7)-cycloalkyl, oxo, difluoromethoxy, trifluoromethoxy,
thiooxo and a group of the formula -M-R13,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl,
(C3-C7)-cycloalkyl,
difluoromethoxy and trifluoromethoxy,
the ring P2 represents 5-membered heteroaryl,
in which 5-membered heteroaryl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
halogen, cyano, difluoromethyl, trifluoromethyl, trideuteromethyl, (C1-C6)-
alkyl, (C2-C6)-alkenyl, (C3-C7)-cycloalkyl, oxo, difluoromethoxy,
trifluoromethoxy, thiooxo and a group of the formula -M-R13,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
selected independently of one another from the group consisting of
fluorine, cyano, trifluoromethyl,
(C3-C7)-cycloalkyl,
difluoromethoxy and trifluoromethoxy,
and in which in each case
M represents a bond or (C1-C4)-
alkanediyl,

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 8 -
R13 represents -(C=0),-OR14, -(C=0),-NR14R15, _C(=S)-
Nee, _NR14-
(C=0)-0R17, -NR14-
(C=0)_NR15R16, _
NR14-S02-NR15R16, _NR14-S02-R17, -
S(0),-R17, ¨S02-NR14'-'K15, 4- to 7-membered heterocyclyl,
phenyl, benzyl or 5- or 6-membered heteroaryl,
in which
represents the number 0 or 1,
represents the number 0, 1 or 2,
R14, R15 and R16
independently of one another each
represent hydrogen, (C1-C6)-alkyl,
(C3-C8)-cycloallcyl, 4- to 7-
membered heterocyclyl, phenyl,
benzyl or 5- or 6-membered
heteroaryl,
or
R14 and le
together with the atom(s) to which they are
respectively attached form a 4- to 7-
membered heterocycle,
in which the 4- to 7-membered heterocycle
for its part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
cyano, trifluoromethyl, (Ci-C6)-alkyl,
hydroxy, oxo, (C1-
C6)-alkoxy,
trifluoromethoxy, (C1-C6)-alkoxycarbonyl,
amino, mono-(C1-C6)-allcylamino and di-
(C1-C6)-alkylamino,
or

CA
BHC 12 1 012-Foreign Countries 02866213 2014-09-03
- 9 -
R14 and R15
together with the atom(s) to which they are
respectively attached form a 4- to 7-
membered heterocycle,
in which the 4- to 7-membered heterocycle
for its part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
cyano, trifluoromethyl, (C1-C6)-alkyl,
hydroxy, oxo, (Ci-
C6)-alkoxy,
trifluoromethoxy, (C1-C6)-alkoxycarbonyl,
amino, mono-(C1-C6)-alkylarnino and di-
(C1-C6)-alkylamino,
R17 represents (Ci-C6)-alkyl or (C3-C7)-
cycloalkyl,
or
R14 and R17 together with the atom(s) to which
they are
respectively attached form a 4- to 7-
membered heterocycle,
in which the 4- to 7-membered heterocycle
for its part may be substituted by 1 or 2
substituents independently of one another
selected from the group consisting of
cyano, trifluoromethyl, (C i-
C6)-alkyl,
hydroxy, oxo, (C1-
C6)-alkoxy,
trifluoromethoxy, (CI-C6)-alkoxycarbonyl,
amino, mono-(C1-C6)-alkylamino and di-
(C1-C6)-alkylamino,
and
in which 4- to 7-membered heterocyclyl, phenyl, benzyl
and 5- or 6-membered heteroaryl for their part may be
substituted by 1 to 3 substituents independently of one
another selected from the group consisting of halogen,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
k
- 10 -
cyano, difluoromethyl, trifluoromethyl, (C1-C6)-alkyl, (C3-
C7)-cycloalkyl, hydroxy, oxo, thioxo and (C1-C4)-alkoxy,
and
in which the (C1-C4)-alkyl, (C1-C6)-alkyl, (C3-C8)-cycloalkyl and 4-
to 7-membered heterocyclyl groups mentioned above, unless stated
otherwise, may each independently of one another additionally be
substituted by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, (C 1-C6)-alkyl, (C3-C7)-cycloalkyl, hydroxy,
difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy,
hydroxycarbonyl, (C1-C4)-alkoxycarbonyl, amino, phenyl, 4- to 7-
membered heterocyclyl and 5- or 6-membered heteroaryl,
and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-
oxides or salts thereof,
except for the compounds:
2 -[1-(2-fluorobenzy1)-1H-pyrazolo [3,4-1)] pyridin-3 -yl] -8-methy1-9H-
purine,
241-(2-fluorobenzy1)-1H-pyrazolo [3,4-1)] pyri din-3-y1]-8-methy1-9H-purine-6-
amine,
N-butyl-2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-8-methy1-9H-
purine-6-amine.
Compounds according to the invention are the compounds of the formula (I) and
their salts,
solvates and solvates of the salts, the compounds, comprised by formula (I),
of the formulae
mentioned below and their salts, solvates and solvates of the salts and the
compounds comprised
by formula (I), mentioned below as working examples, and their salts, solvates
and solvates of the
salts, if the compounds, comprised by formula (I), mentioned below are not
already salts, solvates
and solvates of the salts.
Preferred salts in the context of the present invention are physiologically
acceptable salts of the
compounds according to the invention. Also encompassed are salts which are not
themselves
suitable for pharmaceutical applications but can be used, for example, for
isolation or purification
of the compounds according to the invention.
Physiologically acceptable salts of the compounds according to the invention
include acid addition
salts of mineral acids, carboxylic acids and sulphonic acids, for example
salts of hydrochloric acid,
hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid,
ethanesulphonic acid,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 11 -
toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid,
formic acid, acetic
acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic
acid, citric acid, fumaric
acid, maleic acid and benzoic acid.
Physiologically acceptable salts of the compounds according to the invention
also include salts of
procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine
and N-
methylpiperidine.
In the context of the invention, solvates refer to those forms of the
compounds according to the
invention which, in the solid or liquid state, form a complex by coordination
with solvent
molecules. Hydrates are a specific form of solvates in which the coordination
is with water.
The compounds according to the invention may, depending on their structure,
exist in different
stereoisomeric forms, i.e. in the form of configurational isomers or else
optionally as
conformational isomers (enantiomers and/or diastereomers, including those in
the case of
atropisomers). The present invention therefore encompasses the enantiomers and
diastereomers,
Where the compounds according to the invention can occur in tautomeric forms,
the present
The present invention also encompasses all suitable isotopic variants of the
compounds according
to the invention. An isotopic variant of a compound according to the invention
is understood here
to mean a compound in which at least one atom within the compound according to
the invention
has been exchanged for another atom of the same atomic number, but with a
different atomic mass
(deuterium), 314 (tritium), 13C, 14c, 15N, 170, 180, 32F, 33F, 33s, 34s, 35s,
36s, 18F, 36c1, 82Br, 1231, 1241,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 12 -
1291 and 1311. Particular isotopic variants of a compound according to the
invention, especially those
in which one or more radioactive isotopes have been incorporated, may be
beneficial, for example,
for the examination of the mechanism of action or of the active ingredient
distribution in the body;
due to comparatively easy preparability and detectability, especially
compounds labelled with 3I-1
or 14C isotopes are suitable for this purpose. Furthermore, the incorporation
of isotopes, for
example of deuterium, can lead to particular therapeutic advantages as a
consequence of greater
metabolic stability of the compound, for example an extension of the half-life
in the body or a
reduction in the active dose required; such modifications of the compounds
according to the
invention may therefore, in some cases, also constitute a preferred embodiment
of the present
invention. Isotopic variants of the compounds according to the invention can
be prepared by the
processes known to those skilled in the art, for example by the methods
described below and the
procedures described in the working examples, by using corresponding isotopic
modifications of
the respective reagents and/or starting compounds.
Moreover, the present invention also encompasses prodrugs of the compounds
according to the
invention. Here, the term "prodrugs" refers to compounds which for their part
can be biologically
active or inactive, but are converted (for example metabolically or
hydrolytically) into compounds
according to the invention during their dwell time in the body.
In the context of the present invention, the substituents, unless specified
otherwise, are each
defined as follows:
Alkyl in the context of the invention is a straight-chain or branched alkyl
radical having the
number of carbon atoms specified in each case. The following may be mentioned
by way of
example and by way of preference: methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, 1-
methylpropyl, tert-butyl, n-pentyl, isopentyl, 1-ethylpropyl, 1-methylbutyl, 2-
methylbutyl, 3-
methylbutyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-
methylpentyl, 3,3-
dimethylbutyl, 1-ethylbutyl and 2-ethylbutyl.
Cycloalkyl or carbocycle in the context of the invention is a monocyclic
saturated alkyl radical
having the number of carbon atoms specified in each case. The following may be
mentioned by
way of example and by way of preference: cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl and
cycloheptyl.
5- to 7-membered saturated or partly unsaturated carbocycle in the context of
the present invention
is a saturated or partly unsaturated cyclic alkyl radical having the number of
carbon atoms
specified in each case. The following may be mentioned by way of example and
by way of
preference: cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl
and cycloheptenyl.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
,
- 13 -
Alkanediy1 in the context of the invention is a straight-chain or branched
divalent alkyl radical
having 1 to 4 carbon atoms. The following may be mentioned by way of example
and by way of
preference: methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl,
propane-1,1-diyl,
propane-1,2-diyl, propane-2,2-diyl, butane-1,4-diyl, butane-1,2-diyl, butane-
1,3-diy1 and butane-
2,3-diyl. Preference is given to: methylene, ethane-1,2-diyl, propane-1,3-diy1
and butane-1,4-diyl.
Alkenyl in the context of the invention is a straight-chain or branched
alkenyl radical having 2 to 6
or 2 to 4 carbon atoms and a double bond. The following may be mentioned by
way of example
and by way of preference: vinyl, allyl, isopropenyl and n-but-2-en-l-yl.
Alkynyl in the context of the invention is a straight-chain or branched
alkynyl radical having 2 to 4
carbon atoms and one triple bond. The following may be mentioned by way of
example and by
way of preference: ethynyl, n-prop-1-yn-1-yl, n-prop-2-yn-l-yl, n-but-2-yn-1-
y1 and n-but-3-yn-1-
Yl=
Alkoxy in the context of the invention is a straight-chain or branched alkoxy
radical having 1 to 6
or 1 to 4 carbon atoms. The following may be mentioned by way of example:
methoxy, ethoxy, n-
propoxy, isopropoxy, 1-methylpropoxy, n-butoxy, iso-butoxy, tert-butoxy, n-
pentoxy, isopentoxy,
1-ethylpropoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy and n-hexoxy.
Preference is
given to a linear or branched alkoxy radical having 1 to 4 carbon atoms. The
following may be
mentioned by way of example and by way of preference: methoxy, ethoxy, n-
propoxy, isopropoxy,
1-methylpropoxy, n-butoxy, isobutoxy and tert-butoxy.
Alkylcarbonyl in the context of the invention is a linear or branched alkyl
radical having 1 to 6 or 1
to 4 carbon atoms and a carbonyl group attached in the 1 position. The
following may be
mentioned by way of example and by way of preference: methylcarbonyl,
ethylcarbonyl, n-
propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl and tert-
butylcarbonyl.
Alkoxycarbonyl in the context of the invention is a straight-chain or branched
alkoxy radical
having 1 to 6 or 1 to 4 carbon atoms and a carbonyl group attached to the
oxygen. The following
may be mentioned by way of example and by way of preference: methoxycarbonyl,
ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.
Monoalkylamino in the context of the invention is an amino group having a
straight-chain or
branched alkyl substituent having 1 to 6 carbon atoms. The following may be
mentioned by way of
example and by way of preference: methylamino, ethylamino, n-propylamino,
isopropylamino and
tert-butylamino.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
=
- 14 -
Dialkylamino in the context of the invention is an amino group having two
identical or different,
straight-chain or branched alkyl substituents each having 1 to 6 carbon atoms.
The following may
be mentioned by way of example and by way of preference: /V,N-dimethylamino,
N,N-
diethylamino, N-ethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-
propylamino,
N-tert-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-
methylamino.
5- to 7-membered saturated or partly unsaturated heterocycle in the context of
the invention is a
saturated or partly unsaturated heterocycle which has a total of 5 to 7 ring
atoms and contains one
ring heteroatom from the group of N, 0, S, SO and/or SO2. The following may be
mentioned by
way of example: pyrrolidinyl, tetrahydrofuranyl, piperidinyl,
tetrahydropyranyl, dihydropyrrolyl,
dihydropyridyl.
Heterocyclyl or heterocycle in the context of the invention is a saturated
heterocycle which has a
total of 4 to 7 ring atoms and contains one or two ring heteroatoms from the
group consisting of N,
0, S, SO and/or SO2. The following may be mentioned by way of example:
azetidinyl, oxetanyl,
pyrrolidinyl, pyrazolidinyl, imidazolinyl, tetrahydrofuranyl, piperidinyl,
piperazinyl,
tetrahydropyranyl, morpholinyl, thiomorpholinyl and dioxidothiomorpholinyl.
Preference is given
to azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl,
tetrahydropyranyl and
morpholinyl.
5- or 6-membered heteroaryl in the context of the invention is a monocyclic
aromatic heterocycle
(heteroaromatic) which has a total of 5 or 6 ring atoms, contains up to three
identical or different
ring heteroatoms from the group consisting of N, 0 and/or S and is attached
via a ring carbon atom
or optionally via a ring nitrogen atom. The following may be mentioned by way
of example and by
way of preference: furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl,
oxazolyl, isoxazolyl,
isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl,
pyridazinyl, pyrazinyl and
triazinyl. Preference is given to: pyrazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl.
8- or 9-membered heteroaryl in the context of the invention is a bicyclic
aromatic or partly
unsaturated heterocycle which has a total of 8 or 9 ring atoms and contains at
least two nitrogen
atoms and up to two further, identical or different ring heteroatoms from the
group of N, 0 and/or
S. The following may be mentioned by way of example: dihydrothienopyrazolyl,
thienopyrazolyl,
pyrazolopyrazolyl, imidazothiazolyl, tetrahydrocyclopentapyrazolyl,
dihydrocyclopentapyrazolyl,
tetrahydroindazolyl, dihydroindazolyl, indazolyl, pyrazolopyridinyl,
tetrahydropyrazolopyridinyl,
pyrazolopyrimidinyl, imidazopyridinyl and imidazopyridazinyl.

BHC 12 1 012-Foreign CountriescA 02866213 2014-09-03
4.
4
- 15 -
Halogen in the context of the invention is fluorine, chlorine, bromine and
iodine. Preference is
given to fluorine and chlorine.
An oxo group in the context of the invention is an oxygen atom attached to a
carbon atom via a
double bond.
A thiooxo group in the context of the invention is a sulphur atom attached via
a double bond to a
carbon atom.
In the formula of the group that Q or R3 may represent, the end point of the
line marked by the
symbol *, ** or ## does not represent a carbon atom or a CH2 group but is part
of the bond to the
respective atom to which Q or R3 is attached.
If radicals in the compounds according to the invention are substituted, the
radicals may be mono-
or polysubstituted, unless specified otherwise. In the context of the present
invention, all radicals
which occur more than once are defined independently of one another.
Substitution by one, two or
three identical or different substituents is preferred.
In the context of the present invention, the term "treatment" or "treating"
includes inhibition,
retardation, checking, alleviating, attenuating, restricting, reducing,
suppressing, repelling or
healing of a disease, a condition, a disorder, an injury or a health problem,
or the development, the
course or the progression of such states and/or the symptoms of such states.
The term "therapy" is
understood here to be synonymous with the term "treatment".
The terms "prevention", "prophylaxis" or "preclusion" are used synonymously in
the context of the
present invention and refer to the avoidance or reduction of the risk of
contracting, experiencing,
suffering from or having a disease, a condition, a disorder, an injury or a
health problem, or a
development or progression of such states and/or the symptoms of such states.
The treatment or prevention of a disease, a condition, a disorder, an injury
or a health problem may
be partial or complete.
Preference is given in the context of the present invention to compounds of
the formula (I) in
which
the ring Q represents a group of the formula

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
=
- 16-
*
RiAr.A1.1 fµf
1
A2 il..====µ A2'.'"\N
N N .....*
13 I / N 1 3 ...t....<N
I / A4 -----
=Ak4" AA4 N
\
** , ** ,
,
(a-1-1) (b-1-1) (c-1)
*
Az'Ai.-.%( (R1).. N
i----------4
1 3 i N N I µ N N N
ii141'N< \ i
N------"N(R 1 > =(.%---.Ni
),,
\ \
, ,
(d-1) (e-1) (f-1)
(R1), .j
(Ri)ne---N4
.. .j., N Saµ
S
N I \ N
N S N
\ \
(g-1) (h-1) (i-1)
* *
1 /
(R ), .....y.... S.:.:, N
S
, \
N I \ N (R1), Q1 I N
--\õ:01.---.., / / /
N (Ri)n N
1 \
**
(j-1) (k-1) (1-1)
N4
(R1) Q1 I \/N (Ri)n Qi N oder (R1)n
N
\
**
,
(m-1) (n-1) (o-1)
where
* represents the point of attachment to -CH2-R2,

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
t
,
- 17 -
** represents the point of attachment to R3,
the ring Qi together with the atoms to which it is attached
forms a 5- to 7-membered saturated
or partially unsaturated carbocycle or a 5- to 7-membered saturated or
partially
unsaturated heterocycle,
R' represents fluorine, chlorine, methyl, hydroxy or oxo,
le\ represents hydrogen or methyl,
n represents a number 0, 1 or 2,
A', A2, A3 and A4 independently of one another each represent
N, CH or CR1,
with the proviso that not more than two of the Al, A2, A3 and A4 groups
represent N,
R2 represents trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoroprop-1-yl,
2,2,3,3-
tetrafluorprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyl,
cyclopentyl,
cyclohexyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl
and pyridazinyl may be substituted by 1 or 2 fluorine substituents,
R3 represents a group of the formula

BHC 12 1 012-Foreign CountriescA 02866213 2014-09-03
v
=
- 18 -
*Pit *it
/L /L. ./L
N '... L N L N L
I 1
/ly g y m
E 1 E3
\ 3 \\ E\4);,--
E2=E E2_E1 E5_E6
,
...L...), .),
N L
N L
N L
I 1 I I
GlY R23
N M HNr., A
II \
,1µ1
G2 , 4 U --V R25 W R27
G3-G
a *it
.,L, ..L,
N L N L N L
HN
..II. A (I ,., A HN .......
A
I
N0
OjyN , N
,
R28 ' H R29
## ##
NI ."..Lin .....1......,
jiin
Or H R
31 ....k.'
0 ;El 21M0 0
R3
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
r
,
- 19 -
in which
R4 represents -1e, ¨0R6 or ¨NR7R8,
in which
R5
represents hydrogen, chlorine, cyano, (Ci-C4)-alkyl or (C2-C4)-
allcynyl,
in which (C1-C4)-alkyl and (C2-C4)-allcynyl for their part may be
substituted by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9 and -C(=0)p-
N-R9Rio,
in which
P represents the number 0,
R9 and le
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and RI together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
V
- 20 -
methylamino, ethylamino, dimethylamino and
diethylamino,
R6 represents (C1-C6)-alkyl, cyclopropyl,
cyclobutyl, cyclopentyl,
oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R1 and -NR9-(C=0)-le,
and
in which cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl,
thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or
pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, difluoromethoxy, trifluoromethoxy, oxo, -
(CO)p-OR9 and ¨(C=O)p-NR9Rio,
in which in each case
P represents the number 0 or 1,
R9 and RI
independently of one another each represent
hydrogen, methyl, ethyl,
isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 21 -
R9 and le
together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl
or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
R7 represents hydrogen, methyl or ethyl,
R8
represents hydrogen, (CI-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (Ci-C6)-alkyl, cyclopropyl, cyclobutyl and cyclopentyl
are substituted by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl methyl, ethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R1 , -NR9-(C=0)-R' , oxetanyl,
azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, furanyl, pyrazolyl, imidazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl and
pyrimidinyl,
in which
p represents the number 0 or 1,

CA 02866213 2014-09-03
BHC 12 1 012-Foreign Countries
v
l
- 22 -
R9 and le independently of one
another each
represent hydrogen, methyl, ethyl,
isopropyl,
trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and le together with the
atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, furanyl, pyrazolyl, imidazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl for their part may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, chlorine,
cyano, difluoromethyl, trifluoromethyl, methyl, ethyl,
cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and

CA 02866213 2014-09-03
BHC 12 1 012-Foreign Countries
- 23 -
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl
and pyrimidinyl may be substituted by 1 to 3 substituents independently of
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=0)p-
NR9Rio,
in which
p represents the number 0 or 1,
R9 and le
independently of one another each represent
hydrogen, methyl, ethyl,
isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and le
together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
or
R7 and R8 together with the
nitrogen atom to which they are attached form an
azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
V
- 24 -
dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl, imidazolyl
or triazolyl ring,
in which the azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl,
dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl, irnidazoly1
or triazolyl ring may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, cyano, difluoromethyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, ethyl, 1-
hydroxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
methoxy, ethoxy, difluoromethoxy and trifluoromethoxy,
E1 represents 0, S or NRI8,
in which
R18
represents hydrogen, trifluoromethyl or (Ci-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
E2 represents N,
represents N or CR19,
in which
R19 represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-1,2-
diy1 or propane-1,3-diyl,

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 25 -
1e3 represents -(C=0),-0R14, -(C=0)r-
NR14R15, _c(=s)_NR14R15,
NR14-(C=0)-0R17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
represents the number 0 or 1,
R14 and R15
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy,
ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
le7 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 26 -
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
V` and E6 independently of one another each represent N or CR20
,
in which
Rzo
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-
1,2-diy1 or propane-1,3-diyl,
R13 represents -(C=0),-OR14, -(C=0),-
NR14R15, _c(=s)_NR14R15, _
NR14-(C=0)-OR17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R" independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 27 -
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy,
ethoxy,
hydroxycarbonyl,
methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
E5 represents NR21,
in which
R2' represents hydrogen or (C1-C4)-alkyl,
in which (C1-C4)-alkyl may itself be substituted by 1 or 2 substituents each
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
G', G2, G3 and G4 independently of one another each represent N or CR22,
in which
R22
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R13,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
r
1
- 28 -
in which (Ci-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-
1,2-diy1 or propane-1,3-diyl,
R13
represents -(C=0),-OR14, -(C=0),-NRHR15, -C(=S)-NR14R15, _
NR14-(C=0)-0R17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl,
methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 29 -
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
with the proviso that not more than two of the GI, G2, G3 and G4 groups
represent nitrogen,
and
with the proviso that at least one of the GI, G2, G3 and G4 groups represents
CH,
represents C=0, C---S or SO2,
V represents 0 or NR24,
in which
R24
represents hydrogen, trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-
C7)-cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or benzyl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy,
ethoxy, methylsulphonyl, ethylsulphonyl, azetidinyl, oxetanyl,
pyrrolidinyl, piperidinyl and morpholinyl,
in which azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and
morpholinyl for their part may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,
methyl and ethyl,
in which antidinyl, pyrrolidinyl and piperidinyl for their part may be
substituted by 1 or 2 substituents independently of one another selected

CA 02866213 2014-09-03
BHC 12 1 012-Foreign Countries
,
,
- 30 -
from the group consisting of fluorine, trifluoromethyl, methyl, ethyl,
cyclopropyl and cyclobutyl,
in which methyl and ethyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, trifluoromethyl, cyclopropyl,
cyclobutyl, hydroxy, methoxy and ethoxy,
and
in which benzyl may itself be substituted by 1 or 2 fluorine, chlorine,
trifluoromethyl, methyl, ethyl, methylsulphonyl and ethylsulphonyl
substituents,
W represents N or CR25,
in which
R25 represents hydrogen or oxo,
R23 represents hydrogen, trideuteromethyl, (C1-C6)-
alkyl or (C2-C6)-alkenyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
R25 represents hydrogen or oxo,
R27 represents hydrogen, (C1-C3)-alkoxycarbonyl or
aminosulphonyl,
in which (C1-C3)-alkoxycarbonyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of fluorine,
trifluoromethyl, hydroxy, methoxy and ethoxy,
R28 represents hydrogen, trifluoromethyl, (C i-C4)-
alkyl, (C3-C6)-cycloalkyl and phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine, chlorine,
trifluoromethyl,
(C1-C4)-alkyl, methoxy and ethoxy,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
s
- 31 -
R29 represents hydrogen, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl and
phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine, chlorine,
trifluoromethyl,
methyl, ethyl, methoxy and ethoxy,
R3 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
R3' represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
and their salts, solvates and solvates of the salts.
Particular preference is given in the context of the present invention to
compounds of the formula
(I) in which
the ring Q represents a group of the formula
* *
RIB
R 1 C
\ N
I / N N
0 N
** **
'
(a-1-1) (b-1-1) (c-1-1)
* * *
....? or
CqiN
**
'
(C-1-2) (d-1)
(1-1-1)

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 32 -
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
RiA
represents hydrogen or methyl,
RIB represents hydrogen or fluorine,
Ric represents hydrogen or chlorine,
AI represents N or CH,
R2 represents 3,3,3-trifluoroprop-1-yl, 2,2,3,3-tetrafluoroprop-1-yl,
2,2,3,3,3-pentafluoroprop-
1-yl, phenyl or pyridyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where pyridyl may be substituted by 1 fluorine substituent,
R3 represents a group of the formula
## 4 4 #1
N1 N
or
23
R
E2 3 U --V
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4 represents -le, ¨0R6 or ¨NR7R8,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 33 -
in which
R5 represents hydrogen or (Ci-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, -(C=O)p-OR9 and -C(=0)p- RNR9 io,
in which
P represents the number 0,
R9 and R' independently of one another each
represent
hydrogen, methyl, ethyl, trifluoromethyl, 2,2,2-
trifluoroethyl,
1,1,2,2,2-pentafluoroethyl,
cyclopropyl or cyclobutyl,
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, -(C=O)p-OR9 and -C(=0)p-NR9R1 ,
in which
P represents the number 0 or 1,
R9 and le independently of one another each
represent
hydrogen or methyl,
or
R9 and le together with the atom(s) to which they
are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
.
- 34 -
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
and
in which pyrazolyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,
R8 represents hydrogen, (Ci-C6)-alkyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, trifluoromethoxy, -(C=O)p-OR9, -(C---0)p-NR9R10
,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl, furanyl,
pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which
P represents the number 0 or
1,
R9 and le independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl,
2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,
and

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 35 -
in which tetrahydrofuranyl,
pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl,
triazolyl and pyridyl for their part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of fluorine, chlorine, cyano,
difluoromethyl, trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl
and pyrimidinyl may be substituted by 1 to 3 substituents independently of
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl and trifluoromethoxy,
represents NR18,
in which
Ris represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen, fluorine, difluoromethyl,
trifluoromethyl, (CI-C4)-
alkyl or a group of the formula -M-R13,
in which (CI-CO-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond, methylene, ethane-1,2-diy1 or
propane-1,3-diyl,

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 36 -
Rn
represents -(C=0),--0e, -(C=0)1-NR14R15, phenyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl,
in which
represents the number 0 or 1,
e and le independently of one another
each represent
hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl
or phenyl,
in which methyl and ethyl may additionally be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, difluoromethyl,
trifluoromethyl,
cyclopropyl, cyclobutyl,
hydroxy,
trifluoromethoxy and methoxy,
and
in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and
pyrimidinyl may each in turn be substituted by 1 or 2 substituents
selected independently of one another from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl,
2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl,
cyclobutyl, cyclopropylmethyl and cyclobutylmethyl,
represents C(----0),
V represents NR24,
in which
R24 represents trideuteromethyl, (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
azetidin-3-yl, pyrrolidin-3-y1 or piperidin-4-yl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, oxetanyl and
morpholin-4-yl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
,
- 37 -
and
in which azetidin-3-yl, pyrrolidin-3-y1 and piperidin-4-y1 for their part may
be substituted by 1 or 2 substituents independently of one another selected
from the group consisting of fluorine, trifluoromethyl, 2,2-difluoroethyl,
2,2,2-trifluoroethyl, cyclopropyl and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
Preference is given in the context of the present invention to compounds of
the formula (I) in
which
the ring Q represents a group of the formula
*
2
R 4:11,õri 2 41 \
I / or I P
R 1 c
. .
(a-1-2) (b- 1 -2)
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
Ric represents hydrogen or fluorine,
A2 represents N or CH,
R2 represents cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl or pyridazinyl,
where cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl
and pyridazinyl may be substituted by 1 or 2 fluorine substituents,
R3 represents a group of the formula

CA 02866213 2014-09-03
BHC 12 1 012-Foreign Countries
- 38 -
-="'
NL L N''' L N L
,11,/,',, E3,11,,,;;, M
El E411
\ 3 \2_E1 \ 6
E2=E E E5¨E
/I\
N'.. L
N'.. L
N L
II II
Gi ,,,ly,,,
kil R2L-Nki HN
112 -G4 \
UV R25WR27
#it
)1...11-1
0 NIC-Xin0
ei
R29 ,
## ##
.4,4,,,, xi...5
H; or HN
0
,...., R" ..%
0
R3
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 39 -
in which
R4 represents -le, ¨0R6 or ¨NR7R8,
in which
R5
represents hydrogen, chlorine, cyano, (C1-C4)-alkyl or (C2-C4)-
alkynyl,
in which (C1-C4)-alkyl and (C2-C4)-allcynyl for their part may be
substituted by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9 and -C(=O)-
in which
P represents the number 0,
R9 and le
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and RI together with the atom(s) to
which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 40 -
methylamino, ethylamino, dimethylamino and
diethylamino,
R6 represents (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl,
oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=O)p-NR9R1 and -NR9-(C=0)-R' ,
and
in which cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl,
thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or
pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, difluoromethoxy, trifluoromethoxy, oxo, -
(CO)p-OR9 and ¨(C=0)p-NR9R1 ,
in which
p represents the number 0 or 1,
R9 and RI
independently of one another each represent
hydrogen, methyl, ethyl,
isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 41 -
R9 and R1
together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl
or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
R7 represents hydrogen, methyl or ethyl,
R8
represents hydrogen, (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl, cyclopropyl, cyclobutyl and cyclopentyl
are substituted by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl methyl, ethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9, -
(C=0)p-NR9R10, -NR9-(C=0)-R' , oxetanyl,
azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, furanyl, pyrazolyl, imidazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl and
pyrimidinyl,
in which
P represents the number 0 or 1,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 42 -
R9 and RI independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl,
2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or
R9 and RI together with the atom(s) to which
they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, furanyl, pyrazolyl, imidazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl for their part may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, chlorine,
cyano, difluoromethyl, trifluoromethyl, methyl, ethyl,
cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and

CA 02866213 2014-09-03
BHC 12 1 012-Foreign Countries
- 43 -
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl
and pyrimidinyl may be substituted by 1 to 3 substituents independently of
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=O)-
in which
p represents the number 0 or 1,
R9 and RI independently of one another each
represent
hydrogen, methyl, ethyl,
isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and R' together with the atom(s) to which they
are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl
or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
or
R7 and R8 together with the nitrogen atom to which they are attached form
an
azetidinyl, pyrrolidinyl, imidazolidinyl,
piperidinyl,

BHC 121 012-Foreign Countries CA 02866213 2014-09-03
- 44 -
dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl, imidazolyl
or triazolyl ring,
in which the azetidinyl, pyrrolidinyl, imida7olidinyl, piperidinyl,
dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl, imidazolyl
or triazolyl ring may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, cyano, difluoromethyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, ethyl, 1-
hydroxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
methoxy, ethoxy, difluoromethoxy and trifluoromethoxy,
El represents 0, S or NR18,
in which
R18 represents hydrogen, trifluoromethyl or (CI-CO-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
E2 represents N,
E3 represents N or CR19,
in which
R19
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
represents a bond, methylene, ethane-1,2-diy1 or propane-1,3-diyl,

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
.,
- 45 -
R13
represents -(C=0)1-0R14, -(C=0)r-NR14R15, _C(=S)-NR14R15, _
NR14-(C=0)-0R17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
r represents the number 0 or 1,
RH and R15
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy,
ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 46 -
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
E4 and E6 independently of one another each represent N or CR20
,
in which
Rzo
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R'',
in which (Ci-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-1,2-diy1 or
propane-1,3-diyl,
R13 represents -(C=0),.-OR14, -(C=0)1NR14R15, _C(=S)-
NR14R15,
NR14-(C=0)-0R17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
represents the number 0 or 1,
lel and RI' independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
A
- 47 -
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy,
ethoxy,
hydroxycarbonyl,
methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
E5 represents NR21,
in which
R21 represents hydrogen or (C1-C4)-alkyl,
in which (C1-C4)-alkyl may itself be substituted by 1 or 2 substituents each
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
G1, G2, G3 and G4 independently of one another each represent N or CR22,
in which
R22
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R",

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
4.
- 48 -
in which (Ci-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-
1,2-diy1 or propane-1,3-diyl,
R13 represents -(C=0),-OR14, -(C=0)r-
NRI4R15, _c(=s)_NR14R15, _
NR14-(C=0)-0R17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
r represents the number 0 or 1,
12.14 and R15
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl,
methoxycarbonyl,
ethoxycarbonyl and amino,
R17 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 49 -
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
with the proviso that not more than two of the 0, G2, G3 and G4 groups
represent nitrogen,
and
with the proviso that at least one of the G1, G2, G3 and G4 groups represents
CH,
represents C=0, C=S or SO2,
V represents 0 or NR24,
in which
R24
represents hydrogen, trideuteromethyl, (Ci-C6)-alkyl, (C2-C6)-alkenyl, (C3-
C7)-cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or benzyl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy,
ethoxy, methylsulphonyl, ethylsulphonyl, azetidinyl, oxetanyl,
pyrrolidinyl, piperidinyl and morpholinyl,
in which azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and
morpholinyl for their part may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,
methyl and ethyl,
in which azetidinyl, pyrrolidinyl and piperidinyl for their part may be
substituted by 1 or 2 substituents independently of one another selected

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
4
- 50 -
from the group consisting of fluorine, trifluoromethyl, methyl, ethyl,
cyclopropyl and cyclobutyl,
in which methyl and ethyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, trifluoromethyl, cyclopropyl,
cyclobutyl, hydroxy, methoxy and ethoxy,
and
in which benzyl may itself be substituted by 1 or 2 fluorine, chlorine,
trifluoromethyl, methyl, ethyl, methylsulphonyl and ethylsulphonyl
substituents,
represents N or CR25,
in which
R25 represents hydrogen or oxo,
R23 represents hydrogen, trideuteromethyl, (C1-C6)-alkyl
or (C2-C6)-alkenyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
R25 represents hydrogen or oxo,
R2' represents hydrogen, (C1-C3)-alkoxycarbonyl or
aminosulphonyl,
in which (C1-C3)-alkoxycarbonyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of fluorine,
trifluoromethyl, hydroxy, methoxy and ethoxy,
R28 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl,
(C3-C6)-cycloalkyl and phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine, chlorine,
trifluoromethyl,
(C1-C4)-alkyl, methoxy and ethoxy,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 51 -
R29 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl,
cyclopropyl, cyclobutyl and
phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine, chlorine,
trifluoromethyl,
methyl, ethyl, methoxy and ethoxy,
R3 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
R31 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
and their salts, solvates and solvates of the salts.
Preference is given in the context of the present invention to compounds of
the formula (I) in
which
the ring Q represents a group of the formula
2"N ,
I / or I 'pi
R1c R1c
(a-1-2) (b-1-2)
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
Ric represents hydrogen or fluorine,

, BHC 121 012-Foreign Countries CA 02866213 2014-09-03
.t
- 52 -
A2 represents N or CH,
R2 represents trifluoromethyl, 2,2,2-
trifluoroethyl, 3,3 ,3-trifluoroprop-1-yl, 2,2,3,3-
tetrafluorprop-l-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyl,
cyclopentyl,
cyclohexyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl,
pyrazinyl
and pyridazinyl may be substituted by 1 or 2 fluorine substituents,
R3 represents a group of the formula
#:# *It *ft
N - L N - L N L
II
E\1 3 E 3
EN /
\\ 1
E2= E E2¨ E E5¨ E6
##
#1t *4
/L
/L.
N L
../1 N - L
-
N - L
I I /ly A
m 3 HN
R2----NI
II \ N
G2 sG4 U ¨V R"WõR"
G3
'
N ="' L N L
H N L
,LT,A HN
),...r11,1 .....krA
N
I
0
H ,
R28 ,
R29

. BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
*,
- 53 -
## #41
F 1 1
0 or H
R3 1
0 0
R"
where
## represents the point of attachment to the ring Q,
L represents CH or N,
M represents CR4 or N,
in which
R4 represents -R5, ¨OW or ¨NR7R8,
in which
R5 represents trifluoromethyl or (C1-C4)-
alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of difluoromethyl, trifluoromethyl, cyclopropyl,
cyclobutyl, cyclopentyl, difluoromethoxy, trifluoromethoxy, -
(CO)p-OR9 and -C(=0)p-NR91e,
in which
P represents the number 0,
R9 and RI independently of one another
each represent
methyl, ethyl, isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl,
1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,
or

. BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
k
- 54 -
R9 and le
together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
R6
represents (Ci-C6)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl,
oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, -
(C=0)-0R9, -(C=0)_NR9R10 and _NR9-(C=0)-Rio,
in which
R9 and RI
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and 11_1 together with the atom(s) to
which they are
respectively attached form an azetidinyl,

= BHC 12 1 012-Foreign CountriescA 02866213 2014-09-03
=
- 55 -
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
di ethylamino,
and
in which cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl,
thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or
pyrimidinyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, difluoromethoxy, trifluoromethoxy, oxo, -
(C=O)p-OR9 and ¨(C=0)p-NR9R10
,
in which in each case
P represents the number 0 or 1,
R9 and le
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and le together with the atom(s) to
which they are
respectively attached form an azetidinyl,

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
=
- 56 -
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
R7 represents hydrogen, methyl or ethyl,
R8 represents (C1-C6)-alkyl, cyclopropyl,
cyclobutyl, cyclopentyl,
oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl, cyclopropyl, cyclobutyl and cyclopentyl
are substituted by 1 to 3 substituents independently of one another
selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl methyl, ethyl, cyclopropyl, cyclobutyl,
cyclopentyl, difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, -
(C=0)-0R9, -(C=0)-NR9R19, -NR9-(C=0)-1e9, oxetanyl,
azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl, furanyl, pyrazolyl,
imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl,
in which
R9 and RI
independently of one another each
represent hydrogen, methyl, ethyl,
isopropyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl, cyclobutyl or cyclopentyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 57 -
or
R9 and le
together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl and morpholinyl
ring for its part may be substituted by 1 or
2 substituents independently of one
another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino
and diethylamino
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, furanyl, pyrazolyl, imidazolyl,
oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl and pyrimidinyl for their part may be substituted
by 1 or 2 substituents independently of one another
selected from the group consisting of fluorine, chlorine,
cyano, difluoromethyl, trifluoromethyl, methyl, ethyl,
cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl
and pyrimidinyl may be substituted by 1 to 3 substituents independently of
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 58 -
difluoromethoxy, trifluoromethoxy, oxo, -(C=O)p-OR9 and -(C=0)p-
NR9R1 ,
in which
represents the number 0 or 1,
R9 and R' independently of one another
each represent
hydrogen, methyl, ethyl,
isopropyl,
trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl, cyclobutyl or
cyclopentyl,
or
R9 and R'
together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl
or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
or
R7 and R8
together with the nitrogen atom to which they are attached form an
azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl,
dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl, imidazolyl
or triazolyl ring,
in which the azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl,
dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl, imidazolyl
or triazolyl ring may be substituted by 1 or 2 substituents

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 59 -
independently of one another selected from the group consisting of
fluorine, cyano, difluoromethyl, trifluoromethyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, ethyl, 1-
hydroxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo,
methoxy, ethoxy, difluoromethoxy and trifluoromethoxy,
E' represents 0, S or NR18,
in which
Ris represents hydrogen, trifluoromethyl or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
E2 represents N,
E3 represents N or CR19,
in which
R'9 represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C i-
C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R",
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-1,2-diy1 or
propane-1,3-diyl,
R" represents -(C=0),-OR14, -(C=0),-NR14R15, -C(=S)-
NR1411_15, -
NR14-(C=0)-OR17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 60 -
r represents the number 0 or 1,
R14 and R''
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy,
ethoxy,
hydroxycarbonyl, methoxycarbonyl,
ethoxycarbonyl and amino,
Ri7 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
E4 and E6 independently of one another each represent N or CR20
,
in which

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
-61 -
R2o
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (CI-CO-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R",
in which (Ci-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which
M represents a bond, methylene, ethane-1,2-diy1 or
propane-1,3-diyl,
ft" represents -(C=0)r0R14, -
(C=0)r-NR14R15, _C(=S)-NR14R15, -
NR14-(C=0)-0R17, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
r represents the number 0 or 1,
R14 and R15
independently of one another each represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy,
difluoromethoxy,
trifluoromethoxy, methoxy,
ethoxy,
hydroxycarbonyl,
methoxycarbonyl,
ethoxycarbonyl and amino,

BHC 121 012-Foreign Countries CA 02866213 2014-09-03
=
- 62 -
R'7 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
E5 represents NR21,
in which
R21 represents hydrogen or (C1-C4)-alkyl,
in which (C1-C4)-alkyl may itself be substituted by 1 or 2 substituents each
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, hydroxy, methoxy and ethoxy,
GI, G2, G3 and G4 independently of one another each represent N or CR22,
in which
R22
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-
R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents selected
independently of one another from the group consisting of fluorine, cyano,
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy
and trifluoromethoxy,
and in which

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 63 -
M represents a bond, methylene, ethane-1,2-diy1 or
propane-1,3-diyl,
Ft represents -(C---0),-0R14,
-(C=0)1-NR1115, -C(=S)-NR14R15,
NR14-(C=0)-01e, oxadiazolonyl, oxadiazolethionyl, phenyl,
oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
pyridyl, pyrimidinyl or pyrazinyl,
in which
represents the number 0 or 1,
R'4 and le independently of one another each
represent
hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl or pyridyl,
in which methyl, ethyl and isopropyl may
additionally be substituted by 1 or 2 substituents
independently of one another selected from the
group consisting of fluorine, difluoromethyl,
trifluoromethyl, cyclopropyl,
cyclobutyl,
cyclopentyl, hydroxy, di
fluoromethoxy,
trifluoromethoxy, methoxy, ethoxy,
hydroxycarbonyl,
methoxycarbonyl,
ethoxycarbonyl and amino,
le7 represents methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl,
and
in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl,
thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl and pyrazinyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, chlorine, cyano, difluoromethyl,
trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 64 -
1,1,2,2,2-pentafluoroethyl, cyclopropyl,
cyclobutyl,
cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and
ethoxy,
with the proviso that not more than two of the G', G2, G3 and G4 groups
represent nitrogen,
and
with the proviso that at least one of the G', G2, G3 and G4 groups represents
CH,
U represents C=0, C=S or SO2,
V represents 0 or NR24,
in which
R24 represents hydrogen,
trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (Cr
C7)-cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl or benzyl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, methoxy,
ethoxy, methylsulphonyl, ethylsulphonyl, azetidinyl, oxetanyl,
pyrrolidinyl, piperidinyl and morpholinyl,
in which azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl and
morpholinyl for their part may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,
methyl and ethyl,
in which azetidinyl, pyrrolidinyl and piperidinyl for their part may be
substituted by 1 or 2 substituents independently of one another selected
from the group consisting of fluorine, trifluoromethyl, methyl, ethyl,
cyclopropyl and cyclobutyl,
in which methyl and ethyl for their part may be substituted by 1 or
2 substituents independently of one another selected from the
group consisting of fluorine, trifluoromethyl, cyclopropyl,
cyclobutyl, hydroxy, methoxy and ethoxy,

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 65 -
and
in which benzyl may itself be substituted by 1 or 2 fluorine, chlorine,
trifluoromethyl, methyl, ethyl, methylsulphonyl and ethyl sulphonyl
substituents,
W represents N or CR25,
in which
R25 represents hydrogen or oxo,
R23 represents hydrogen, trideuteromethyl, (Ci-C6)-alkyl or (C2-C6)-
alkenyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
R25 represents hydrogen or oxo,
R27 represents hydrogen, (C1-C3)-alkoxycarbonyl or aminosulphonyl,
in which (C1-C3)-alkoxycarbonyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of fluorine,
trifluoromethyl, hydroxy, methoxy and ethoxy,
R28 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl, (C3-C6)-
cycloalkyl and phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine, chlorine,
trifluoromethyl,
(C1-C4)-alkyl, methoxy and ethoxy,
R29 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl,
cyclopropyl, cyclobutyl and
phenyl,
in which phenyl may be substituted by 1 or 2 substituents independently of one
another selected from the group consisting of fluorine, chlorine,
trifluoromethyl,
methyl, ethyl, methoxy and ethoxy,
R3 represents hydrogen or (C1-C6)-alkyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 66 -
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
R31 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently
of
one another selected from the group consisting of fluorine, trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy, methoxy and ethoxy,
and their salts, solvates and solvates of the salts,
except for the compounds:
2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-8-methyl-9H-purine,
2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-8-methy1-9H-purine-6-
amine,
N-buty1-2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-8-methy1-9H-
purine-6-amine.
Preference is given in the context of the present invention to compounds of
the formula (I) in
which
the ring Q represents a group of the formula
* *
2 .1.1 2+1 µ
I / or I ) \ 1
Ric R1'
** **
(a-1-2) (b- 1 -2)
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
Ric represents hydrogen, fluorine or methyl,
A2 represents CH,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 67 -
R2 represents pyridyl or pyrimidinyl,
where pyridyl and pyrimidinyl may be substituted by 1 fluorine substituent,
represents a group of the formula
## ##
or
E 1YM R23
where
## represents the point of attachment to the ring Q,
represents N,
represents CR4,
in which
R4
represents -R5, ¨0R6 or ¨NR7R8,
in which
R5 represents hydrogen, trifluoromethyl or (C1-C4)-
alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of fluorine, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, -(CO)p-OR9 and -C(=0)p-NR9R16,
in which
represents the number 0,
R9 and le
independently of one another each represent
hydrogen, methyl, ethyl, trifluoromethyl, 2,2,2-
trifluoroethyl,
1,1,2,2,2-pentafluoroethyl,
cyclopropyl or cyclobutyl,

BHC 121 012-Foreign Countries CA 02866213 2014-09-03
,
- 68 -
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, -(C---0)p-OR9 and -C(-0)p-
RNR9 io,
in which
P represents the number 0 or 1,
R9 and Ril) independently of one another
each represent
hydrogen or methyl,
or
R9 and le together with the atom(s) to which they are
respectively attached form an azetidinyl,
pyrrolidinyl, piperidinyl,
piperazinyl or
morpholinyl ring,
in which the azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl and morpholinyl ring for its part may
be substituted by 1 or 2 substituents independently
of one another selected from the group consisting
of fluorine, trifluoromethyl, methyl, ethyl,
hydroxy, oxo, methoxy, ethoxy, amino,
methylamino, ethylamino, dimethylamino and
diethylamino,
and
in which pyrazolyl may be substituted by 1 or 2 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 69 -
R8 represents hydrogen, (C1-C6)-alkyl, oxetanyl, azetidinyl,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (Ci-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl, trifluoromethoxy, -(C=O)p-OR9, -(CO)p-NR9R1 ,
tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl, furanyl,
pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which
P represents the number 0 or 1,
R9 and le
independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,
and
in which tetrahydrofuranyl,
pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl,
triazolyl and pyridyl for their part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of fluorine, chlorine, cyano,
difluoromethyl, trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl
and pyrimidinyl may be substituted by 1 to 3 substituents independently of

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
..
- 70 -
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl and trifluoromethoxy,
E' represents NR',
in which
R18 represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen, fluorine, difluoromethyl,
trifluoromethyl, (C1-C4)-
alkyl or a group of the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond, methylene, ethane-1,2-diy1 or propane-1,3-diyl,
R'' represents -(C=0),-OR", -(C=0)1-NR14R15,
phenyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl,
in which
r represents the number 0 or 1,
R" and R15 independently of one another
each represent
hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl
or phenyl,
in which methyl and ethyl may additionally be
substituted by 1 to 2 substituents independently of
one another selected from the group consisting of
fluorine, difluoromethyl,
trifluoromethyl,

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 71 -
cyclopropyl, cyclobutyl,
hydroxy,
trifluoromethoxy and methoxy,
and
in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and
pyrimidinyl may each in turn be substituted by 1 or 2 substituents
selected independently of one another from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl,
2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl,
cyclopropyl,
cyclobutyl, cyclopropylmethyl and cyclobutylmethyl,
U represents C(=0),
V represents NR24,
in which
R24 represents trideuteromethyl, (Ci-C6)-alkyl, cyclopropyl, cyclobutyl,
azetidin-3-yl, pyrrolidin-3-y1 or piperidin-4-yl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, oxetanyl and
morpholin-4-yl,
and
in which azetidin-3-yl, pyrrolidin-3-y1 and piperidin-4-y1 for their part may
be substituted by 1 or 2 substituents independently of one another selected
from the group consisting of fluorine, trifluoromethyl, 2,2-difluoroethyl,
2,2,2-trifluoroethyl, cyclopropyl and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
Preference is given in the context of the present invention to compounds of
the formula (I) in
which
the ring Q represents a group of the formula

BHC 12 1 012-Foreign CountriescA 02866213 2014-09-03
- 72 -
R R
* *
/
+I
2 1 \
I / or 2 1 \)%i
ic
ic
'kir ink
(a-1-2) (b-1-2)
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
Ric
represents hydrogen or fluorine,
A2 represents CH,
R2 represents 3-fluoropyrid-2-yl,
R3 represents a group of the formula
1# ##
Ill or
El N/iri\A R23----N\--'1"111 k Airi
E2 3 U---V
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4
represents -R5 or ¨NR7R8,
in which

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 73 -
R5 represents hydrogen,
R7 represents hydrogen,
R8 represents hydrogen or (Ci-C6)-alkyl,
in which (Ci-C6)-alkyl is substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, -(CO)p-OR9
and -C(-0)p-NR9R1 ,
in which
P represents the number
0,
R9 and 11_1 independently of one another each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentalluoroethyl, cyclopropyl or
cyclobutyl,
E1 represents NR18,
in which
les represents hydrogen,
E2 represents N,
E3 represents CR19,
in which
R19 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl or a
group of the
formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 74 -
M represents a bond,
R13 represents -(C=0),-OR" or -(C=0),-NR14R15,
in which
represents the number 0,
R" and R15 independently of one another
each represent
hydrogen, methyl, ethyl, cyclopropyl or
cyclobutyl,
represents C(=0),
V represents NR24,
in which
R24
represents (C1-C6)-alkyl,
in which (C1-C6)-alkyl may itself be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl and hydroxy,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
Preference is given in the context of the present invention to compounds of
the formula (I) in
which
the ring Q represents a group of the formula
2 4\1
I/ or
R1 c R1 c
(a- 1 -2) (b-1-2)
where

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 75 -
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
Ric represents hydrogen or fluorine,
A2 represents CH,
R2 represents 3,3,3-trifluoroprop-1-yl, 2,2,3,3-tetrafluoroprop-1-yl,
2,2,3,3,3-pentafluoroprop-
1-yl, phenyl, pyridyl or pyrimidinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and
where pyridyl and pyrimidinyl may be substituted by 1 fluorine substituent,
R3 represents a group of the formula
tic#
IIL,..%:11-1 or
El R23---N
µ 2E-I
E -- U ¨V
where
114# represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4 represents -R5, ¨0R6 or ¨NR7R8,
in which
R5 represents trifluoromethyl or (C1-C4)-alkyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 76 -
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of trifluoromethyl, cyclopropyl, cyclobutyl,
difluoromethoxy, trifluoromethoxy, -(C=O)p-OR9 and -C(=-0)--
NR9R1 ,
in which
represents the number 0,
R9 and le independently of one another each
represent
methyl, ethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,
Or
R9 and le together with the atom(s) to which they
are
respectively attached form a pyrrolidinyl,
piperidinyl, piperazinyl or morpholinyl ring,
in which the pyrrolidinyl, piperidinyl, piperazinyl
and morpholinyl ring for its part may be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, trifluoromethyl, methyl, ethyl, hydroxy,
oxo, methoxy, ethoxy, amino, methylamino,
ethylamino, dimethylamino and diethylamino,
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (Ci-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
trifluoromethyl, cyclopropyl, cyclobutyl,
cyclopentyl,
difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, -(C=0)-0R9
and -(C=0)-NR9R1 ,
in which

CA 02866213 2014-09-03
BHC 12 1 012-Foreign Countries
- 77 -
R9 and le independently of one another each
represent
hydrogen, methyl, ethyl, trifluoromethyl, 2,2,2-
trifluoroethyl,
1,1,2,2,2-pentafluoroethyl,
cyclopropyl or cyclobutyl,
and
in which pyrazolyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,
R8 represents (Ci-C6)-alkyl, oxetanyl, azetidinyl,
tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (Ci-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
trifluoromethyl, cyclopropyl, cyclobutyl, trifluoromethoxy, (Cr
C4)-alkoxy, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
phenyl, furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which tetrahydrofuranyl,
pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl,
triazolyl and pyridyl for their part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of fluorine, chlorine, cyano,
difluoromethyl, trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and
in which
oxetanyl, azetidinyl, - tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl

BHC 12 1 012-Foreign CountriescA 02866213 2014-09-03
,
- 78 -
and pyrimidinyl may be substituted by 1 to 3 substituents independently of
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, trifluoromethoxy and oxo,
E1 represents NR18,
in which
R'8 represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which
R19 represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl or a group of the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond, methylene, ethane-1,2-
diy1 or propane-1,3-diyl,
R13 represents -(C=0),-OR14, -(C=0),-NR14R15,
phenyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl,
in which
r represents the number 0 or 1,
R14 and Ris
independently of one another each represent
hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl
or phenyl,
in which methyl and ethyl may additionally be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, difluoromethyl,
trifluoromethyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
-
- 79 -
cyclopropyl, cyclobutyl,
hydroxy,
trifluoromethoxy and methoxy,
and
in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and
pyrimidinyl may each in turn be substituted by 1 or 2 substituents
selected independently of one another from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl,
2,2,2-trifluoroethyl, 1,1,2,2,2-
pentafluoroethyl, cyclopropyl,
cyclobutyl, cyclopropylmethyl and cyclobutylmethyl,
U represents C(=0),
V represents NR24,
in which
R24
represents trideuteromethyl, (Ci-C6)-alkyl, cyclopropyl, cyclobutyl,
azetidin-3-yl, pyrrolidin-3-y1 or piperidin-4-yl,
in which (C1-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, oxetanyl and
morpholin-4-yl,
and
in which azetidin-3-yl, pyrrolidin-3-y1 and piperidin-4-y1 for their part may
be substituted by 1 or 2 substituents independently of one another selected
from the group consisting of fluorine, trifluoromethyl, 2,2-difluoroethyl,
2,2,2-trifluoroethyl, cyclopropyl and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
In the context of the present invention, preference is also given to compounds
of the formula (I) in
which
R3 represents a group of the formula

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
-
- 80 -
ni or
El N'irlµA R23----NvINI R A-lin
E23
U --V
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4 represents -R5 or ¨NR7R8,
in which
R5 represents hydrogen,
R7
represents hydrogen,
R8 represents hydrogen or (C1-C6)-alkyl,
in which (C1-C6)-alkyl is substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, -(CO)p-OR9
and -C(=0)p- 9NR Rio,
in which
P represents the number 0,
R9 and RI independently of one another
each
represent hydrogen, methyl, ethyl,
trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 81 -
E1 represents NR',
in which
R18 represents hydrogen,
E2 represents N,
E3 represents CR19,
in which
R19 represents hydrogen, trifluoromethyl, (C1-C4)-
alkyl or a group of the
formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond,
R13 represents -(C=0),-OR14 or -(C=0),-
NR14R15,
in which
r represents the number 0,
R14 and R15
independently of one another each represent
hydrogen, methyl, ethyl, cyclopropyl or
cyclobutyl,
U represents C(=0),
V represents NR24,
in which
R24 represents (Ci-C6)-alkyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 82 -
in which (C1-C6)-alkyl may itself be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl and hydroxy,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
In the context of the present invention, preference is also given to compounds
of the formula (I) in
which
the ring Q represents a group of the formula
-N
A2-
)/(N
Ric)
(a-1-2)
where
represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,
Ric represents hydrogen or fluorine,
A2 represents CH,
and their salts, solvates and solvates of the salts.
In the context of the present invention, preference is also given to compounds
of the formula (I) in
which
R2 represents 3,3,3-trifluoroprop-1-yl, 2,2,3,3-tetrafluoroprop-1-yl,
2,2,3,3,3-pentafluoroprop-
1-yl, phenyl, pyridyl or pyrimidinyl,
where phenyl is substituted by 1 to 3 fluorine substituents,
and

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 83 -
where pyridyl and pyrimidinyl may be substituted by 1 fluorine substituent,
R3 represents a group of the formula
1\ ; n or 23
;.1
1
'y R \IA
El .......N
\
E2 3 U ¨V
where
## represents the point of attachment to the ring Q,
L represents N,
M represents CR4,
in which
R4 represents -R5, ¨0R6 or ¨NR7R8,
in which
R5 represents trifluoromethyl or (C1-C4)-alkyl,
in which (C1-C4)-alkyl for its part may be substituted by 1 or 2
substituents independently of one another selected from the group
consisting of trifluoromethyl, cyclopropyl, cyclobutyl,
difluoromethoxy, trifluoromethoxy, -(CO)p-OR9 and -C(0)-
in which
P represents the number 0,
R9 and RI independently of one another each
represent
methyl, ethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, cyclopropyl or
cyclobutyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 84 -
or
R9 and le
together with the atom(s) to which they are
respectively attached form a pyrrolidinyl,
piperidinyl, piperazinyl or morpholinyl ring,
in which the pyrrolidinyl, piperidinyl, piperazinyl
and morpholinyl ring for its part may be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, trifluoromethyl, methyl, ethyl, hydroxy,
oxo, methoxy, ethoxy, amino, methylamino,
ethylamino, dimethylamino and diethylamino,
R6 represents (C1-C6)-alkyl or pyrazolyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl,
difluoromethoxy, trifluoromethoxy, (C1-C4)-alkoxy, -(C=0)-0R9
and -(C=0)-NR91e,
in which
R9 and RI
independently of one another each represent
hydrogen, methyl, ethyl, trifluoromethyl, 2,2,2-
trifluoroethyl,
1,1,2,2,2-pentafluoroethyl,
cyclopropyl or cyclobutyl,
and
in which pyrazolyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,
1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl and
cyclopentyl,
R7 represents hydrogen, methyl or ethyl,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 85 -
R8
represents (C1-C6)-alkyl, oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl,
morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl,
oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
trifluoromethyl, cyclopropyl, cyclobutyl, trifluoromethoxy, (Cr
C4)-alkoxy, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl,
phenyl, furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl,
in which tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl,
triazolyl and pyridyl for their part may be substituted by 1
or 2 substituents independently of one another selected
from the group consisting of fluorine, chlorine, cyano,
difluoromethyl, trifluoromethyl, methyl, ethyl, oxo,
difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
and
in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl,
tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl,
pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl
and pyrimidinyl may be substituted by 1 to 3 substituents independently of
one another selected from the group consisting of fluorine, difluoromethyl,
trifluoromethyl, methyl, ethyl, trifluoromethoxy and oxo,
El represents NR18,
in which
R18 represents hydrogen,
E2 represents N,
E3 represents N or CR19,
in which

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 86 -
R19
represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C1-C4)-
alkyl or a group of the formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
M represents a bond, methylene, ethane-1,2-diy1 or
propane-1,3-diyl,
R13
represents -(C=0),--01e, -(C=0)r-Nele, phenyl, thiazolyl,
triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl,
in which
represents the number 0 or 1,
Rm and R15
independently of one another each represent
hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl
or phenyl,
in which methyl and ethyl may additionally be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, difluoromethyl,
trifluoromethyl,
cyclopropyl, cyclobutyl,
hydroxy,
trifluoromethoxy and methoxy,
and
in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and
pyrimidinyl may each in turn be substituted by 1 or 2 substituents
selected independently from the group consisting of fluorine,
difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-
trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl,
cyclopropylmethyl and cyclobutylmethyl,
represents C(=0),

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 87 -
V represents NR24,
in which
R24 represents trideuteromethyl, (C1-C6)-alkyl, cyclopropyl, cyclobutyl,
azetidin-3-yl, pyrrolidin-3-y1 or piperidin-4-yl,
in which (Ci-C6)-alkyl for its part may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, oxetanyl and
morpholin-4-yl,
and
in which azetidin-3-yl, pyrrolidin-3-y1 and piperidin-4-y1 for their part may
be substituted by 1 or 2 substituents independently of one another selected
from the group consisting of fluorine, trifluoromethyl, 2,2-difluoroethyl,
2,2,2-trifluoroethyl, cyclopropyl and cyclobutyl,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
In the context of the present invention, preference is also given to compounds
of the formula (I) in
which
R2 is 3,3,3 -tri fluoroprop-l-yl, 2,2,3,3-tetrafluoroprop-1-yl, 2,2,3
,3,3-pentafluoroprop-1-yl, 2-
fluorophenyl or 3-fluoropyrid-2-yl,
R3 represents a group of the formula
1 1
or23
zy
'.(N1
El R...._N
\ 2E-r 3
E ¨ U ¨V
where
## represents the point of attachment to the ring Q,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 88 -
L represents N,
represents CR4,
in which
R4 represents ¨NR7R8,
in which
R7 represents hydrogen or methyl,
R8 represents (C1-C6)-alkyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
trifluoromethyl, cyclopropyl, cyclobutyl, trifluoromethoxy and
(CI-C4)-alkoxy,
E1 represents NR',
in which
R18 represents hydrogen,
E2 represents N,
E3 represents CR19,
in which
R19 represents hydrogen, trifluoromethyl, (C1-C4)-alkyl or a
group of the
formula -M-R13,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl and cyclobutyl,
and in which
represents a bond,
R13 represents -(C=0),-OR14 or -(C=0),-NR14R15,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 89 -
in which
represents the number 0,
R14 and R15 independently of one another each
represent
hydrogen, methyl, ethyl, cyclopropyl or
cyclobutyl,
in which methyl and ethyl may additionally be
substituted by 1 or 2 substituents independently of
one another selected from the group consisting of
fluorine, difluoromethyl,
trifluoromethyl,
cyclopropyl, cyclobutyl, hydroxy,
trifluoromethoxy and methoxy,
represents C(=0),
V represents NR24,
in which
R24
represents (C1-C6)-alkyl,
in which (C1-C6)-alkyl may itself be substituted by 1 to 3 substituents
independently of one another selected from the group consisting of
fluorine, trifluoromethyl, cyclopropyl, cyclobutyl and hydroxy,
R23 represents hydrogen,
and their salts, solvates and solvates of the salts.
The individual radical definitions specified in the particular combinations or
preferred
combinations of radicals are, independently of the particular combinations of
the radicals
specified, also replaced as desired by radical definitions of other
combinations.
Particular preference is given to combinations of two or more of the preferred
ranges mentioned
above.
The invention further provides a process for preparing the compounds of the
formula (I) according
to the invention, characterized in that

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 90 -
[A] a compound of the formula (II)
R2
(R1)n QA
CN (1)
in which R2 has the meaning given above and
the ring QA represents a group of the formula
A2'71 N '-^....--µ y..--(
A2 N
A2.;A
A4...."" j.......(N
\
,
(a-1) (c-1) (d-1)
/
,n, 1\
kr` ins"N4
.. j.......<N (R1 N
e ) Q1 I z N
S
** 7 **
,
(g-1) (1-1)
* *
A __1_1------(---
(R1) Q1 or (R1) ....(::.....,11 N ......f
.
** **
(n-1 ) (o- 1 )
where
* represents the point of attachment to -CH2-R2,
** represents the point of attachment to R3,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 91 -
the ring Q1 together with the atoms to which it is attached forms a 5-
to 7-membered
saturated or partially unsaturated carbocycle or a 5- to 7-membered
saturated or partially unsaturated heterocycle,
1Z1 represents fluorine, chlorine, methyl, hydroxy or oxo,
n represents a number 0, 1 or 2,
A1, A2, 3
A and A4 independently of one another each represent N, CH or
CR1,
with the proviso that not more than two of the Al, A2, A3 and A4 groups
represent N,
is reacted in an inert solvent in the presence of a suitable base with a
compound of the
formula (III-1) or (III-2)
NCµ) H2 NC )_ H 2
-
or E123
G2¨G3
(III- 1 ) (III-2)
in which GI, G2, G3, ¨4,
EI, E2 and E3 each have the meanings given above,
to give a compound of the formula (I-A-1) or (I-A-2)
2 2
(R1), QA (1:21)n QA
or
H2 H2
Gi
, .G4
Eiµ
G---G 3 E2
(I-A- 1 ) (I-A-2)
in which n, R2, GI, G2, G3, G4, EI, E2,
and QA each have the meanings given above,
or

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
=
- 92 -
[B] a compound of the formula (I-B-1) or (I-B-2)
2
2 '
(R1)õ Q (R1)0 Q
H2 or
/ / \
\ H2
--....
P2
P1
(1-B- 1) (I-B-2)
,
in which n, pi, /32, RI, R2 ano. . .-.,
y
each have the meanings given above,
is reacted in an inert solvent with a suitable nitrite to give a compound of
the formula (I4-
3) or (I-I-4)
. 2
. 2
(R1), Q (R1)0 Q
or
8
,
\
P2
p1
(1-B-3) (I-B-4)
,
in which n, pl, /32, RI, R2 and Q each have the meanings given above,
or
[C] a compound of the formula (I-B-1) or (I-B-2) is converted in an inert
solvent into a
compound of the formula (IV-1) or (w-2)

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
=
- 93 -
. 2
2
"
(R1)n Q (R1)õ Q
/
or /
\
\2 2
........
P2
F11
(1V- 1) (IV-2)
,
in which n, F,I, F.2, RI, R2 and = ---
y
each have the meanings given above and
X2 represents bromine, iodine or chlorine,
and this is then reacted in an inert solvent, optionally in the presence of a
suitable base,
with a compound of the formula (V)
R4A u
" (V)
in which
R4 represents ¨OR6 or ¨NR7R8,
where R6, R7 and R8 each have the meanings given above,
to give a compound of the formula (I-C-1) or (I-C-2)
. 2
2
(R1)nQ (R1), Q
.4A
or
8......R.
/ \
4A
P2
p1
(I-C-1) (I-C-2)
,
in which n, 131, F.2, RI, R2, K -=-= 4A
and Q each have the meanings given above,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
a
\
- 94 -
or
[D] a compound of the formula (VI)
R2
(R1) Q
/
L
N \\
M
H2N).------7--< 0---T
rils-Ac 1
0 (VI)
in which n, Q, RI and R2 are each as defined above and
11 represents (C1-C4)-alkyl
is reacted in an inert solvent in the presence of a suitable base with a
compound of the
formula (VII)
24A 1
R ¨X (VII)
in which
R24A represents trideuteromethyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C7)-
cycloalkyl,
azetidinyl, pyrrolidinyl, piperidinyl or benzyl,
in which (Ci-C6)-alkyl, azetidinyl, pyrrolidinyl, piperidinyl and benzyl may
be
substituted within the scope of the meaning given above,
and
X' represents a suitable leaving group, for example halogen, especially
chlorine or
bromine, mesylate or tosylate,
to give a compound of the formula (VIII)

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 95 -
R2
(R1)n
L
' 1
R24A/
0
in which n, Q, R2 and R24A each have the meanings above,
and this is then cyclized in an inert solvent in the presence of a suitable
base to give a
compound of the formula (I-D)
R2
(R1)õ,
L
HN)---1
y.-.R24A
0 (I-D)
in which n, Q, R1, R2 and R24A each have the meanings above,
and any protecting groups present are detached by methods known to those
skilled in the art, and
the resulting compounds of the formula (I) are optionally converted optionally
with the appropriate
(i) solvents and/or (ii) acids or bases to the solvates, salts and/or solvates
of the salts thereof.
Inert solvents for the process step (II) + (III-1) ¨> (I-A-1) or (II) + (III-
2) ¨> (I-A-2) are, for
example, halogenated hydrocarbons and hydrocarbons such as benzene, toluene,
xylene, hexane,
cyclohexane or mineral oil fractions, or other solvents such as acetone,
methyl ethyl ketone, ethyl
acetate, acetonitrile, /V,N-dimethylformamide (DMF), dimethyl sulphoxide
(DMSO), N,N'-
dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), sulpholane or
pyridine. It is also
possible to use mixtures of the solvents mentioned. Preference is given to
using DMF.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
4
- 96 -
Suitable bases for the process step (II) + (III-1) -3 (I-A-1) or (II) + (III-
2) --> (I-A-2) are the
customary inorganic or organic bases. These preferably include alkali metal
alkoxides such as
sodium or potassium methoxide, sodium or potassium ethoxide or sodium or
potassium tert-
butoxide, alkali metal hydrides such as sodium or potassium hydride, or amides
such as sodium
amide, lithium or potassium bis(trimethylsilyl)amide or lithium
diisopropylamide. Preference is
given to using potassium tert-butoxide.
The process step (II) + (III-1) --> (I-A-1) or (II) + (III-2) ¨> (I-A-2) is
generally performed within a
temperature range from +100 C to +200 C, preferably at +140 C to +180 C,
preferably in a
microwave. The conversion can be carried out at atmospheric, elevated or
reduced pressure (for
example from 0.5 to 5 bar).
Suitable nitrites for the conversions (I-B-1) or (I-B-2) ¨> (I-B-3) or (I-B-4)
are, for example,
sodium nitrite, isopentyl nitrite or tert-butyl nitrite.
Inert solvents for the conversions (I-B-1) or (I-B-2) ¨> (I-B-3) or (I-B-4)
are, for example, ethers
such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or
diethylene glycol dimethyl
ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide
(DMSO), N,N'-
dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine or
acetonitrile. It is also
possible to use mixtures of the solvents mentioned. Preference is given to
tetrahydrofuran or DMF.
The reactions (I-B-1) or (I-B-2) ¨> (I-B-3) or (I-B-4) are generally performed
within a temperature
range from 0 C to +120 C, preferably at +40 C to +80 C. The conversion can be
carried out at
atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar). The
reaction is
generally carried out at atmospheric pressure.
The process step (I-B-1) ¨> (IV-1) or (I-B-2) ¨> (IV-2) is carried out with or
without solvents.
Suitable solvents are all organic solvents which are inert under the reaction
conditions. The
preferred solvent is dimethoxyethane.
The reaction (I-B-1) ¨> (IV-1) or (I-B-2) (IV-2) is
generally carried out within a temperature
range from +20 C to +100 C, preferably within the range from +50 C to +100 C,
optionally in a
microwave. The conversion can be carried out at atmospheric, elevated or
reduced pressure (for
example in the range from 0.5 to 5 bar). The reaction is generally carried out
at atmospheric
pressure.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
g
=
- 97 -
The process step (I-B-1) ¨> (IV-1) or (I-B-2) ¨> (IV-2) is generally carried
out using a molar ratio
of 10 to 30 mol of isopentyl nitrite and 10 to 30 mol of the iodine equivalent
based on 1 mol of the
compound of the formula (I-B-1) or (I-B-2).
Suitable halogen sources in the conversion (I-B-1) --> (IV-1) or (I-B-2) ¨>
(IV-2) are, for example,
diiodomethane, a mixture of caesium iodide, iodine and copper(I) iodide or
copper(II) bromide and
also phosphoryl chloride.
Inert solvents for the process step (I-B-1) ¨> (I-B-3) or (I-B-2) ¨> (I-B-4)
are alcohols such as
methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol or 1,2-
ethanediol, ethers such
as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or
diethylene glycol dimethyl
ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide
(DMSO), N,N'-
dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine,
acetonitrile or else water.
It is also possible to use mixtures of the solvents mentioned. Preference is
given to DMF.
The reduction (I-B-1) ¨> (I-B-3) or (I-B-2) ¨> (I-B-4) is carried out using
hydrogen in conjunction
with transition metal catalysts, for example palladium (10% on activated
carbon), Raney nickel or
palladium hydroxide.
The reaction (I-B-1) --> (I-B-3) or (I-B-2) ¨> (I-B-4) is generally carried
out within a temperature
range from +20 C to +50 C. The conversion can be carried out at atmospheric or
elevated pressure
(for example in the range from 0.5 to 5 bar). The reaction is generally
carried out at atmospheric
pressure.
Inert solvents for the process step (IV-1) or (IV-2) + (V) ¨> (I-C-1) or (I-C-
2) are, for example,
ethers such as diethyl ether, dioxane, dimethoxyethane, tetrahydrofuran,
glycol dimethyl ether or
diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene,
toluene, hexane,
cyclohexane or mineral oil fractions, or other solvents such as
dimethylformamide (DMF),
dimethyl sulphoxide (DMSO), N,N'-dimethylpropyleneurea (DMPU), N-
methylpyrrolidone
(NMP), pyridine, acetonitrile or sulpholane. It is also possible to use
mixtures of the solvents
mentioned. Preference is given to NMP.
In the case of R4A = -0R6, the reaction (IV-1) or (IV-2) + (V) ¨> (I-C-1) or
(I-C-2) is preferably
carried out in the absence of a solvent.
In the case of R4A = -0R6, the reaction (IV-1) or (IV-2) + (V) ¨> (I-C-1) or
(I-C-2) is carried out in
the presence of a suitable copper catalyst such as, for example, copper(I)
iodide, with addition of
3,4,7,8-tetramethy1-1,10-phenanthroline, and a suitable base such as, for
example, alkaline earth

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
4
- 98 -
metal carbonates such as lithium carbonate, sodium carbonate, potassium
carbonate, calcium
carbonate or caesium carbonate, preferably caesium carbonate.
Alternatively, in the case of R4A = -0R6 the preparation of the compounds of
the formula (I-C-1) or
(I-C-2) can also be carried out under Mitsunobu conditions [see: a) Hughes, D.
L. "The Mitsunobu
Reaction," Organic Reactions; John Wiley & Sons, Ltd, 1992, vol. 42, p. 335.
b) Hughes, D. L.
Org. Prep. Proceed. Int. 1996, 28, 127.] starting with a compound of the
formula (IX-1) or (IX-2)
'2
.2
(R1), Q (R1)n
=H or
= H
P2
(D<-1) (IX-2)
in which n, L, Q, P, P2, RI and R2 are each as defined above.
Here, the Mitsunobu reaction is carried out using triphenylphosphine, or tri-n-
butylphosphine, 1,2-
bis(diphenylphosphino)ethane (DPPE), dipheny1(2-pyridyl)phosphine (Ph2P-Py),
(p-
dimethylaminophenyl)diphenylphosphine (DAP-DP), tris(4-
dimethylaminophenyl)phosphine (tris-
DAP), and a suitable dialkyl azodicarboxylate, for example diethyl
azodicarboxylate (DEAD),
diisopropyl azodicarboxylate (DIAD), di-tert-butyl azodicarboxylate, N,N,N'N'-
tetramethylazodicarboxamide (TMAD), 1,1'-(azodicarbonyl)dipiperidine (ADDP) or
4,7-dimethyl-
3,5,7-hexahydro-1,2,4,7-tetrazocine-3,8-dione (DHTD). Preference is given to
using
triphenylphosphine and diisopropyl azodicarboxylate (DIAD), or a suitable
azodicarboxamide such
as, for example, N,N,N',N'-tetramethyldiazene-1,2-dicarboxamide.
Inert solvents for the Mitsunobu reaction (IV-1) or (IV-2) + (V) ---> (I-C-1)
or (I-C-2) are, for
example, ethers such as tetrahydrofuran, diethyl ether, hydrocarbons such as
benzene, toluene,
xylene, halohydrocarbons such as dichloromethane, dichloroethane or other
solvents such as
acetonitrile, DMF or NMP. It is also possible to use mixtures of the solvents
mentioned.
Preference is given to using THF.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
- 99 -
The Mitsunobu reaction (IV-1) or (IV-2) + (V) --> (I-C-1) or (I-C-2) is
generally carried out in a
temperature range from -78 C to +180 C, preferably at 0 C to +50 C, optionally
in a microwave.
The conversions can be performed at atmospheric, elevated or reduced pressure
(for example from
0.5 to 5 bar).
In the case of R4A = -NR7R8, if R7 and le together with the nitrogen atom to
which they are
attached form a 5- or 6-membered heteroaryl, which may be substituted within
the scope of the
meaning given above, the conversion (IV-1) or (IV-2) + (V) ¨> (I-C-1) or (I-C-
2) is carried out in
the presence of a suitable copper catalyst such as, for example, copper(I)
oxide, with addition of 2-
hydroxybenzaldehyde oxime, and a suitable base such as, for example, alkaline
earth metal
carbonates such as lithium carbonate, sodium carbonate, potassium carbonate,
calcium carbonate
or caesium carbonate, preferably caesium carbonate.
The reaction (IV-1) or (IV-2) + (V) ---> (I-C-1) or (I-C-2) is generally
carried out in a temperature
range from +20 C to +200 C, preferably at +150 C to +200 C, preferably in a
microwave. The
conversion can be carried out at atmospheric, elevated or reduced pressure
(for example from 0.5
to 5 bar).
Suitable inert solvents for the cyclization (VIII) ¨> (I-D) are ethers such as
diethyl ether, dioxane,
tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether,
hydrocarbons such as
benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or
other solvents such as
dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N'-
dimethylpropyleneurea (DMPU),
dimethylacetamide, N-methylpyrrolidone (NMP), pyridine, acetonitrile or
sulpholane. It is also
possible to use mixtures of the solvents mentioned. Preference is given to
tetrahydrofuran.
Suitable bases for the cyclization (VIII) ¨> (I-D) are the customary inorganic
or organic bases.
These preferably include alkali metal hydroxides, for example lithium
hydroxide, sodium
hydroxide or potassium hydroxide, alkali metal or alkaline earth metal
carbonates such as lithium
carbonate, sodium carbonate, potassium carbonate, calcium carbonate or caesium
carbonate, alkali
metal alkoxides such as sodium methoxide or potassium methoxide, sodium
ethoxide or potassium
ethoxide or sodium or potassium tert-butoxide, alkali metal hydrides such as
sodium hydride or
potassium hydride, amides such as sodium amide, lithium
bis(trimethylsilyl)amide, sodium
bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide or lithium
diisopropylamide, or
organic amines such as triethylamine, N-methylmorpholine, N-methylpiperidine,
N,N-
diisopropylethylamine, pyridine, 1,5-diazabicyclo[4.3.0]non-5-ene
(DBN), 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,4-diazabicyclo[2.2.2]octarie (DABC0
). Preference is
given to using sodium bis(trimethylsilyl)amide.

BHC 12 1 012-Foreign CountriesCA 02866213 2014-09-03
- 100 -
The reaction (VIII) --> (I-D) is generally conducted within a temperature
range of -10 C to +80 C,
preferably at +10 C to +30 C. The conversion can be carried out at
atmospheric, elevated or
reduced pressure (for example from 0.5 to 5 bar). The reaction is generally
carried out at
atmospheric pressure.
Inert solvents for the reaction (VI) + (VII) --> (VIII) are ethers such as
diethyl ether, dioxane,
tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether,
hydrocarbons such as
benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or
other solvents such as
dimethylformamide (DMF), dimethyl sulphoxide (DMSO), N,N'-
dimethylpropyleneurea (DMPU),
dimethylacetamide, N-methylpyrrolidone (NMP), pyridine, acetonitrile or
sulpholane. It is also
possible to use mixtures of the solvents mentioned. Preference is given to
tetrahydrofuran.
Suitable bases for the reaction (VI) + (VII) ¨> (VIII) are the customary
inorganic or organic bases.
These preferably include alkali metal hydroxides, for example lithium
hydroxide, sodium
hydroxide or potassium hydroxide, alkali metal or alkaline earth metal
carbonates such as lithium
carbonate, sodium carbonate, potassium carbonate, calcium carbonate or caesium
carbonate, alkali
metal alkoxides such as sodium methoxide or potassium methoxide, sodium
ethoxide or potassium
ethoxide or sodium or potassium tert-butoxide, alkali metal hydrides such as
sodium hydride or
potassium hydride, amides such as sodium amide, lithium
bis(trimethylsilyl)amide, sodium
bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide or lithium
diisopropylamide, or
organic amines such as triethylamine, N-methylmorpholine, N-methylpiperidine,
N,N-
diisopropylethylamine, pyridine, 1,5-diazabicyclo[4.3.0Jnon-5-ene (DBN), 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,4-diazabicyclo[2.2.2]octane (DABC0
). Preference is
given to using sodium hydride.
The reaction (VI) + (VII) ¨> (VIII) is generally carried out in a temperature
range from -10 C to
+80 C, preferably from +10 C to +30 C. The conversion can be carried out at
atmospheric,
elevated or reduced pressure (for example from 0.5 to 5 bar). The reaction is
generally carried out
at atmospheric pressure.
Suitable nitrites for the conversions (I-B-1) or (I-B-2) --> (I-B-3) or (I-B-
4) are, for example,
sodium nitrite, isopentyl nitrite or tert-butyl nitrite.
Inert solvents for the conversions (I-B-1) or (I-B-2) ¨> (I-B-3) or (I-B-4)
are, for example, ethers
such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or
diethylene glycol dimethyl
ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide
(DMSO), N,N'-

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 101 -
dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine or
acetonitrile. It is also
possible to use mixtures of the solvents mentioned. Preference is given to
tetrahydrofuran or DMF.
The reactions (I-B-1) or (I-B-2) ¨> (I-B-3) or (I-B-4) are generally carried
out in a temperature
range from 0 C to +120 C, preferably at +40 C to +80 C. The conversion can be
carried out at
atmospheric, elevated or reduced pressure (for example from 0.5 to 5 bar). The
reaction is
generally carried out at atmospheric pressure.
The process step (I-B-1) --> (IV-1) or (I-B-2) --> (IV-2) is carried out with
or without solvents.
Suitable solvents are all organic solvents which are inert under the reaction
conditions. The
preferred solvent is dimethoxyethane.
The reaction (I-B-1) ---> (IV-1) or (I-B-2) --> (IV-2) is generally carried
out within a temperature
range from +20 C to +100 C, preferably within the range from +50 C to +100 C,
optionally in a
microwave. The conversion can be carried out at atmospheric, elevated or
reduced pressure (for
example in the range from 0.5 to 5 bar). The reaction is generally carried out
at atmospheric
pressure.
The process step (I-B-1) ---> (IV-1) or (I-B-2) ¨> (W-2) is generally carried
out using a molar ratio
of 10 to 30 mol of isopentyl nitrite and 10 to 30 mol of the iodine equivalent
based on 1 mol of the
compound of the formula (I-B-1) or (I-B-2).
Examples of suitable iodine sources in the conversion (I-B-1) --> (IV-1) or (I-
B-2) --> (W-2)
include diiodomethane or a mixture of caesium iodide, iodine and copper(I)
iodide.
Inert solvents for the process step (I-B-1) --> (I-B-3) or (I-B-2) (I-B-4)
are alcohols such as
methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol or 1,2-
ethanediol, ethers such
as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or
diethylene glycol dimethyl
ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide
(DMSO), N,Nr-
dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), pyridine,
acetonitrile or else water.
It is also possible to use mixtures of the solvents mentioned. Preference is
given to DMF.
The reduction (I-B-1) --> (I-B-3) or (I-B-2) --> (I-B-4) is carried out using
hydrogen in conjunction
with transition metal catalysts, for example palladium (10% on activated
carbon), Raney nickel or
palladium hydroxide.
The reaction (I-B-1) ---> (I-B-3) or (I-B-2) --> (I-B-4) is generally carried
out within a temperature
range from +20 C to +50 C. The conversion can be carried out at atmospheric or
elevated pressure

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
,
- 102 -
(for example in the range from 0.5 to 5 bar). The reaction is generally
carried out at atmospheric
pressure.
The preparation processes described above are illustrated by way of example by
the following
synthesis schemes (Schemes 1 and 2):
Scheme 1:
F
/----0
___________________________________________________ N N
...j..zTiN\
CN I-12N
CN
H2Ni
i
1 / N
N/ \
F..xci
FIN):S.,...CH,
N
C N
I
F F
N N N ....
,x..N........N. \ N
\
LX
F
F F
N
N H N
H 2
/ \e H N
= ----
N CH3
[potassium tert-butoxide, DMF, microwave, 160 C].

BHC 121 012-Foreign Countries CA 02866213 2014-09-03
- 103 -
Scheme 2:
41Ik
I /N
I /N
N
N\_ a) N
CI ,
HN
)or
0 F=>. F
[a): 3,3,3-trifluoropropy1-1-amine hydrochloride, N,N-diisopropylethylamine,
NMP, microwave,
150 C].
The compounds of the formulae (III-1), (III-2), (V) and (VII) are commercially
available, known
from the literature or can be prepared in analogy to literature processes.
The compounds of the formulae (II), (I-B-1), (I-B-2), (IV-1), (IV-2) and (VI)
are known from the
literature, can be prepared analogously to processes known from the literature
or as described in
the present experimental section.
The compounds according to the invention are potent stimulators of soluble
guanylate cyclase,
have valuable pharmacological properties and have an improved therapeutic
profile, for example
with respect to the in vivo properties thereof and/or the pharmacokinetic
characteristics and/or
metabolic profile thereof. They are therefore suitable for the treatment
and/or prophylaxis of
diseases in humans and animals.
The compounds according to the invention bring about vasorelaxation and
inhibition of platelet
aggregation, and lead to a decrease in blood pressure and to a rise in
coronary blood flow. These
effects are mediated by a direct stimulation of soluble guanylate cyclase and
an intracellular rise in
cGMP. In addition, the compounds according to the invention enhance the action
of substances
which increase the cGMP level, for example EDRF (endothelium-derived relaxing
factor), NO
donors, protoporphyrin IX, arachidonic acid or phenylhydrazine derivatives.
The compounds according to the invention are suitable for the treatment and/or
prophylaxis of
cardiovascular, pulmonary, thromboembolic and fibrotic disorders.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 104 -
Accordingly, the compounds according to the invention can be used in
medicaments for the
treatment and/or prophylaxis of cardiovascular disorders such as, for example,
hypertension, acute
and chronic heart failure, coronary heart disease, stable and unstable angina
pectoris, peripheral
and cardiac vascular disorders, arrhythmias, atrial and ventricular
arrhythmias and impaired
conduction such as, for example, atrioventricular blocks degrees I-III (AB
block I-III),
supraventricular tachyarrhythrnia, atrial fibrillation, atrial flutter,
ventricular fibrillation,
ventricular flutter, ventricular tachyarrhythmia, Torsade de pointes
tachycardia, atrial and
ventricular extrasystoles, AV-junctional extrasystoles, sick sinus syndrome,
syncopes, AV-nodal
re-entry tachycardia, Wolff-Parkinson-White syndrome, of acute coronary
syndrome (ACS),
autoimmune cardiac disorders (pericarditis, endocarditis, valvolitis,
aortitis, cardiomyopathies),
shock such as cardiogenic shock, septic shock and anaphylactic shock,
aneurysms, boxer
cardiomyopathy (premature ventricular contraction (PVC)), for the treatment
and/or prophylaxis of
thromboembolic disorders and ischaemias such as myocardial ischaemia,
myocardial infarction,
stroke, cardiac hypertrophy, transient and ischaemic attacks, preeclampsia,
inflammatory
cardiovascular disorders, spasms of the coronary arteries and peripheral
arteries, oedema formation
such as, for example, pulmonary oedema, cerebral oedema, renal oedema or
oedema caused by
heart failure, peripheral circulatory disturbances, reperfusion damage,
arterial and venous
thromboses, microalbuminuria, myocardial insufficiency, endothelial
dysfunction, to prevent
restenoses, for example after thrombolysis therapies, percutaneous
transluminal angioplasties
(PTA), transluminal coronary angioplasties (PTCA), heart transplants and
bypass operations, and
also micro- and macrovascular damage (vasculitis), increased levels of
fibrinogen and of low-
density lipoprotein (LDL) and increased concentrations of plasminogen
activator inhibitor 1 (PAI-
1), and also for the treatment and/or prophylaxis of erectile dysfunction and
female sexual
dysfunction.
In the context of the present invention, the term heart failure also includes
more specific or related
types of disease, such as acute decompensated heart failure, right heart
failure, left heart failure,
global failure, ischaemic cardiomyopathy, dilated cardiomyopathy, hypertrophic
cardiomyopathy,
idiopathic cardiomyopathy, congenital heart defects, heart valve defects,
heart failure associated
with heart valve defects, mitral stenosis, mitral insufficiency, aortic
stenosis, aortic insufficiency,
tricuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis,
pulmonary valve
insufficiency, combined heart valve defects, myocardial inflammation
(myocarditis), chronic
myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure,
alcoholic cardiomyopathy,
cardiac storage disorders, and diastolic and systolic heart failure.
In addition, the compounds according to the invention can also be used for the
treatment and/or
prophylaxis of arteriosclerosis, impaired lipid metabolism,
hypolipoproteinaemias, dyslipidaemias,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 105 -
hypertriglyceridaemias , hyperlipidaemias, hyperchol esterolaemias,
abetalipoproteinaemia,
sitosterolaemia, xanthomatosis, Tangier disease, adiposity, obesity and of
combined
hyperlipidaemias and metabolic syndrome.
The compounds according to the invention can additionally be used for the
treatment and/or
prophylaxis of primary and secondary Raynaud's phenomenon, of microcirculation
impairments,
claudication, peripheral and autonomic neuropathies, diabetic
microangiopathies, diabetic
retinopathy, diabetic ulcers on the extremities, gangrene, CREST syndrome,
erythematosis,
onychomycosis, rheumatic disorders and for promoting wound healing.
The compounds according to the invention are furthermore suitable for treating
urological
disorders such as, for example, benign prostate syndrome (BPS), benign
prostate hyperplasia
(BPH), benign prostate enlargement (BPE), bladder outlet obstruction (BOO),
lower urinary tract
syndromes (LUTS, including Feline Urological Syndrome (FUS)), disorders of the
urogenital
system including neurogenic overactive bladder (OAB) and (IC), incontinence
(UI) such as, for
example, mixed urinary incontinence, urge urinary incontinence, stress urinary
incontinence or
overflow urinary incontinence (MUI, UUI, SUI, OUI), pelvic pain, benign and
malignant disorders
of the organs of the male and female urogenital system.
The compounds according to the invention are furthermore suitable for the
treatment and/or
prophylaxis of kidney disorders, in particular of acute and chronic renal
insufficiency and acute
and chronic renal failure. In the context of the present invention, the term
renal insufficiency
comprises both acute and chronic manifestations thereof, as well as underlying
or related kidney
diseases such as renal hypoperfusion, intradialytic hypotension, obstructive
uropathy,
glomerulopathies, glomerulonephritis, acute glomerulonephritis,
glomerulosclerosis,
tubulointerstitial diseases, nephropathic diseases such as primary and
congenital kidney disease,
nephritis, immunological kidney diseases such as kidney graft rejection and
immunocomplex-
induced kidney diseases, nephropathy induced by toxic substances, nephropathy
induced by
contrast agents, diabetic and non-diabetic nephropathy, pyelonephritis, renal
cysts,
nephrosclerosis, hypertensive nephrosclerosis and nephrotic syndrome, which
can be characterized
diagnostically for example by abnormally reduced creatinine and/or water
excretion, abnormally
raised blood concentrations of urea, nitrogen, potassium and/or creatinine,
altered activity of renal
enzymes such as, for example, glutamyl synthetase, altered urine osmolarity or
urine volume,
increased microalbuminuria, macroalbuminuria, lesions on glomerulae and
arterioles, tubular
dilatation, hyperphosphataemia and/or need for dialysis. The present invention
also encompasses
the use of the compounds according to the invention for the treatment and/or
prophylaxis of
sequelae of renal insufficiency, for example pulmonary oedema, heart failure,
uraemia, anaemia,

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 106 -
electrolyte disturbances (for example hyperkalaemia, hyponatraemia) and
disturbances in bone and
carbohydrate metabolism.
Furthermore, the compounds according to the invention are also suitable for
the treatment and/or
prophylaxis of asthmatic disorders, pulmonary arterial hypertension (PAH) and
other forms of
pulmonary hypertension (PH) including left-heart disease, HIV, sickle cell
anaemia,
thromboembolisms (CTEPH), sarcoidosis, COPD or pulmonary fibrosis-associated
pulmonary
hypertension, chronic-obstructive pulmonary disease (COPD), acute respiratory
distress syndrome
(ARDS), acute lung injury (ALT), alpha-1 -antitrypsin deficiency (AATD),
pulmonary fibrosis,
pulmonary emphysema (for example pulmonary emphysema induced by cigarette
smoke) and
cystic fibrosis (CF).
The compounds described in the present invention are also active compounds for
control of central
nervous system disorders characterized by disturbances of the NO/cGMP system.
They are suitable
in particular for improving perception, concentration, learning or memory
after cognitive
impairments like those occurring in particular in association with
situations/diseases/syndromes
such as mild cognitive impairment, age-associated learning and memory
impairments, age-
associated memory losses, vascular dementia, craniocerebral trauma, stroke,
dementia occurring
after strokes (post stroke dementia), post-traumatic craniocerebral trauma,
general concentration
impairments, concentration impairments in children with learning and memory
problems,
Alzheimer's disease, Lewy body dementia, dementia with degeneration of the
frontal lobes
including Pick's syndrome, Parkinson's disease, progressive nuclear palsy,
dementia with
corticobasal degeneration, amyolateral sclerosis (ALS), Huntington's disease,
demyelinisation,
multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV
dementia,
schizophrenia with dementia or Korsakoff s psychosis. They are also suitable
for the treatment
and/or prophylaxis of central nervous system disorders such as states of
anxiety, tension and
depression, CNS-related sexual dysfunctions and sleep disturbances, and for
controlling
pathological disturbances of the intake of food, stimulants and addictive
substances.
Furthermore, the compounds according to the invention are also suitable for
regulating cerebral
blood flow and are thus effective agents for control of migraine. They are
also suitable for
prophylaxis and control of sequelae of cerebral infarction (cerebral apoplexy)
such as stroke,
cerebral ischaemia and craniocerebral trauma. The compounds according to the
invention can
likewise be employed for controlling states of pain and tinnitus.
In addition, the compounds according to the invention have antiinflammatory
action and can
therefore be used as antiinflarnmatory agents for the treatment and/or
prophylaxis of sepsis (SIRS),

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 107 -
multiple organ failure (MODS, MOF), inflammatory disorders of the kidney,
chronic intestinal
inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis,
rheumatoid disorders,
inflammatory skin diseases and inflammatory eye diseases.
Furthermore, the compounds according to the invention can also be used for the
treatment and/or
prophylaxis of autoimmune diseases.
The compounds according to the invention are furthermore suitable for the
treatment and/or
prophylaxis of fibrotic disorders of the internal organs such as, for example,
the lung, the heart, the
kidney, the bone marrow and in particular the liver, and also dermatological
fibroses and fibrotic
eye disorders. In the context of the present invention, the term fibrotic
disorders includes in
particular the following terms: hepatic fibrosis, cirrhosis of the liver,
pulmonary fibrosis,
endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal
fibrosis, fibrotic
damage resulting from diabetes, bone marrow fibrosis and similar fibrotic
disorders, scleroderma,
morphea, keloids, hypertrophic scarring (also following surgical procedures),
naevi, diabetic
retinopathy, proliferative vitroretinopathy and disorders of the connective
tissue (for example
sarkoidosis).
The compounds according to the invention are furthermore suitable for
controlling postoperative
scarring, for example as a result of glaucoma operations.
The compounds according to the invention can also be used cosmetically for
ageing and
keratinized skin.
Moreover, the compounds according to the invention are suitable for the
treatment and/or
prophylaxis of hepatitis, neoplasms, osteoporosis, glaucoma and gastroparesis.
The present invention further provides for the use of the compounds according
to the invention for
the treatment and/or prophylaxis of disorders, in particular the disorders
mentioned above.
The present invention further provides for the use of the compounds according
to the invention for
the treatment and/or prophylaxis of heart failure, angina pectoris,
hypertension, pulmonary
hypertension, ischaemias, vascular disorders, renal insufficiency,
thromboembolic disorders,
fibrotic disorders and arteriosclerosis.
The present invention further provides the compounds according to the
invention for use in a
method for the treatment and/or prophylaxis of heart failure, angina pectoris,
hypertension,
pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency,
thromboembolic
disorders, fibrotic disorders and arteriosclerosis.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 108 -
The present invention further provides for the use of the compounds according
to the invention for
production of a medicament for the treatment and/or prophylaxis of disorders,
especially of the
aforementioned disorders.
The present invention further provides for the use of the compounds according
to the invention for
producing a medicament for the treatment and/or prophylaxis of heart failure,
angina pectoris,
hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal
insufficiency,
thromboembolic disorders, fibrotic disorders and arteriosclerosis.
The present invention further provides a method for the treatment and/or
prophylaxis of disorders,
in particular the disorders mentioned above, using an effective amount of at
least one of the
compounds according to the invention.
The present invention further provides a method for the treatment and/or
prophylaxis of heart
failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias,
vascular disorders,
renal insufficiency, thromboernbolic disorders, fibrotic disorders and
arteriosclerosis using an
effective amount of at least one of the compounds according to the invention.
The compounds according to the invention can be employed alone or, if
required, in combination
with other active compounds. The present invention further provides
medicaments comprising at
least one of the compounds according to the invention and one or more further
active compounds,
especially for the treatment and/or prophylaxis of the aforementioned
disorders. Preferred
examples of suitable active compound combinations include:
= organic nitrates and NO donors, for example sodium nitroprusside,
nitroglycerin, isosorbide
mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
= compounds which inhibit the breakdown of cyclic guanosine monophosphate
(cGMP), for
example inhibitors of phosphodiesterases (PDE) 1, 2 and/or 5, in particular
PDE 5 inhibitors
such as sildenafil, vardenafil and tadalafil;
= agents having antithrombotic activity, for example and with preference from
the group of
platelet aggregation inhibitors, of anticoagulants or of profibrinolytic
substances;
= active compounds lowering blood pressure, for example and preferably from
the group of
calcium antagonists, angiotensin All antagonists, ACE inhibitors, endothelin
antagonists, renin
inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid
receptor
antagonists, and of diuretics; and/or

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 109 -
= active compounds altering lipid metabolism, for example and with
preference from the group of
thyroid receptor agonists, cholesterol synthesis inhibitors such as, by way of
example and
preferably, HMG-CoA reductase inhibitors or squalene synthesis inhibitors, of
ACAT
inhibitors, CETP inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or
PPAR-delta
agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile
acid adsorbents,
bile acid reabsorption inhibitors and lipoprotein(a) antagonists.
Antithrombotic agents are preferably understood to mean compounds from the
group of the
platelet aggregation inhibitors, the anticoagulants or the profibrinolytic
substances.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a platelet aggregation inhibitor, by way of
example and with
preference aspirin, clopidogrel, ticlopidin or dipyridamole.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a thrombin inhibitor, by way of example and
with preference
ximelagatran, dabigatran, melagatran, bivalirudin or clexane.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a GPIIb/IIIa antagonist such as, by way of
example and with
preference, tirofiban or abciximab.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a factor Xa inhibitor, by way of example and
with preference
rivaroxaban (BAY 59-7939), DU-176b, apixaban, otamixaban, fidexaban,
razaxaban,
fondaparinux, idraparinux, PMD-3112, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-
1021,
DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with heparin or with a low molecular weight (LMW)
heparin
derivative.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a vitamin K antagonist, by way of example and
with preference
coumarin.
Hypotensive agents are preferably understood to mean compounds from the group
of calcium
antagonists, angiotensin All antagonists, ACE inhibitors, endothelin
antagonists, renin inhibitors,

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
=
- 110 -
alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor
antagonists, and the
diuretics.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a calcium antagonist, by way of example and
with preference
nifedipine, amlodipine, verapamil or diltiazem.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an alpha-1 -receptor blocker, by way of
example and with
preference prazosin.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a beta-receptor blocker, by way of example
and with preference
propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol,
bupranolol,
metipranolol, nadolol, mepindolol, carazalol, sotalol, metoprolol, betaxolol,
celiprolol, bisoprolol,
carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol,
epanolol or bucindolol.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an angiotensin All antagonist, by way of
example and with
preference losartan, candesartan, valsartan, telmisartan or embusartan.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an ACE inhibitor, by way of example and with
preference
enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril,
perindopril or trandopril.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an endothelin antagonist, by way of example
and with
preference bosentan, darusentan, ambrisentan or sitaxsentan.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a renin inhibitor, by way of example and with
preference
aliskiren, SPP-600 or SPP-800.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a mineralocorticoid receptor antagonist, by
way of example and
with preference spironolactone or eplerenone.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a loop diuretic, for example furosemide,
torasemide, bumetanide

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 111 -
and piretanide, with potassium-sparing diuretics, for example amiloride and
triamterene, with
aldosterone antagonists, for example spironolactone, potassium canrenoate and
eplerenone, and
also thiazide diuretics, for example hydrochlorothiazide, chlorthalidone,
xipamide and indapamide.
Lipid metabolism modifiers are preferably understood to mean compounds from
the group of the
CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors
such as HMG-CoA
reductase inhibitors or squalene synthesis inhibitors, the ACAT inhibitors,
MTP inhibitors, PPAR-
alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption
inhibitors, polymeric bile
acid adsorbents, bile acid reabsorption inhibitors, lipase inhibitors and the
lipoprotein (a)
antagonists.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a CETP inhibitor, by way of example and with
preference
dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a thyroid receptor agonist, by way of example
and with
preference D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome
(CGS 26214).
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an HMG-CoA reductase inhibitor from the class
of statins, by
way of example and with preference lovastatin, simvastatin, pravastatin,
fluvastatin, atorvastatin,
rosuvastatin or pitavastatin.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a squalene synthesis inhibitor, by way of
example and with
preference BMS-188494 or TAK-475.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an ACAT inhibitor, by way of example and with
preference
avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with an MTP inhibitor, by way of example and with
preference
implitapide, BMS-201038, R-103757 or JTT-130.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a PPAR-gamma agonist, by way of example and
with preference
pioglitazone or rosiglitazone.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 112 -
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a PPAR-delta agonist, by way of example and
with preference
GW 501516 or BAY 68-5042.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a cholesterol absorption inhibitor, by way of
example and with
preference ezetimibe, tiqueside or pamaqueside.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a lipase inhibitor, a preferred example being
orlistat.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a polymeric bile acid adsorbent, by way of
example and with
preference cholestyramine, colestipol, colesolvam, CholestaGel or colestimide.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a bile acid reabsorption inhibitor, by way of
example and with
preference ASBT (= IBAT) inhibitors, for example AZD-7806, S-8921, AK-105,
BARI-1741, SC-
435 or SC-635.
In a preferred embodiment of the invention, the compounds according to the
invention are
administered in combination with a lipoprotein(a) antagonist, by way of
example and with
preference gemcabene calcium (CI-1027) or nicotinic acid.
The present invention further provides medicaments which comprise at least one
compound
according to the invention, typically together with one or more inert, non-
toxic, pharmaceutically
suitable excipients, and for the use thereof for the aforementioned purposes.
The compounds according to the invention may act systemically and/or locally.
For this purpose,
they can be administered in a suitable manner, for example by the oral,
parenteral, pulmonal, nasal,
sublingual, lingual, buccal, rectal, dermal, transderrnal, conjunctival or
otic route, or as an implant
or stent.
The compounds according to the invention can be administered in administration
forms suitable
for these administration routes.
Administration forms which function according to the prior art, release the
compounds according
to the invention rapidly and/or in a modified manner and contain the compounds
according to the
invention in crystalline and/or amorphized and/or dissolved form are suitable
for oral

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
- 113 -
administration, such as e.g. tablets (non-coated or coated tablets, for
example with enteric coatings
or coatings that dissolve in a delayed manner or are insoluble and control the
release of the
compound according to the invention), tablets or films/oblates,
films/lyophilizates or capsules
which disintegrate rapidly in the oral cavity (for example hard or soft
gelatine capsules), sugar-
coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols
or solutions.
Parenteral administration can bypass an absorption step (e.g. intravenously,
intraarterially,
intracardially, intraspinally or intralumbally) or include an absorption (e.g.
intramuscularly,
subcutaneously, intracutaneously, percutaneously or intraperitoneally).
Suitable administration
forms for parenteral administration include injection and infusion
formulations in the form of
solutions, suspensions, emulsions, lyophilizates or sterile powders.
For the other administration routes, suitable examples are inhalable
medicament forms (including
powder inhalers, nebulizers), nasal drops, solutions or sprays, tablets,
films/oblates or capsules for
lingual, sublingual or buccal administration, suppositories, ear or eye
preparations, vaginal
capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic
suspensions, ointments,
creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams,
sprinkling powders,
implants or stents.
Preference is given to oral or parenteral administration, especially oral
administration.
The compounds according to the invention can be converted to the
administration forms
mentioned. This can be done in a manner known per se, by mixing with inert,
nontoxic,
pharmaceutically suitable excipients. These excipients include carriers (for
example
microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid
polyethylene glycols),
emulsifiers and dispersing or wetting agents (for example sodium
dodecylsulphate,
polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic
and natural
polymers (for example albumin), stabilizers (e.g. antioxidants, for example
ascorbic acid), dyes
(e.g. inorganic pigments, for example iron oxides) and flavour and/or odour
correctants.
In general, it has been found to be advantageous in the case of parenteral
administration to
administer amounts of about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5
mg/kg, of body weight
to achieve effective results. In the case of oral administration, the dose is
about 0.001 to 2 mg/kg,
preferably about 0.001 to 1 mg/kg, of body weight.
It may nevertheless be necessary where appropriate to deviate from the stated
amounts, specifically
as a function of the body weight, route of administration, individual response
to the active
compound, nature of the preparation and time or interval over which
administration takes place.

BHC 121 012-Foreign Countries CA 02866213 2014-09-03
- 114 -
For instance, in some cases, less than the aforementioned minimum amount may
be sufficient,
while in other cases the upper limit mentioned must be exceeded. In the case
of administration of
greater amounts, it may be advisable to divide them into several individual
doses over the day.
The working examples which follow illustrate the invention. The invention is
not limited to the
examples.
The percentages in the tests and examples which follow are, unless indicated
otherwise,
percentages by weight; parts are parts by weight. Solvent ratios, dilution
ratios and concentration
figures for liquid/liquid solutions are each based on volume.

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
=
- 115 -
A. Examples
Abbreviations and acronyms:
aq. aqueous solution
calc. calculated
DCI direct chemical ionization (in MS)
DMF dimethylformamide
DMSO dimethyl sulphoxide
eq. equivalent(s)
ESI electrospray ionization (in MS)
Et ethyl
hour(s)
HPLC high-pressure, high-performance liquid
chromatography
FIRMS high-resolution mass spectrometry
conc. concentrated
LC/MS liquid chromatography-coupled mass spectrometry
LiHMDS lithium hexamethyldisilazide
Me methyl
min minute(s)
MS mass spectrometry
NMR nuclear magnetic resonance spectrometry
Pd/C palladium on activated carbon (10%)
Ph phenyl
RT room temperature
Rt retention time (in HPLC)
t-Bu tert-butyl
TFA trifluoroacetic acid
THF tetrahydrofuran
UV ultraviolet spectrometry
v/v ratio by volume (of a solution)
XPHOS dicyclohexyl(21,4',61-triisopropylbipheny1-2-
yl)phosphine

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 116 -
HPLC and LC/MS methods:
Method 1 (LC-MS):
Instrument: Waters ACQUITY SQD UPLC System; column: Waters Acquity UPLC HSS T3
1.8u
50 x lmm; mobile phase A: 11 of water + 0.25 ml of 99% strength formic acid,
mobile phase B: 1
I of acetonitrile + 0.25 ml of 99% strength formic acid; gradient: 0.0 min 90%
A ¨+ 1.2 min 5% A
---> 2.0 min 5% A; oven: 50 C; flow rate: 0.40 mUmin; UV detection: 210 ¨ 400
nm.
Method 2 (LC-MS):
Instrument: Waters ACQUITY SQD UPLC System; column: Waters Acquity UPLC HSS T3
1.8
30 x 2 mm; mobile phase A: 11 of water + 0.25 ml of 99% strength formic acid,
mobile phase B: 1
1 of acetonitrile + 0.25 ml of 99% strength formic acid; gradient: 0.0 min 90%
A ¨+ 1.2 min 5% A
--+ 2.0 min 5% A; oven: 50 C; flow rate: 0.60 ml/min; UV detection: 208 ¨ 400
nm.
Method 3 (LC-MS):
Instrument: Micromass QuattroPremier with Waters UPLC Acquity; column: Thermo
Hypersil
GOLD 1.91L, 50 mm x 1 mm; mobile phase A: 11 of water + 0.5 ml of 50% strength
formic acid,
mobile phase B: 11 of acetonitrile + 0.5 ml of 50% strength formic acid;
gradient: 0.0 min 90% A
¨* 0.1 min 90% A --> 1.5 min 10% A ---> 2.2 mm 10% A; flow rate: 0.33 ml/min;
oven: 50 C; UV
detection: 210 nm.
General procedures:
General procedure 1:
In a microwave vessel with stirrer magnet, 1.0 eq of example 2A (100 mg, 0.369
mmol) was
dissolved together with 1.0 eq of the appropriate aminonitrile and 1.0 eq of
potassium tert-
butoxide in dimethylformamide (2.5 ml), and the vessel was closed and heated
at 160 C under
microwave irradiation for 2 h. This was followed by reaction analysis. In the
case of incomplete
conversion, a further 0.5 eq of potassium tert-butoxide was added and the
mixture was heated
again at 160 C under microwave irradiation until complete conversion. The
reaction mixture was
purified by preparative HPLC (mobile phase: acetonitrile/water with 0.05% of
formic acid,
gradient).
General procedure 2:

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 117 -
In a microwave vessel with stirrer magnet, 1.0 eq of example 2A (100 mg, 0.32
mmol) was
dissolved together with 1.0 eq of the appropriate aminonitrile and 1.0 eq of
potassium tert-
butoxide in dimethylformamide (2 ml), and the vessel was closed and heated at
160 C under
microwave irradiation for 2 h. This was followed by reaction analysis. If
required (cf. examples),
further reagents were added and the mixture was heated again under microwave
irradiation. The
reaction mixture was purified by preparative HPLC (mobile phase:
acetonitrile/water with 0.01%
of formic acid, gradient).

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 118 -
Starting materials and intermediates:
Example 1A
5-Fluoro-1 -[(3-fluoropyridin-2 -yl)methy1]-3-iodo-1H-pyrazolo [3,4-13]
pyridine
FN
6.291 g (23.921 mmol) of 5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine (described
in WO
2011/147809, Example 1, page 42) and 8.573 g (26.313 mmol) of caesium
carbonate were initially
charged in DMF (10 ml), and 5.00 g (26.313 mmol) of 2-(bromomethyl)-3-
fluoropyridine
dissolved in DMF (20 ml) were then added dropwise. The mixture was stirred at
RT overnight.
The mixture was then cooled and poured into 200 ml of water. A precipitate was
filtered off with
suction, washed with water and dried under high vacuum overnight. This gave
6.28 g (70% of
theory) of the title compound.
LC-MS (Method 3): Rt = 2.17 min
MS (ESIpos): m/z = 373 (M+H)+
NMR (400 MHz; DMSO-d6): 8 = 5.88 (s, 2H), 7.42-7.46 (m, 1H), 7.77 (dd, 1H),
7.93 (dd, 1H),
8.27 (d, 111), 8.67 (t, 1H).
Example 2A
5 -Fluoro-1 -[(3-fluoropyridin-2-yOmethyl]-1H-pyrazolo [3 ,4-b]pyridine-3 -
carbonitrile

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 119 -
F
r
Ns......õN\
I ,N
/
F
\\
N
6.280 g (16.876 mmol) of Example 1A and 1.663 g (18.564 mmol) of copper(I)
cyanide were
initially charged in DMSO (100 ml) and stirred at 150 C for 3 h. After
cooling, the reaction
mixture was filtered through Celite and the filter cake was washed with ethyl
acetate. The filtrate
was extracted four times with saturated aqueous ammonium chloride solution and
conc. aqueous
ammonia (3:1 v/v), and the organic phase was separated off. The organic phase
was then washed
with saturated aqueous sodium chloride solution, dried over sodium sulphate,
filtered and
concentrated under reduced pressure. This gave 3.97 g (86% of theory) of the
title compound.
LC-MS (Method 1): R, = 0.92 min
MS (ESIpos): m/z = 272 (M+H)
11-1 NMR (400 MHz; DMSO-d6): 8 = 6.04 (s, 2H), 7.44-7.48 (m, 1H), 7.61 (t,
1H), 8.26 (d, 1H),
8.52 (dd, 1H), 8.83 (dd, 1H).
Example 3A
Methyl {4,6-diamino-245-fluoro-1 -(2-fluorobenzy1)-1H-pyrazolo [3,4-b]pyridin-
3-yl]pyrimidin-5-
yl}(2,2,2-trifluoroethyl)carbamate

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
-
- 120 -
F
=
N N
1 \N
/
F
/ N
N).............
NH2
H2N N---e
....... (:)."-CH3
F
F F
The synthesis of this compound is described in WO 2011/147809, Example 3, page
44.
Example 4A
6-Amino-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-13]pyridin-3-y1]-7-
(2,2,2-trifluoroethyl)-
7,9-dihydro-8H-purin-8-one
F
N
1
F \N
/
/ N
N).......?___
NH2
HN)rN
0 -......
Fõ,.- F
F
Under an argon atmosphere, 5.005 g (6.458 mmol) of the compound from Example
3A were
dissolved in 355 ml of tetrahydrofuran and cooled to 0 C, and 16.145 ml
(16.145 mmol) of a 1N
solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran were added
dropwise. The mixture

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
-
- 121 -
was stirred at 0 C for 2 h and then at RT for 16 h. 16.145 ml (16.145 mmol) of
1N hydrochloric
acid were added and the mixture was concentrated on a rotary evaporator. The
residue was taken
up in ethyl acetate and the organic phase was washed twice with water, dried
over sodium sulphate
and concentrated on a rotary evaporator. This gave 6.13 g of the title
compound (purity by HPLC
61%). 500 mg of the residue were purified by preparative HPLC (mobile phase:
methanol/water,
gradient 30:70 ¨> 90:10). This gave 93 mg of the title compound (36% of
theory).
LC-MS (Method 1): R., = 1.01 mm; MS (EIpos): rn/z = 477 [M+11].
11-1 NMR (400 MHz; DMSO-d6): 8 [ppm] = 4.91 (q, 2H), 5.80 (s, 2H), 7.01 (s br,
2H), 7.13-7.18
(m, 1H), 7.21-7.26 (m, 2H), 7.34-7.40 (m, 1H), 8.70 (dd, 1H), 8.87 (dd, 1H),
11.96 (s, 1H).
Example 5A
2-[5-Fluoro-1-(2-fluorobenzy1)-1H-pyrazolo [3,4-b]pyridin-3-y1]-6-iodo-7-
(2,2,2-trifluoroethyl)-
7,9-dihydro-8H-purin-8-one
F
glik
Nlsk....õ1\1\
N
F
N),....?....õ1
0 õ,...-.......
F F
F
4.650 g (5.954 mmol) of the compound from Example 4A were dissolved in 12 ml
of
diiodomethane and 12.76 ml (95.270 mmol) of isopentyl nitrite were added. The
reaction mixture
was heated to 85 C for 16 h and, after cooling, concentrated on a rotary
evaporator. This gave 5 g
of the crude product (purity 54%). 1.2 g of the residue were purified by
preparative HPLC (mobile
phase: acetonitrile/water with 0.05% formic acid, gradient 40:60 ¨> 95:5).
This gave 128 mg of the
title compound (15% of theory).
LC-MS (Method 1): R,= 1.23 min; MS (EIpos): m/z = 588 [M+H].

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
,
- 122 -
1H NMR (400 MHz; DMSO-d6): 5 [ppm] = 4.95 (q, 2H), 5.86 (s, 2H), 7.14-7.18 (m,
1H), 7.21-7.27
(m, 2H), 7.35-7.41 (m, 1H), 8.47 (dd, 1H), 8.76 (dd, 1H), 12.79 (s, 1H).
Example 6A
6-Chloro-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-7-
(2,2,2-trifluoroethyl)-
7,9-dihydro-8H-purin-8-one
F
=
N
FI \N
/
/ N
N).........?õ.
CI
HNyN,
0 ......--...õ.
F F
F
262 mg (0.446 mmol) of the compound from Example 5A in 4 ml of phosphoryl
chloride were
heated at 85 C for 2 hours. The reaction was then poured into warm water and
stirred for 1 hour. A
solid formed, which was filtered off and washed with a little water. After
drying under high
vacuum, this gave 198 mg of the title compound (89% of theory).
LC-MS (Method 1): R, = 1.29 min; MS (EIpos): m/z = 496 [M+11]+.
1H NMR (400 MHz; DMSO-d6): 8 [ppm] = 4.86 (q, 2H), 5.86 (s, 2H), 7.15-7.19 (m,
1H), 7.21-7.30
(m, 2H), 7.35-7.41 (m, 1H), 8.49 (dd, 1H), 8.77 (dd, 1H), 12.95 (s, 1H).
Example 7A
2-(2-Fluoropheny1)-N-[(6-oxo-1,4,5,6-tetrahydropyridazin-3-yOmethyl]acetamide

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
-123-
0
HN
1411
200.00 g (1.101 mol) of methyl 5-amino-4-oxopentanoate hydrochloride were
initially charged in
ethanol (3500 ml), 64.28 ml (1.321 mol) of hydrazine hydrate were added and
the mixture was
then heated at reflux for 45 min. After cooling, triethylamine (152 ml) was
added and the mixture
was evaporated to dryness. Water (500 ml) was added to the residue, and the
mixture was
concentrated. Ethanol (500 ml) was then added, the mixture was concentrated,
and then toluene
(500 ml) was added twice, followed in each case by evaporation to dryness. The
residue (140 g)
was dissolved in acetonitrile (500 ml) and, at 0 C, slowly added to a solution
of 307.85 g (1.784
mol) of (2-fluorophenyl)acetyl chloride (preparation: Journal of Organic
Chemistry; 22; 1957;
879) and 304.86 ml (2.202 mol) of triethylamine in acetonitrile (1500 ml) and
molecular sieve.
The mixture was stirred at 20 C for 3 days. The mixture was then filtered and
the precipitate was
washed with tert-butyl methyl ether and then dried. This gave 458 g of the
target compound (90%
of theory).
LC-MS (Method 1): R1 = 0.57 mm; MS (EIpos): tniz = 264 [M+H].
Example 8A
2-(2-Fluoropheny1)-N-[(6-oxo-1,6-dihydropyridazin-3-yOmethyl]acetamide
0
HN
0
458 g (1.740 mol) of the compound obtained in Example 7A were initially
charged in acetic acid
(2250 ml), and the mixture was warmed to 50 C. At this temperature, 98.16 ml
(1.914 mol) of
bromine were added dropwise with vigorous stirring, and stirring was then
continued at 50 C for 3
h. After cooling, the reaction mixture was concentrated to dryness. The
residue was stirred with
saturated aqueous sodium bicarbonate solution (4800 m1). The mixture was then
filtered and the
precipitate was washed with a little water. The filtrate was extracted twice
with ethyl acetate. The

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 124 -
organic phases were combined, dried and concentrated. This gave 117 g of the
target compound
(25% of theory).
LC-MS (Method 1): R, = 0.56 min; MS (EIpos): m/z = 262 [M+H].
'11 NMR (400 MHz; DMSO-d6): 8 [ppm] ¨ 3.54 (s, 2H), 4.16 (d, 2H), 6.86 (d,
1H), 7.12-7.16 (m,
Example 9A
2-Chloro-7-(2-fluorobenzyl )imida 7o [1,5-b] pyridazine
F
CIN,
'-=%'' -N \
N
65.00 g (248.79 mmol) of the compound obtained in Example 8A were initially
charged in
LC-MS (Method 1): R., = 1.00 min; MS (EIpos): m/z = 262 [M+H].
1H), 8.19 (d, 1H).
Example 10A
7-(2-Fluorobenzyl)imidazo[1,5-b]pyridazine

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 125 -
F
N
N \
2.004 g of palladium on carbon (5%) were initially charged under argon, and
20.04 g (76.58 mmol)
of the compound obtained in Example 9A in ethyl acetate (750 ml) were then
added. 21.348 ml
(153.159 mmol) of triethylamine were then added, and the reaction mixture was
hydrogenated at
standard hydrogen pressure and 20 C for 16 hours. The same amount of catalyst
as indicated
above was then added, and the reaction mixture was hydrogenated at standard
hydrogen pressure
and 20 C for another night. The mixture was then filtered through Celite, the
filter cake was
washed with ethanol and the filtrate was concentrated and dried under high
vacuum. This gave
22.79 g of the target compound (about 100% of theory, contaminated with
triethylamine).
LC-MS (Method 1): Rt = 0.77 min; MS (EIpos): m/z = 228 [M-f-H]
'1-1NMR (400 MHz; DMSO-d6): 8 [ppm] = 4.44 (s, 2H), 6.70 (dd, 1H), 7.08-7.31
(m, 4H), 7.45 (s,
1H), 8.09 (dd, 1H), 8.28 (dd, 1H).
Example 11A
5 -Bromo-7-(2-fl uorobenzyl)imidazo [1,5 -b] pyridazine
N
N \
B r
22.46 g (98.837 mmol) of the compound obtained in Example 10A were initially
charged in
dichloromethane (400 ml), and 17.591 g (98.837 mmol) of N-bromosuccinimide
were added. The
mixture was then stirred at 20 C for 10 min. Water was then added to the
reaction mixture, the
phases were separated and the organic phase was washed with water. The aqueous
phase was
extracted twice with dichloromethane and the combined organic phases were
washed with

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 126 -
saturated aqueous sodium chloride solution, dried over sodium sulphate,
filtered and concentrated.
This gave 22.78 g of the target compound (75% of theory).
LC-MS (Method 1): R, = 1.05 min; MS (EIpos): m/z = 306, 308 [M+H, bromine
pattern] '.
1H NMR (400 MHz; DMSO-d6): 8 [ppm] = 4.45 (s, 2H), 6.81 (dd, 1H), 7.12-7.34
(m, 4H), 7.94
(dd, 1H), 8.28 (dd, 1H).
Example 12A
7-(2-Fluorobenzyl)imidazo[1,5-b]ppidazine-5-carbonitrile
F
-N \
N
,.... .1,....<----
CN
1.00 g (3.266 mmol) of the compound obtained in Example 11A were initially
charged in dry
DMSO (25 ml), 1.170 g (13.066 mmol) of copper(I) cyanide were added and, with
stirring, the
mixture was heated at 170 C for 3.5 h. The mixture was filtered through
Celite, and the filter cake
was washed with ethyl acetate and tetrahydrofuran. The filtrate was then
extracted four times with
a mixture of saturated aqueous ammonium chloride solution/aqueous ammonia
(33%) (3:1, v/v)
and washed once with saturated aqueous sodium chloride solution. The phases
were separated and
the organic phase was dried with sodium sulphate, filtered and concentrated.
The residue was
treated with ethanol in an ultrasonic bath, and water was then added. The
precipiate formed was
filtered off, washed with ethanol and then dried under high vacuum. This gave
586 mg of the target
compound (71% of theory).
LC-MS (Method 1): R, = 0.95 mm; MS (EIpos): in/z = 253 [M+H].
11-1 NMR (400 MHz; DMSO-d6): 8 [ppm] = 4.49 (s, 2H), 7.13-7.35 (m, 5H), 8.40
(d, 111), 8.61 (d,
1H).
Example 13A
5-Fluoro-3 -iodo-1-(3,3 ,4,4,4-pentafluorobuty1)-1H-pyrazolo [3,4-b]pyridine

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
- 127 -
-
F
rFss........_
F F
N
Nss
N
F-
I
5.0 g (19.010 mmol) of 5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine were
initially charged in DMF
(100 ml), and then 20.83 g (76.042 mmol) of 1,1,1,2,2-pentafluoro-4-
iodobutane, and also 14.86 g
(45.65 mmol) of caesium carbonate and 0.63 g (3.802 mmol) of potassium iodide
were added. The
mixture was stirred at 140 C overnight. The mixture was then cooled and
combined with a prior
experiment which had been carried out analogously using 200 mg of 5-fluoro-3-
iodo-1H-
pyrazolo[3,4-b]pyridine. Solids were filtered off with suction and washed with
DMF, and then the
filtrate was concentrated under high vacuum. The residue was purified by
preparative HPLC
(methanol:water gradient). This gave 4.34 g (52% of theory) of the title
compound.
LC-MS (Method 2): R, = 1.30 min
MS (ESIpos): m/z = 410 (M+H)+
1H NMR (400 MHz; DMSO-d6): 8 = 2.84-3.00 (m, 2H), 4.79 (t, 211), 7.93 (dd,
1H), 8.71 (dd, 1H).
Example 14A
5-Fluoro-1-(3,3,4,4,4-pentafluorobuty1)-1H-pyrazolo[3,4-b]pyridine-3-
carbonitrile
F
r.F....F.......
F F
N N
1 N
,... i
F
\ \
N
A suspension of 4.34 g (10.609 mmol) of Example 13A and 1.045 g (11.670 mmol)
of copper(I)
cyanide was initially charged in DMSO (30 ml) and stirred at 150 C for 2 h.
After cooling, the
mixture was filtered through Celite, the filter cake was washed with ethyl
acetate and THE' and the

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 128 -
filtrate was then extracted four times with a solution of saturated aqueous
ammonium chloride
solution and conc. aqueous ammonia (3:1 v/v). The combined organic phases were
washed with
saturated aqueous sodium chloride solution, dried over sodium sulphate,
filtered and concentrated
under reduced pressure.
Yield: 3.19 g (97% of theory)
1H NMR (400 MHz; DMSO-d6): 8 = 2.94-3.09 (m, 2H), 4.93 (t, 2H), 8.54 (dd, 1H),
8.88 (dd, 1H).

BHC 12 1 012-Foreign CountriescA 02866213 2014-09-03
- 129 -
Working examples:
Example 1
6-{5-Fluoro-1-[(3-fluoropyridin-2-ypmethyl]-1H-pyrazolo[3,4-b]pyridin-3-y11-3-
methy1-111-
pyrazolo[3,4-d]pyrimidine-4-amine
r
N
NNI
/
N
HN
N CH3
According to General Procedure 1, 100 mg (0.369 mmol) of Example 2A were
reacted with 5-
amino-3-methy1-1H-pyrazole-4-carbonitrile.
Yield: 14 mg (10% of theory)
LC-MS (Method 1): Rt = 0.71 min; MS (EIpos): m/z = 394 [M+H].
'1-1 NMR (400 MHz; DMSO-d6): 5 [ppm] = methyl group, 3H probably under DMSO
signal, 5.96
(s, 2H), 7.42-7.46(m, 111), 7.76 (t, 1H), 8.28 (d, 1H), 8.67 (s br, 1H), 8.90
(dd, 1H), 12.97 (s br,
1H).
Example 2
143,N3-Diethy1-6-{5-fluoro-1-[(3-fluoropyridin-2-yOmethyl]-1H-pyrazolo [3,4-
b]pyridin-3-y1 -1H-
pyrazolo[3,4-d]pyrimidine-3,4-diamine

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
.
- 130 -
F
r "----
.. %...,N,
N
F
Vi....... N H2
H N
= ----
1 .....-L
N NCH3
LC H3
According to General Procedure 1, 100 mg (0.369 mmol) of Example 2A were
reacted with 5-
amino-3-(diethylamino)-1H-pyrazole-4-carbonitrile.
Yield: 37 mg (22% of theory)
LC-MS (Method 1): Rt = 0.93 min; MS (EIpos): m/z = 451 [M+Hr.
1H NMR (400 MHz; DMSO-d6): 8 [ppm] = 1.04 (t, 6H), 3.22 (q, 4H), 5.96 (s, 2H),
7.42-7.46(m,
1H), 7.75-7.80 (m, 1H), 8.27-8.29 (m, 1H), 8.66 (dd, 1H), 8.90 (dd, 1H), 12.55
(s br, 1H).
Example 3
2- {5-Fluoro-1 -[(3-fluoropyri din-2-yl)methyl] -1H-pyrazol o[3,4-b]pyri din-3
-yl } pyrido[2,3-
dlpyrimidine-4-amine
F
r--- "--
N N
N
F
Ne.....N H2
Ni / \

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
- 131 -
According to General Procedure 1, 100 mg (0.369 mmol) of Example 2A were
reacted with 2-
aminopyridinecarbonitrile.
Yield: 19 mg (13% of theory)
LC-MS (Method 1): R, = 0.71 min; MS (EIpos): m/z = 391 [M+H].
III NMR (400 MHz; DMSO-d6): 8 [ppm] = 6.01 (s, 2H), 7.43-7.47 (m, 1H), 7.52
(dd, 1H), (7.76-
7.81 (m, 1H), 8.28-8.30 (m, 1H), 8.33 (s br, 2H), 8.67-8.70 (m, 2H), 8.90 (dd,
1H), 9.01 (dd, 1H).
Example 4
6-{5-Fluoro-1-[(3-fluoropyridin-2-yOmethyl]-1H-pyrazolo[3,4-b]pyridin-3-y11-3-
methoxy-1H-
pyrazolo[3,4-d]pyrimidine-4-amine
rO
F NH2
N
HN _
=
0
CH3
According to General Procedure 1, 100 mg (0.369 mmol) of Example 2A were
reacted with 5-
amino-3-methoxy-1H-pyrazole-4-carbonitrile.
Yield: 18 mg (12% of theory)
LC-MS (Method 1): R, = 0.79 mm; MS (EIpos): m/z = 410 [M+H].
1HNMR (400 MHz; DM50-d6): 8 [ppm] = 3.98 (s, 3H), 5.96 (s, 2H), 7.42-7.46 (m,
111), 7.75-7.80
(m, 1H), 8.27-8.29 (m, 1H), 8.66 (dd, 1H), 8.88 (dd, 1H), 12.41 (s br, 1H).

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 132 -
Erlp_Igl
6-[(Cyclopropylmethyl)amino]-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-
b]pyridin-3-y1]-7-
(2,2,2-trifluoroethyl)-7,9-dihydro-8H-purin-8-one
F
N
Nss,
N
F
'''..-7.....---1 / N
H
N
H N
0 F
F F
In a microwave vessel with stirrer magnet, 90 mg (0.182 mmol) of Example 6A
were dissolved in
2 ml of NMP, aminomethylcyclopropane (0.5 ml) was added and the mixture was
then heated at
150 C under microwave irradiation for 3 h. The reaction mixture was purified
by preparative
HPLC (mobile phase: acetonitrile/water with 0.05% of formic acid, gradient).
Yield: 18 mg (18% of theory)
LC-MS (Method 1): Rt = 1.26 min; MS (EIpos): m/z = 531 [M+H].
II-1 NMR (400 MHz; DMSO-d6): 8 [ppm] = 0.32-0.35 (m, 211), 0.43-0.48 (m, 2H),
1.23-1.28 (m,
1H), 3.51 (dd, 2H), 4.96 (q, 2H), 5.82 (s, 2H), 6.91 (t, 1H), 7.13-7.17 (m,
1H), 7.20-7.27 (m, 2H),
7.35-7.40 (m, 1H), 8.57 (dd, 1H), 8.72 (dd, 1H), 11.99 (s, 1H).
Example
2-[5-Fluoro-1-(2-fluorobenzy1)-1H-pyrazolo [3 ,4-b]pyridin-3-y1]-7-(2,2,2-
trifluoroethyl)-6-[(3,3,3-
trifluoropropyl)amino]-7,9-dihydro-8H-purin-8-one

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
- 133 -
F
441k
N
N
H
H N
0 JCF F F
F F
In a microwave vessel with stirrer magnet, 90 mg (0.182 mmol) of Example 6A
were dissolved in
2 ml of NMP, 122 mg (0.817 n-u-riol) of 3,3,3-trifluoropropy1-1-amine
hydrochloride and 0.164 ml
(0.944 mmol) of N,N-diisopropylethylamine were added and the mixture was then
heated at 150 C
under microwave irradiation for 3 h. The reaction mixture was purified by
preparative HPLC
(mobile phase: acetonitrile/water with 0.05% of formic acid, gradient). 54 mg
still containing
starting material were isolated. In a microwave vessel with stirrer magnet, 44
mg of this mixture
were then dissolved in 1 ml of NMP, 60 mg (0.405 mmol) of 3,3,3-
trifluoropropy1-1-amine
hydrochloride and 81 1 (0.468 mmol) of N,N-diisopropylethylamine were added
and the mixture
was then heated at 150 C under microwave irradiation for 6 h. The reaction
mixture was purified
by preparative HPLC (mobile phase: acetonitrile/water with 0.05% of formic
acid, gradient).
Yield: 34 mg (33% of theory)
LC-MS (Method 1): Rt = 1.22 mm; MS (EIpos): m/z = 573 [M+H].
'H NMR (400 MHz; DMSO-d6): 6 [ppm] = 2.65-2.72 (m, 2H), 3.85-3.90 (q, 2H),
4.90-4.97 (q,
2H), 5.82 (s, 2H), 6.97 (t, 1H), 7.16 (t, 1H), 7.20-7.29 (m, 2H), 7.34-7.40
(m, 1H), 8.46 (dd, 1H),
8.72 (dd, 1H), 12.09 (s, 1H).
Exam ple 7
647-(2-Fluorobenzypimidazo[1,5-b]pyridazin-5-y1]-3-methy1-1H-pyrazolo[3,4-
d]pyrimidine-4-
amine

BHC 12 1 012-Foreign Countries
CA 02866213 2014-09-03
e
- 134 -
F
,N.
\
...... N
/ N
NH2
HN
\ ,....-
N CH3
According to General Procedure 1, 100 mg (0.369 mmol) of Example 12A were
reacted with 5-
amino-3-methy1-1H-pyrazole-4-carbonitrile at 200 C.
Yield: 19 mg (13% of theory)
LC-MS (Method 1): It, = 0.77 mm; MS (EIpos): m/z = 375 [M+H]+.
Ili NMR (400 MHz; DMSO-d6): 8 [ppm] = methyl group, 3H probably under DMSO
signal, 4.50
(s, 2H), 6.95 (dd, 1H), 7.12-7.23 (m, 2H), 7.29-7.34 (m, 2H), 8.41 (dd, 111),
9.11 (dd, 1H), 12.80
(s br, 1H).
Example 8
645-Fluoro-1-(3,3,4,4,4-pentafluorobuty1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-3-
methy1-1H-
pyrazolo[3,4-d]pyrimidine-4-amine
F F
<
F
F
N.k.z.....õN\
I N
/
F
/ N
N)..õ.1.....
NH2
HN
µ .......-
N CH3

BHC 12 1 012-Foreign Countries cA 02866213 2014-09-03
N
- 135 -
According to General Procedure 2, 200 mg (0.65 mmol) of Example 14A, 5-fluoro-
1-(3,3,4,4,4-
pentafluorobuty1)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile, were reacted with
5-amino-3-methyl-
1H-pyrazole-4-carbonitrile.
Yield: 6.6 mg (2% of theory)
LC-MS (Method 1): R, = 0.92 min; MS (EIpos): in/z = 431 [M+H].
111 NMR (400 MHz; DMSO-d6): 8 [ppm]= 2.57 (s, 3H), 2.90 - 3.12 (m, 2H), 4.88
(t, 2H), 7.50 (br.
s, 2H), 8.68 - 8.74 (m, 1H), 8.94 (dd, 111), 13.03 (br. s, 111).
Example 9
N3,N3 -Diethy1-6-{ 5-fluoro-1-[(3-fluoropyridin-2-yOmethyl]-1H-pyrazolo[3,4-
b]pyridin-3-y11-1H-
pyrazolo [3 ,4-d]pyrimidine-3,4-diamine
F
F
N ,N
I \N
F
/ N
NO, NH2
HN
µ ----
1 ,....-L
N N CH3
L. C H3
According to General Procedure 2, 100 mg (0.32 mmol) of Example 14A, 5-fluoro-
1-(3,3,4,4,4-
pentafluorobuty1)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile, were reacted with
5-amino-3-
(diethylamino)-1H-pyrazole-4-carbonitrile. The mixture was then heated at 200
C for a further 2 h
and finally at 160 C under microwave irradiation for 10 h.
Yield: 5.2 mg (3% of theory)
LC-MS (Method 1): R, = 1.09 min; MS (EIpos): m/z = 488 [M+H].

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 136 -11-1 NMR (400 MHz; DMSO-c16): ö [ppm]= 1.05 (t, 6H), 2.86 - 3.13 (m,
3H), 3.22 (q, 4H), 4.88 (t,
2H), 7.22 (br. s, 2H), 8.70 (dd, 114), 8.95 (dd, 1H), 12.61 (s, 1H).
Example 10
2-[5-Fluoro-1-(3,3 ,4,4,4-pentafluorobuty1)-1H-pyrazolo [3,4-b]pyridin-3-
yl]pyrido [2,3-
d]pyrimidine-4-amine
F F
rF),....(F\ F
,..../N:k.õ....-INN
N
F
Ne.....NH2
NJ / \
According to General Procedure 2, 200 mg (0.65 mmol) of Example 14A, 5-fluoro-
1-(3,3,4,4,4-
pentafluorobuty1)-1H-pyrazolo [3 ,4-b]pyridine-3-carbonitrile, were
reacted with 2-
aminopyridinecarbonitrile. The mixture was then heated at 180 C under
microwave irradiation for
a further 3 h. Finally, a further 80 mg (0.67 mmol) of 2-
aminopyridinecarbonitrile and 73 mg (0.65
mmol) of potassium tert-butoxide were added, and the mixture was heated at 180
C under
microwave irradiation for 3 h.
Yield: 6.6 mg (2% of theory)
LC-MS (Method 1): R, = 0.89 min; MS (EIpos): m/z = 428 [M+H].
11-1 NMR (400 MHz, DMSO-d6): 5 [ppm]= 2.94 - 3.12 (m, 2H), 4.93 (t, 2H), 7.50 -
7.59 (m, 1H),
8.37 (br. s., 1H), 8.70 (d, 1H), 8.75 (br. s., 1H), 8.91 (dd, 1H), 9.04 (br.
s., 1H).

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 137 -
B. Assessment of pharmacological efficacy
The pharmacological effect of the compounds according to the invention can be
shown in the
following assays:
B-1. Vasorelaxant effect in vitro
Rabbits are stunned by a blow to the neck and exsanguinated. The aorta is
removed, freed from
adhering tissue and divided into rings of a width of 1.5 mm. The rings are
placed individually
under an initial tension in 5 ml organ baths with Krebs-Henseleit solution
which is at 37 C, is
gassed with carbogen and has the following composition (in each case m_M):
sodium chloride: 119;
potassium chloride: 4.8; calcium chloride dihydrate: 1; magnesium sulphate
heptahydrate: 1.4;
potassium dihydrogenphosphate: 1.2; sodium bicarbonate: 25; glucose: 10. The
contractile force is
determined with Statham UC2 cells, amplified and digitalized using A/D
transducers (DAS-1802
HC, Keithley Instruments Munich), and recorded in parallel on linear
recorders. To produce a
contraction, phenylephrine is added to the bath cumulatively in increasing
concentration. After
several control cycles, the substance to be investigated is added in each
further run in increasing
dosage in each case, and the height of the contraction achieved is compared
with the height of the
contraction reached in the last preceding run. This is used to calculate the
concentration needed to
reduce the magnitude of the control value by 50% (IC50 value). The standard
administration
volume is 5 I; the DMSO content in the bath solution corresponds to 0.1%.
B-2. Effect on a recombinant guanylate cyclase reporter cell line
The cellular activity of the compounds according to the invention is
determined using a
recombinant guanylate cyclase reporter cell line, as described in F. Wunder et
al., Anal. Biochem.
339, 104-112 (2005).
Representative values (MEC = minimum effective concentration) for the
compounds according to
the invention are shown in the table below (Table 2):
Table 2:
Example MEC
1 0.3
2 0.1

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 138 -
Example MEC
FILM]
3 10
4 0.3
0.3
7 0.01
8 0.1
9 0.03
0.3
B-3. Radiotelemetric measurement of blood pressure on conscious spontaneously
hypertensive
rats
A commercially available telemetry system from DATA SCIENCES INTERNATIONAL
DSI,
5 USA, is employed for the blood pressure measurement on
conscious rats described below.
The system consists of 3 main components:
¨ implantable transmitters (Physiotel telemetry transmitter)
¨ receivers (Physiotel receiver) which are linked via a multiplexer (DSI
Data Exchange Matrix)
to a
10 ¨ data acquisition computer.
The telemetry system makes it possible to continuously record blood pressure,
heart rate and body
motion of conscious animals in their usual habitat.
Animal material
The investigations are carried out on adult female spontaneously hypertensive
rats (SIR Okamoto)
with a body weight of >200 g. SHR/NCrl from the Okamoto Kyoto School of
Medicine, 1963

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 139 -
were a cross of male Wistar Kyoto rats with highly elevated blood pressure and
female rats having
a slightly elevated blood pressure and at F13 handed over to the U.S. National
Institutes of Health.
After transmitter implantation, the experimental animals are housed singly in
type 3 Makrolon
cages. They have free access to standard feed and water.
The day/night rhythm in the experimental laboratory is changed by the room
lighting at 6:00 am
and at 7:00 pm.
Transmitter implantation
The telemetry transmitters TAll PA ¨ C40 used are surgically implanted under
aseptic conditions
in the experimental animals at least 14 days before the first experimental
use. The animals
instrumented in this way can be employed repeatedly after the wound has healed
and the implant
has settled.
For the implantation, the fasted animals are anaesthetized with pentobarbital
(Nembutal, Sanofi:
50 mg/kg i.p.) and shaved and disinfected over a large area of their abdomens.
After the abdominal
cavity has been opened along the linea alba, the liquid-filled measuring
catheter of the system is
inserted into the descending aorta in the cranial direction above the
bifurcation and fixed with
tissue glue (VetBonD TM, 3M). The transmitter housing is fixed
intraperitoneally to the
abdominal wall muscle, and layered closure of the wound is performed.
An antibiotic (Tardomyocel COMP, Bayer, 1 ml/kg s.c.) is administered
postoperatively for
prophylaxis of infection.
Substances and solutions
Unless indicated otherwise, the substances to be investigated are administered
orally by gavage in
each case to a group of animals (n = 6). The test substances are dissolved in
suitable solvent
mixtures, or suspended in 0.5% strength Tylose, appropriate for an
administration volume of 5
ml/kg of body weight.
A solvent-treated group of animals is employed as control.
Test procedure
The telemetry measuring unit present is configured for 24 animals. Each
experiment is recorded
under an experiment number (Vyear month day).

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
i
- 140 -
Each of the instrumented rats living in the system is assigned a separate
receiving antenna (1010
Receiver, DSI).
The implanted transmitters can be activated externally by means of an
incorporated magnetic
switch. They are switched to transmission in the run-up to the experiment. The
signals emitted can
be detected online by a data acquisition system (Dataquest TM A.R.T. for
WINDOWS, DSI) and
processed accordingly. The data are stored in each case in a file created for
this purpose and
bearing the experiment number.
In the standard procedure, the following are measured for 10-second periods in
each case:
¨ systolic blood pressure (SBP)
¨ diastolic blood pressure (DBP)
¨ mean arterial pressure (MAP)
¨ heart rate (HR)
¨ activity (ACT).
The acquisition of measurements is repeated under computer control at 5-minute
intervals. The
source data obtained as absolute value are corrected in the diagram with the
currently measured
barometric pressure (Ambient Pressure Reference Monitor; APR-1) and stored as
individual data.
Further technical details are given in the extensive documentation from the
manufacturing
company (DSI).
Unless indicated otherwise, the test substances are administered at 9:00 am on
the day of the
experiment. Following the administration, the parameters described above are
measured over 24
hours.
Evaluation
After the end of the experiment, the acquired individual data are sorted using
the analysis software
(DATAQUEST TM A.R.T. TM ANALYSIS). The blank value is assumed to be the time 2
hours
before administration, and so the selected data set encompasses the period
from 7:00 am on the day
of the experiment to 9:00 am on the following day.
The data are smoothed over a presettable time by determination of the average
(15-minute average)
and transferred as a text file to a storage medium. The measured values
presorted and compressed

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 141 -
in this way are transferred into Excel templates and tabulated. For each day
of the experiment, the
data obtained are stored in a dedicated file bearing the number of the
experiment. Results and test
protocols are filed in paper form sorted by numbers.
Literature
Klaus Witte, Kai Hu, Johanna Swiatek, Claudia Miissig, Georg Ertl and Bjorn
Lemmer:
Experimental heart failure in rats: effects on cardiovascular circadian
rhythms and on myocardial
0-adrenergic signaling. Cardiovasc Res 47 (2): 203-405, 2000; Kozo Okamoto:
Spontaneous
hypertension in rats. Int Rev Exp Pathol 7: 227- 270, 1969; Maarten van den
Buuse: Circadian
Rhythms of Blood Pressure, Heart Rate, and Locomotor Activity in Spontaneously
Hypertensive
Rats as Measured With Radio-Telemetry. Physiology & Behavior 55(4): 783-787,
1994
B-4. Determination of pharmacoldnetic parameters following intravenous and
oral
administration
The pharmacokinetic parameters of the compounds according to the invention are
determined in
male CD-1 mice, male Wistar rats and female beagles. Intravenous
administration in the case of
mice and rats is effected by means of a species-specific plasma/DMSO
formulation, and in the
case of dogs by means of a water/PEG400/ethanol formulation. In all species,
oral administration
of the dissolved substance is performed via gavage, based on a
water/PEG400/ethanol formulation.
The removal of blood from rats is simplified by inserting a silicone catheter
into the right Vena
jugularis externa prior to substance administration. The operation is effected
at least one day prior
to the experiment with isofluran anaesthesia and administration of an
analgesic (atropine/rimadyl
(3/1) 0.1 ml s.c.). The blood is taken (generally more than 10 time points)
within a time window
including terminal time points of at least 24 to a maximum of 72 hours after
substance
administration. The blood is removed into heparinized tubes. The blood plasma
is then obtained by
centrifugation; if required, it can be stored at -20 C until further
processing.
An internal standard (which may also be a chemically unrelated substance) is
added to the samples
of the compounds according to the invention, calibration samples and
qualifiers, and there follows
protein precipitation by means of acetonitrile in excess. Addition of a buffer
solution matched to
the LC conditions, and subsequent vortexing, is followed by centrifugation at
1000 g. The
supernatant is analysed by means of LC-MS/MS using C18 reversed-phase columns
and variable
mobile phase mixtures. The substances are quantified via the peak heights or
areas from extracted
ion chromatograms of specific selected ion monitoring experiments.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
=
,
- 142 -
The plasma concentration/time plots determined are used to calculate the
pharmacokinetic
parameters such as AUC, C, t112 (terminal half life), MRT (mean residence
time) and CL
(clearance), using a validated pharmacokinetic calculation program.
Since the substance quantification is performed in plasma, it is necessary to
determine the
blood/plasma distribution of the substance in order to be able to adjust the
pharmacokinetic
parameters correspondingly. For this purpose, a defined amount of substance is
incubated in
heparinized whole blood of the species in question in a rocking roller mixer
for 20 mM. After
centrifugation at 1000g, the plasma concentration is measured (by means of LC-
MS/MS; see
above) and determined by calculating the ratio of the cbiõõd/coasma value.
B-5. Metabolic study
To determine the metabolic profile of the compounds according to the
invention, they are
incubated with recombinant human cytochrome P450 (CYP) enzymes, liver
microsomes or
primary fresh hepatocytes from various animal species (e.g. rats, dogs), and
also of human origin,
in order to obtain and to compare information about a very substantially
complete hepatic phase I
and phase II metabolism, and about the enzymes involved in the metabolism.
The compounds according to the invention were incubated with a concentration
of about 0.1-10
M. To this end, stock solutions of the compounds according to the invention
having a
concentration of 0.01-1 mM in acetonitrile were prepared, and then pipetted
with 1:100 dilution
into the incubation mixture. Liver microsomes and recombinant enzymes were
incubated at 37 C
in 50 mM potassium phosphate buffer pH 7.4 with and without NADPH-generating
system
consisting of 1 mM NADI)+, 10 mM glucose-6-phosphate and 1 unit glucose-6-
phosphate
dehydrogenase. Primary hepatocytes were incubated in suspension in Williams E
medium,
likewise at 37 C. After an incubation time of 0 - 4 h, the incubation mixtures
were stopped with
acetonitrile (final concentration about 30%) and the protein was centrifuged
off at about 15 000 x
g. The samples thus stopped were either analysed directly or stored at -20 C
until analysis.
The analysis is effected by means of high-performance liquid chromatography
with ultraviolet and
mass spectrometry detection (HPLC-UV-MS/MS). To this end, the supernatants of
the incubation
samples are chromatographed with suitable C18 reversed-phase columns and
variable mobile
phase mixtures of acetonitrile and 10 mM aqueous ammonium formate solution or
0.05% formic
acid. The UV chromatograms in conjunction with mass spectrometry data serve
for identification,
structural elucidation and quantitative estimation of the metabolites, and for
quantitative metabolic
reduction of the compound according to the invention in the incubation
mixtures.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 143 -
C. Working examples of pharmaceutical compositions
The compounds according to the invention can be converted to pharmaceutical
formulations as
follows:
Tablet:
Composition:
100 mg of the compound according to the invention, 50 mg of lactose
(monohydrate), 50 mg of
corn starch (native), 10 mg of polyvinYlpyrrolidone (PVP 25) (BASF,
Ludwigshafen, Germany)
and 2 mg of magnesium stearate.
Tablet weight 212 mg, diameter 8 mm, radius of curvature 12 mm.
Production:
The mixture of compound according to the invention, lactose and starch is
granulated with a 5%
solution (w/w) of the PVP in water. The granules are dried and mixed with the
magnesium stearate
for 5 minutes. This mixture is pressed with a conventional tableting press
(for tablet dimensions
see above). The guide value used for the pressing is a pressing force of 15
IN.
Suspension which can be administered orally:
Composition:
1000 mg of the compound according to the invention, 1000 mg of ethanol (96%),
400 mg of
Rhodigel (xanthan gum from FMC, Pennsylvania, USA) and 99 g of water.
A single dose of 100 mg of the compound according to the invention corresponds
to 10 ml of oral
suspension.
Production:
The Rhodigel is suspended in ethanol and the compound according to the
invention is added to the
suspension. The water is added while stirring. The mixture is stirred for
about 6 h until swelling of
the Rhodigel is complete.

BHC 12 1 012-Foreign Countries CA 02866213 2014-09-03
- 144 -
Solution which can be administered orally:
Composition:
500 mg of the compound according to the invention, 2.5 g of polysorbate and 97
g of polyethylene
glycol 400. A single dose of 100 mg of the compound according to the invention
corresponds to 20
g of oral solution.
Production:
The compound according to the invention is suspended in the mixture of
polyethylene glycol and
polysorbate while stirring. The stirring operation is continued until
dissolution of the compound
according to the invention is complete.
i.v. solution:
The compound according to the invention is dissolved in a concentration below
the saturation
solubility in a physiologically acceptable solvent (e.g. isotonic saline,
glucose solution 5% and/or
PEG 400 solution 30%). The solution is subjected to sterile filtration and
dispensed into sterile and
pyrogen-free injection vessels.